<SEC-DOCUMENT>0001387131-17-003894.txt : 20170803
<SEC-HEADER>0001387131-17-003894.hdr.sgml : 20170803
<ACCEPTANCE-DATETIME>20170803172804
ACCESSION NUMBER:		0001387131-17-003894
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20170630
FILED AS OF DATE:		20170803
DATE AS OF CHANGE:		20170803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		171006180

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>txmd-10q_063017.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>

<HEAD>
    <TITLE>txmd-10q_063017.htm</TITLE>
</HEAD>

<BODY style='font: 10pt Times New Roman, Times, Serif'>
    <!-- Edge Version : 1.7 -->
    <p style="margin-bottom: 0; margin-top: 0; text-align: center;">&nbsp;</p>
    <div align="LEFT">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin-bottom: 0; margin-top: 0; text-align: center;"><b>&nbsp;</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 14pt;"><b>UNITED STATES</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 14pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b>WASHINGTON, D.C. 20549</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt;"><b>FORM 10-Q</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">(Mark One)</p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0pt;"></td>
            <td style="width: 5%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;">&#x2612;</font>
            </td>
            <td style="width: 95%; text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif;">For the quarterly period ended June 30, 2017</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0in;"></td>
            <td style="width: 5%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;">&#x2610;</font>
            </td>
            <td style="width: 95%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">For the transition period from________ to ___________</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">Commission File No. <b><u>001-001000</u></b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: left;">
            <td style="border-bottom: Black 1pt solid; width: 70%; text-align: center;">
                <font style="font-size: 24pt;"><b>THERAPEUTICSMD, INC.</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td style="text-align: center;">(Exact Name of Registrant as Specified in Its Charter)</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-left: 0in; margin-top: 0; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: left;">
            <td style="border-bottom: Black 1pt solid; width: 55%; text-align: center;"><b>Nevada</b></td>
            <td style="width: 3%; text-align: center;"><b>&nbsp;</b></td>
            <td style="border-bottom: Black 1pt solid; width: 42%; text-align: center;"><b>87-0233535</b></td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td style="text-align: center;">(State or Other Jurisdiction of Incorporation or Organization)</td>
            <td>&nbsp;</td>
            <td style="text-align: center;">(I.R.S. Employer Identification No.)</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-left: 0in; margin-top: 0; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: left;">
            <td style="border-bottom: Black 1pt solid; width: 55%; text-align: center;"><b>6800 Broken Sound Parkway NW, Third Floor, Boca Raton, FL 33487</b></td>
            <td style="width: 3%; text-align: center;"><b>&nbsp;</b></td>
            <td style="border-bottom: Black 1pt solid; width: 42%; text-align: center;"><b>(561) 961-1900</b></td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td style="text-align: center;">(Address of Principal Executive Offices)</td>
            <td>&nbsp;</td>
            <td style="text-align: center;">(Issuer&#x2019;s Telephone Number)</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-left: 0in; margin-top: 0; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: left;">
            <td style="width: 70%; text-align: center;">
                <font style="font-size: 10pt;"><b><u>N/A</u></b></font>
            </td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td style="text-align: center;">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-left: 0in; margin-top: 0; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes &#x2612;&nbsp;&nbsp;No &#x2610;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes
        <font style="font-family: Times New Roman, Times, Serif;">&#x2612;</font> &nbsp;&nbsp;No
        <font style="font-family: Times New Roman, Times, Serif;">&#x2610;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer,&#x201D; &#x201C;smaller reporting company&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act (Check one):</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: left;">
            <td style="width: 45%; text-align: center;">Large accelerated filer &#x2612;</td>
            <td style="width: 10%;">&nbsp;</td>
            <td style="width: 45%;">Accelerated filer&nbsp;&#x2610;</td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td style="text-align: center;">Non-accelerated filer &#x2610;</td>
            <td>&nbsp;</td>
            <td>Smaller reporting company &#x2610;</td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td style="text-align: center;">(Do not check if a smaller reporting company)</td>
            <td>&nbsp;</td>
            <td>Emerging growth company &#x2610;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#x2610; &nbsp;No &#x2612;&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The number of shares outstanding of the registrant&#x2019;s common stock, par value $0.001 per share, as of July 31, 2017 was 204,027,142.</p>
    <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <div align="LEFT">
        <div style="border-bottom: Black 2pt solid; border-top: Black 1pt solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  1; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES </b>
            <br> <b>INDEX</b></font>
    </p>
    <p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&nbsp;</b></font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-decoration: underline; font: 10pt Times New Roman, Times, Serif;" colspan="3" nowrap></td>
            <td style="border-bottom: Black 1pt solid; padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Page</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-decoration: underline; font: 10pt Times New Roman, Times, Serif;" colspan="3" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>PART I - FINANCIAL INFORMATION</u></b></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-decoration: underline; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>Item. 1</u></b></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-decoration: underline; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>Financial Statements</u></b></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; width: 2%; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; width: 10%; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; width: 80%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda001">Consolidated Balance Sheets as of June 30, 2017 (Unaudited) and December 31, 2016</a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; width: 8%; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">3</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda002">Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2017 (Unaudited) and 2016 (Unaudited)</a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">4</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda003">Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2017 (Unaudited) and 2016 (Unaudited)</a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">5</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda004">Notes to Consolidated Financial Statements</a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">6</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda005"><b>Item 2.</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda005"><b>Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">21</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda006"><b>Item 3.</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda006"><b>Quantitative and Qualitative Disclosures about Market Risks</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">35</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda007"><b>Item 4.</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda007"><b>Controls and Procedures</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">35</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" colspan="3" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda008"><b>Part II - OTHER INFORMATION</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">36</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda009"><b>Item 1.</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda009"><b>Legal Proceedings</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">36</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda010"><b>Item 1A.</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda010"><b>Risk Factors</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">36</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda011"><b>Item 2.</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda011"><b>Unregistered Sales of Equity Securities and Use of Proceeds</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">37</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda012"><b>Item 6.</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="#txmda012"><b>Exhibits</b></a></font>
            </td>
            <td style="padding-left: 0.75pt; padding-right: 0.75pt; padding-top: 0.75pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">38</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  2; Options:  NewSection; Value:  2; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->2
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b>&nbsp;</font>
    </p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmda001"></a>CONSOLIDATED BALANCE SHEETS</b></font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">June 30, 2017</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">December 31, 2016</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Unaudited)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="9">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">ASSETS</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="9">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Current Assets:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; width: 74%; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Cash</font>
            </td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">96,476,483</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">131,534,101</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Accounts receivable, net of allowance for doubtful accounts of $358,268 and $376,374, respectively</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">3,396,419</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">4,500,699</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Inventory</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,414,015</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,076,321</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other current assets</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2,228,755</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2,299,052</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total current assets</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">103,515,672</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">139,410,173</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.5in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Fixed assets, net</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">483,688</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">516,839</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other Assets:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Intangible assets, net</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2,739,686</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2,405,972</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Security deposit</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">139,036</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">139,036</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total other assets</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2,878,722</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2,545,008</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 2pt; padding-left: 0.625in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total assets</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">106,878,082</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">142,472,020</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.5in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="8">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Current Liabilities:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Accounts payable</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">8,108,034</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">7,358,514</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other current liabilities</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">5,180,218</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">7,624,085</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total current liabilities</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">13,288,252</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">14,982,599</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Commitments and Contingencies - See Note 14</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Stockholders&#x2019; Equity:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Common stock - par value $0.001; 350,000,000 shares authorized; 204,027,142 and 196,688,222 issued and outstanding, respectively</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">204,027</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">196,688</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Additional paid in capital</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">443,952,952</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">436,995,052</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Accumulated deficit</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(350,567,149</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(309,702,319</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total stockholders&#x2019; equity</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">93,589,830</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">127,489,421</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 2pt; padding-left: 0.625in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total liabilities and stockholders&#x2019; equity</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">106,878,082</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">142,472,020</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The accompanying footnotes are an integral part of these consolidated financial statements.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  3; Value:  2; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->3
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b>
            <br> <b><a name="txmda002"></a>CONSOLIDATED STATEMENTS OF OPERATIONS</b>
            <br> <b>(Unaudited)</b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="6">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Three Months Ended
                    <br> June 30,</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="6">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Six Months Ended
                    <br> June 30,</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: center; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2017</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2016</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2017</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2016</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; width: 48%; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Revenues, net</font>
            </td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">4,250,433</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">4,403,247</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">8,235,897</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">9,333,338</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Cost of goods sold</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">681,725</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,130,108</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,341,360</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2,238,551</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Gross profit</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">3,568,708</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">3,273,139</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">6,894,537</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">7,094,787</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Operating expenses:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Sales, general, and administration</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">14,628,927</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">10,619,006</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">31,466,544</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">20,297,558</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Research and development</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">8,716,395</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">13,841,193</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">16,441,235</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">28,938,210</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Depreciation and amortization</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">53,189</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">24,262</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">102,888</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">43,859</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total operating expense</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">23,398,511</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">24,484,461</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">48,010,667</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">49,279,627</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Operating loss</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(19,829,803</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(21,211,322</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(41,116,130</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(42,184,840</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other income:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Miscellaneous income</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">149,054</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">114,320</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">275,022</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">155,937</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Accreted interest</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">3,832</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2,863</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">7,699</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">5,399</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total other income</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">152,886</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">117,183</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">282,721</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">161,336</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Loss before taxes</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(19,676,917</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(21,094,139</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(40,833,409</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(42,023,504</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Provision for income taxes</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net loss</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(19,676,917</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(21,094,139</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(40,833,409</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(42,023,504</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net loss per share, basic and diluted</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(0.10</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(0.11</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(0.20</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(0.21</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Weighted average number of common shares outstanding</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">203,384,610</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">196,325,715</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">200,602,778</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">195,613,639</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The accompanying footnotes are an integral part of these consolidated financial statements.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  4; Value:  2; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->4
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES </b>
            <br> <b><a name="txmda003"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS </b>
            <br> <b>(Unaudited)</b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="6">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Six Months Ended</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">June 30, 2017</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">June 30, 2016</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: left; font: bold 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">CASH FLOWS FROM OPERATING ACTIVITIES</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.25in; width: 74%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net loss</font>
            </td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(40,833,409</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(42,023,504</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.375in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Adjustments to reconcile net loss to net cash flows used in operating activities:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Depreciation of fixed assets</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">69,000</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">19,216</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Amortization of intangible assets</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">33,888</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">24,643</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Recovery of) provision for doubtful accounts</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(18,106</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">447,388</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Share-based compensation</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">3,051,357</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">9,200,844</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Changes in operating assets and liabilities:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.625in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Accounts receivable</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,122,386</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(1,874,980</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.625in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Inventory</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(337,694</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(193,503</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.625in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other current assets</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(58,601</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,001,120</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.625in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Accounts payable</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">749,520</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(86,786</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.625in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other current liabilities</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(2,443,867</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(1,239,743</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net cash used in operating activities</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(38,665,526</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(34,725,305</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: left; font: bold 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">CASH FLOWS FROM INVESTING ACTIVITIES</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Patent costs</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(367,602</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(393,221</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Purchase of fixed assets</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(35,849</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(265,036</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Payment of security deposit</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(4,864</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net cash used in investing activities</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(403,451</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(663,121</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: left; font: bold 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">CASH FLOWS FROM FINANCING ACTIVITIES</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Proceeds from sale of common stock, net of costs</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">134,863,475</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Proceeds from exercise of warrants</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">3,798,999</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,373,000</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Proceeds from exercise of options</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">212,360</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">978,042</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net cash provided by financing activities</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">4,011,359</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">137,214,517</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Decrease) increase in cash</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(35,057,618</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">101,826,091</font>
            </td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Cash, beginning of period</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">131,534,101</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">64,706,355</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Cash, end of period</font>
            </td>
            <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">96,476,483</font>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">166,532,446</font>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The accompanying footnotes are an integral part of these consolidated financial statements.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  5; Value:  2; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->5
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><a name="txmda004"></a>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 1 &#x2013; THE COMPANY</u></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD, or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#x201C;our company,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; or &#x201C;us.&#x201D;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Nature of Business</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are a women&#x2019;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. With our SYMBODA&#x2122; technology, we are developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, iron supplements.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 2 &#x2013; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</u></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Interim Financial Statements</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: #252525;">The accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated balance sheet as of December 31, 2016. The accompanying unaudited interim consolidated financial statements have been prepared in accordance </font>with accounting principles generally accepted in the United States of America, or GAAP
        <font style="color: #252525;">, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim period in the future.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Recently Issued Accounting Pronouncements</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In May 2017, the Financial Accounting Standards Board, or FASB, issued an Accounting Standards Update, or ASU, that clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. The new guidance will allow companies to make certain changes to awards without accounting for them as modifications. This guidance does not change the accounting for modifications. The guidance will be applied prospectively to awards modified on or after the adoption date and is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including in an interim period. We do not expect that adoption of this guidance will have a material effect on our consolidated financial statements.</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  6; Options:  NewSection; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->6
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted with retrospective application. We are currently evaluating the impact of this guidance on our consolidated financial statements and disclosures.</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In March 2016, the FASB issued ASU 2016-09, Compensation &#x2013; Stock Compensation: Improvements to Employee Share-Based Payment Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&nbsp;ASU&nbsp;2016-09&nbsp;effective January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to recognize the previously unrecognized net operating losses from prior periods was made to the valuation allowance through retained earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated financial statements.</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to the accounting for our operating lease.</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We have performed a preliminary review of the requirements of the new revenue standard and are monitoring the activity of the FASB and the transition resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied the five-step model of the new standard to our contracts as well as compared the results to our current accounting practices. At this point of our analysis, we do not believe that the adoption of this standard will have a material effect on our financial statements but will potentially expand our disclosures related to contracts with customers.</p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  7; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->7
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Fair Value of Financial Instruments</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements<i>. </i> The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.85in; text-align: left;"><b>Level 1</b></td>
            <td style="text-align: justify;">unadjusted quoted prices in active markets for identical assets or liabilities;</td>
        </tr>
    </table>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.85in; text-align: left;"><b>Level 2</b></td>
            <td style="text-align: justify;">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td>
        </tr>
    </table>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.85in; text-align: left;"><b>Level 3</b></td>
            <td style="text-align: justify;">unobservable inputs for the asset or liability.</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">At June 30, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with our impairment test. There was no impairment of intangible assets or long-lived assets during the three and six months ended June 30, 2017 and 2016.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Trade Accounts Receivable and Allowance for Doubtful Accounts</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be required.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Revenue Recognition</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  8; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->8
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales. The revenue that is generated by us from major customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note 13. There are no major customers for our OTC prenatal vitamin or other products.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Over-the-Counter Products</u></i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Prescription Products</u></i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy distributors. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees, customer rebates and estimated returns.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Revenue related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Prior to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription products are distributed under the wholesale distributor model described above.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated in contracts and estimate chargebacks based on the number of units sold each period.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  9; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->9
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Share-Based Compensation</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements may include options, restricted stock, restricted stock units, performance-based awards, and share appreciation rights. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to our company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we started using our own stock price in our volatility calculation along with two other peer entities whose stock prices were publicly available that were similar to our company. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life of warrants is based on the contractual terms of the awards. The average expected life of options is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Equity instruments (&#x201C;instruments&#x201D;) issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We recognize the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period.
        <font style="color: #252525;">We adopted ASU 2016-09, effective January 1, 2017, electing to account for forfeitures when they occur. Prior to that, </font>we estimated the forfeiture rate based on our historical experience of forfeitures.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  10; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->10
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Research and Development Expenses</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, laboratory supplies, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $0 at June 30, 2017 and $228,933 at December 31, 2016, all of which were included in other current assets on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration, or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities include professional research and advice regarding R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Segment Reporting</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 4 &#x2013; INVENTORY</u></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Inventory consists of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 92%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">June 30,
                <br>2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">December 31,
                <br>2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 60%; text-align: justify;">Finished product</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">1,399,979</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">1,062,285</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Raw material</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">14,036</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">14,036</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-align: left;">TOTAL INVENTORY</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">1,414,015</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">1,076,321</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 5 &#x2013; OTHER CURRENT ASSETS</u></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Other current assets consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 92%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">June 30,
                <br>2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">December 31,
                <br>2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 60%; text-align: justify;">Prepaid manufacturing costs</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">999,508</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">991,809</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Prepaid marketing costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">535,936</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Prepaid insurance</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">350,571</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">628,039</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Prepaid research and development costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">100,035</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Prepaid consulting</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">128,898</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Prepaid vendor deposits</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5,000</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">44,311</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Other prepaid costs</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">337,740</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">405,960</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-align: left;">TOTAL OTHER CURRENT ASSETS</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">2,228,755</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">2,299,052</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  11; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->11
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 6 &#x2013; FIXED ASSETS</u></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Fixed assets consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 92%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">June 30,
                <br>2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">December 31,
                <br>2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 60%; text-align: justify;">Accounting system</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">301,096</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">301,096</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Equipment</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">247,568</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">215,182</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Computer hardware</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">80,211</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">80,211</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Furniture and fixtures</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">116,542</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">113,079</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Leasehold improvements</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">37,888</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">37,888</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">783,305</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">747,456</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Accumulated depreciation</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(299,617</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(230,617</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL FIXED ASSETS</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">483,688</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">516,839</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Depreciation expense for the three months ended June 30, 2017 and 2016 was $35,400 and $10,853 respectively, and $69,000 and $19,216 for the six months ended June 30, 2017 and 2016, respectively.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 7 &#x2013; INTANGIBLE ASSETS</u></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of June 30, 2017 and December 31, 2016:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">June 30, 2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Gross
                <br> Carrying
                <br> Amount</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Accumulated
                <br> Amortization</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Net
                <br> Amount</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted-
                <br> Average
                <br>Remaining
                <br> Amortization
                <br> Period (yrs.)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Amortizing intangible assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; width: 40%; text-align: left; text-indent: -0.125in;">OPERA<sup>&#xAE;</sup> software patent</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">31,951</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">(7,488</td>
            <td style="width: 1%; text-align: left;">)</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">24,463</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">12.25</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Development costs of &nbsp;corporate website</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">91,743</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(91,743</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Approved hormone&nbsp;therapy drug&nbsp;candidate patents</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,207,267</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(135,282</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">1,071,985</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">15.5</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Hormone therapy drug&nbsp;candidate patents&nbsp;(pending)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,444,581</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,444,581</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Non-amortizing intangible assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Multiple trademarks</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">198,657</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">198,657</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">indefinite</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in;">Total</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">2,974,199</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">(234,513</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">)</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">2,739,686</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <!-- Field: Page; Sequence:  12; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->12
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">December 31, 2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Gross
                <br> Carrying
                <br> Amount</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Accumulated
                <br> Amortization</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Net
                <br>Amount</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted-
                <br> Average
                <br>Remaining
                <br> Amortization
                <br> Period (yrs.)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Amortizing intangible assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; width: 40%; text-align: left; text-indent: -0.125in;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">OPERA<sup>&#xAE;</sup> software patent</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">31,951</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">(6,490</td>
            <td style="width: 1%; text-align: left;">)</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">25,461</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">12.75</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Development costs of corporate website</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">91,743</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(91,743</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Approved hormone
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;therapy drug</font>&nbsp;candidate patents</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,093,452</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(102,393</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">991,059</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">16</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Hormone therapy drug
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;candidate patents&nbsp;(pending)</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,203,987</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,203,987</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Non-amortizing intangible assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Multiple trademarks</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">185,465</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">185,465</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">indefinite</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in;">Total</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">2,606,598</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">(200,626</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">)</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">2,405,972</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight line method over the estimated useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the six months ended June 30, 2017 and year ended December 31, 2016, there was no impairment recognized related to intangible assets.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">In addition to numerous pending patent applications, as of June 30, 2017, we had 17 issued patents, including:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in;"></td>
            <td style="width: 0.25in;">&#x25CF;</td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif;">13 utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.</font>
            </td>
        </tr>
    </table>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in;"></td>
            <td style="width: 0.25in;">&#x25CF;</td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif;">two utility patent that relates to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establishes an important intellectual property foundation for TX-004HR, which are owned by us and are U.S. jurisdiction patents with an expiration date in 2033.&nbsp; We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.</font>
            </td>
        </tr>
    </table>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in;"></td>
            <td style="width: 0.25in;">&#x25CF;</td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif;">one utility patent that relates to a pipeline transdermal patch technology, which is owned by us and is a U.S. jurisdiction patent with an expiration in 2032. We have pending patent application with respect to this patent in Australia, Brazil, Canada, Europe, Mexico, and Japan.</font>
            </td>
        </tr>
    </table>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in;"></td>
            <td style="width: 0.25in;">&#x25CF;</td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif;">one utility patent that relates to our OPERA&#xAE; information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029.</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  13; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->13
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Amortization expense was $17,789 and $13,409 for the three months ended June 30, 2017 and 2016, respectively, and $33,888 and $24,643 for the six months ended June 30, 2017 and 2016, respectively. Estimated amortization expense for the next five years for the patent cost currently being amortized is as follows:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Year Ending
                <br> December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Estimated
                <br> Amortization</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 20%; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2017(6 months)</font>
            </td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 20%; text-align: right;">35,579</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2018</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">71,157</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2019</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">71,157</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2020</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">71,157</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2021</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">71,157</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Thereafter</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">776,241</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 8 &#x2013; OTHER CURRENT LIABILITIES</u></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Other current liabilities consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-left: 0.25in; width: 83%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">June 30,
                <br>2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">December 31,
                <br>2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 50%; text-align: justify;">Accrued clinical trial costs</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">527,979</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">1,281,080</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Accrued payroll, bonuses and commission costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,738,495</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">3,531,440</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Accrued compensated absences</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">934,370</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">665,561</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Accrued legal and accounting expense</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">263,375</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">176,518</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Accrued sales and marketing costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">100,821</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">665,773</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Other accrued expenses</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">171,487</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">224,865</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Allowance for wholesale distributor fees</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">98,729</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">76,510</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Accrued royalties</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">71,775</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">26,507</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Allowance for coupons and returns</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,019,853</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">794,816</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Accrued rent</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">253,334</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">181,015</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL OTHER CURRENT LIABILITIES</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">5,180,218</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">7,624,085</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 9 &#x2013; NET LOSS PER SHARE</u></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of Common Stock outstanding plus all potentially dilutive shares of Common Stock outstanding during the period. Such potentially dilutive shares of Common Stock consist of options and warrants and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Three and Six months ended</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">June 30, 2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">June 30, 2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 70%; text-align: justify;">Stock options</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">23,402,100</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">20,668,657</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Warrants</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">3,115,905</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">12,060,571</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">26,518,005</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">32,729,228</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 10 &#x2013; STOCKHOLDERS&#x2019; EQUITY</u></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Preferred Stock</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">At June 30, 2017, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred stock were issued or outstanding.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  14; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->14
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Common Stock</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">At June 30, 2017, we had 350,000,000 shares of Common Stock authorized for issuance, of which 204,027,142 shares of Common Stock were issued and outstanding.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Issuances During 2017</u></i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the three months ended June 30, 2017, certain individuals exercised stock options to purchase 5,000 shares of Common Stock for $20,050 in cash. During the six months ended June 30, 2017, certain individuals exercised stock options to purchase 100,046 shares of Common Stock for $212,360 in cash.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Issuances During 2016</u></i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On January 6, 2016, we entered into an underwriting agreement with Goldman Sachs &#38; Co. and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of Common Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $134,864,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on January 12, 2016 and we issued 17,424,242 shares of Common Stock.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the three months ended June 30, 2016, certain individuals exercised stock options to purchase 77,123 shares of Common Stock for $191,592 in cash. During the six months ended June 30, 2016, certain individuals exercised stock options to purchase 417,168 shares of Common Stock for $978,042 in cash.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><u>Warrants to Purchase Common Stock</u></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As of June 30, 2017, we had warrants outstanding to purchase an aggregate of 3,115,905 shares of Common Stock with a weighted-average contractual remaining life of approximately 2.3 years, and exercise prices ranging from $0.24 to $8.20 per share, resulting in a weighted average exercise price of $2.58 per share.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-size: 10pt;">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant. During the six months ended June 30, 2017, we granted warrants to purchase 125,000 shares of Common Stock to outside consultants at an exercise price of $6.83 per share. The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of five years; volatility of 63.24%; risk free rate of 1.47%; and dividend yield of 0%. The grant date fair value of the warrants was $3.67 per share. The warrants are vesting ratably over a 12-month period and have an expiration date of March 15, 2022.</font> During the six months ended June 30, 2016, we granted warrants to purchase 245,000 shares of Common Stock to outside consultants at a weighted average exercise price of $7.90 per share. The weighted average grant date fair value of these warrants was $4.78 per share. The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of five years; volatility of 74.10%-74.15%; risk free rate of 1.04%-1.28%; and dividend yield of 0%. These warrants vest and have expiration dates as follows: warrants to purchase 75,000 shares of Common Stock vested on April 21, 2016 and have an expiration date of April 21, 2021, warrants to purchase 50,000 shares of Common Stock vest ratably over a 24-month period and have an expiration date of April 21, 2021, and warrants to purchase 120,000 shares of Common Stock vest ratable over a 12-month period and have an expiration date of January 21, 2021.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  15; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->15
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the three months ended June 30, 2017 and 2016, we recorded $68,089 and $556,125, respectively, and during the six months ended June 30, 2017 and 2016 we recorded $115,774 and $683,590, respectively, as share-based compensation expense in the accompanying consolidated financial statements related to warrants. As of June 30, 2017, unamortized costs associated with these warrants totaled approximately $420,000.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In May 2013, we entered into a consulting agreement with Sancilio and Company, Inc., or SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain FDA approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares of Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in;"></td>
            <td style="width: 0.25in;">1.</td>
            <td style="text-align: justify;">283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;</td>
        </tr>
    </table>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in;"></td>
            <td style="width: 0.25in;">2.</td>
            <td style="text-align: justify;">283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the three months ended June 30, 2017 and 2016, we recorded $0 and $38,509, respectively, as non-cash compensation in the accompanying consolidated financial statements related to this warrant. During the six months ended June 30, 2017 and 2016, we recorded $0 and $77,026, respectively, as non-cash compensation in the accompanying consolidated financial statements related to this warrant. As of June 30, 2016, this warrant was fully amortized; and</td>
        </tr>
    </table>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in;"></td>
            <td style="width: 0.25in;">3.</td>
            <td style="text-align: justify;">283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will occur in the near future.</td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to SCI for services to be rendered over approximately five years beginning in May 2012. The warrants vested upon issuance. Services provided are to include (a) services in support of our drug development efforts, including services in support of our ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. During both the three months ended June 30, 2017 and 2016 and both the six months ended June 30, 2017 and 2016, we recorded $64,449 and $128,898, respectively, as non-cash compensation expense with respect to these warrants in the accompanying consolidated statements of operations. The contract will expire upon the commercial manufacture of a drug product. As of June 30, 2017, the SCI warrants issued in 2013 and 2012 were fully amortized.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  16; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->16
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the three months ended June 30, 2017, certain individuals exercised warrants to purchase 666,666 shares of Common Stock for $1,338,999 in cash. In addition, during the three months ended June 30, 2017, certain individuals exercised warrants to purchase 6,590,000 shares of Common Stock pursuant to the warrants&#x2019; cashless exercise provisions, wherein 4,762,208 shares of Common Stock were issued. During the three months ended June 30, 2016, certain individuals exercised warrants to purchase 161,372 shares of Common Stock for $63,000 in cash.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the six months ended June 30, 2017, certain individuals exercised warrants to purchase 2,476,666 shares of Common Stock for $3,798,999 in cash. In addition, during the six months ended June 30, 2017, certain individuals exercised warrants to purchase 6,590,000 shares of Common Stock pursuant to the warrants&#x2019; cashless exercise provisions, wherein 4,762,208 shares of Common Stock were issued. During the six months ended June 30, 2016, certain individuals exercised warrants to purchase 722,744 shares of Common Stock for $1,373,000 in cash.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><u>Options to Purchase Common Stock</u></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of June 30, 2017, there were non-qualified stock options to purchase 18,611,959 shares of Common Stock outstanding under the 2009 Plan. As of June 30, 2017, there were 2,139,503 shares of Common Stock available to be issued under the 2009 Plan.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of June 30, 2017, there were non-qualified stock options to purchase 4,790,141 shares of Common Stock outstanding under the 2012 Plan. As of June 30, 2017, there were 5,128,333 shares of Common Stock available to be issued under the 2012 Plan.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  17; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->17
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model for options granted during the six months ended June 30, 2017 and 2016 are set forth in the table below.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="padding-right: 5.4pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Six Months Ended</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="padding-right: 5.4pt; width: 44%;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 27%; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">June 30, 2017</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 3%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 26%; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">June 30, 2016</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="padding-right: 5.4pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Risk-free interest rate</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1.84-2.01%</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&nbsp;</td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1.26-1.70%</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="padding-right: 5.4pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Volatility</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">61.56-63.95%</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&nbsp;</td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">70.44-71.22%</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="padding-right: 5.4pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Term (in years)</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">5.5-6.25</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&nbsp;</td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">6.25</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="padding-right: 5.4pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Dividend yield</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.00%</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&nbsp;</td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.00%</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A summary of activity under the 2009 and 2012 Plans and related information follows:</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Number of Shares Underlying Stock Options</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted Average Exercise Price</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted
                <br>Average
                <br>Remaining
                <br>Contractual
                <br>Life in Years</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Aggregate Intrinsic Value</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 40%;">Balance at December 31, 2016</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">21,767,854</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">3.56</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">5.8</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">60,495,730</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in;">Granted</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2,184,500</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">6.61</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in;">Exercised</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(100,046</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">2.12</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">437,667</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in;">Expired/Forfeited</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(450,208</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">6.54</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt;">Balance at June 30, 2017</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">23,402,100</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="padding-bottom: 2pt; text-align: left;">$</td>
            <td style="padding-bottom: 2pt; text-align: right;">3.79</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt; text-align: right;">5.6</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="padding-bottom: 2pt; text-align: left;">$</td>
            <td style="padding-bottom: 2pt; text-align: right;">52,165,428</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Vested and Exercisable at June 30, 2017</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">18,731,808</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3.13</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4.9</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">51,750,547</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td>Unvested at June 30, 2017</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4,670,292</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">6.43</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">8.8</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">414,881</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">At June 30,
    2017, our outstanding stock options had exercise prices ranging from $0.10 to $8.92 per share. The weighted average grant
    date fair value per share of options granted was $3.82 and $5.08 during the six months ended June 30, 2017 and 2016,
    respectively. Share-based compensation expense for options recognized in our results of operations is based on vested awards.
    Share-based compensation expense related to options for the three months ended June 30, 2017 and 2016 was $1,505,625 and
    $4,160,071, respectively, and for the six months ended June 30, 2017 and 2016 was $2,806,685 and $8,311,330, respectively. At
    June 30, 2017, total unrecognized estimated compensation expense related to unvested options granted prior to that date was
    approximately $14,365,000 which may be adjusted for future changes in forfeitures. This cost is expected to be recognized
    over a weighted-average period of 2.4 years. No tax benefit was realized due to a continued pattern of operating losses.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 11 &#x2013; INCOME TAXES</u></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2017 as a result of (a) the losses recorded during the six months ended June 30, 2017, (b) additional losses expected for the remainder of 2017, and/or (c) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#x201C;more likely than not&#x201D; that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2017, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  18; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->18
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 12 &#x2013; RELATED PARTIES</u></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of our company since July 2015. During the three months ended June 30, 2017 and 2016, we were billed by Catalent approximately $1,754,000 and $614,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. During the six months ended June 30, 2017 and 2016, we were billed by Catalent approximately $2,460,000 and $2,079,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of June 30, 2017 and December 31, 2016, there were amounts due to Catalent of approximately $1,132,000 and $57,000, respectively.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 13 - BUSINESS CONCENTRATIONS</u></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We purchase our products from several suppliers with approximately 100% and 96% of our purchases supplied from one vendor for both the three and six months ended June 30, 2017 and 2016, respectively.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. As a result of developments in the pharmaceutical industry that negatively affected independent pharmacies, including such pharmacies&#x2019; reliance on third-party payors, in 2016, we identified that payment periods for our retail pharmacy distributors were becoming longer than in prior years. As a result, during the third quarter of 2016, we centralized the distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies and minimize business risk exposure to any one retail pharmacy. During the third quarter of 2016, we entered into new distribution agreements with our retail pharmacy distributors to effectuate this centralization which were effective September 1, 2016.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the six months ended June 30, 2017, five customers each generated more than 10% of our total revenues and during the six months ended June 30, 2016 three customers each generated more than 10% of our total revenues. Revenue generated from five major customers combined accounted for approximately 70% of our recognized revenue for the six months ended June 30, 2017 and revenue generated from three major customers combined accounted for approximately 60% of our recognized revenue for the six months ended June 30, 2016. During the six months ended June 30, 2017, Pharmacy Innovations TX generated approximately $834,000 of our revenue, Pharmacy Innovations PA generated approximately $1,863,000 of our revenue, AmerisourceBergen generated approximately $1,053,000 of our revenue, Cardinal Health generated approximately $1,119,000 of our revenue and McKesson Corporation generated approximately $907,000 of our revenue. During the six months ended June 30, 2016, Woodstock Pharmaceutical and Compounding generated approximately $2,237,000 of our revenue; Medical Center Pharmacy generated approximately $1,540,000 of our revenue and Due West Pharmacy generated approximately $1,863,000 of our revenue.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 14&#x2013; COMMITMENTS AND CONTINGENCIES</u></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Operating Lease</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  19; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->19
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The rental expense related to our current lease during the three months ended June 30, 2017 and 2016 was approximately $265,000 and $182,000, respectively. The rental expense related to our current lease during the six months ended June 30, 2017 and 2016 was approximately $515,000 and $300,000, respectively.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As of June 30, 2017, future minimum rental payments on non-cancelable operating leases are as follows:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="border-bottom: Black 1pt solid; text-align: center;">Years Ending December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td colspan="2">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 73%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2017 (6 months)</font>
            </td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 4%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 20%; text-align: right;">449,264</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">2018</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">951,194</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">2019</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,094,116</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">2020</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,113,069</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: left;">2021</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">943,127</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total minimum lease payments</font>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2.5pt double; text-align: right;">4,550,770</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0;">&nbsp;</p>
    <p style="margin: 0;">
        <font style="text-decoration: underline;">Legal Proceedings</font>
    </p>
    <p style="text-align: justify; text-indent: 0.5in;">On April 17, 2017, a securities class action lawsuit was filed against our company and certain of our officers and directors in the U.S. District Court for the Southern District of Florida (Case No. 9:17-cv-80473-RLR) that purports to state a claim for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, based on statements made by the defendants concerning the NDA for TX-004HR. The complaint sought unspecified damages, interest, attorneys&#x2019; fees and other costs. On July 18, 2017, the complaint was voluntarily dismissed by the lead plaintiff without prejudice. We and certain of our officers and directors are also subject to two shareholder derivative lawsuits regarding the NDA for TX-004HR, one filed in the U.S. District Court for the Southern District of Florida on May 30, 2017 (Case No. 9:17-cv-80686-RLR) and one filed in Florida state court in Palm Beach County on June 5, 2017 (Case No. 502017CA006289XXXXMB). We believe these lawsuits to be without merit and intend to vigorously defend against them. The derivative lawsuits are in the very early stages and, at this time, no assessment can be made as to their likely outcome or whether the outcome will be material to us.</p>
    <p style="text-indent: 0.5in;">&nbsp;</p>
    <!-- Field: Page; Sequence:  20; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->20
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><a name="txmda005"></a>Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>General</u></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The following discussion and analysis provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read together with our consolidated financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission, or the SEC, on February 28, 2017, or the Annual Report, including the audited financial statements and notes included therein. The reported results will not necessarily reflect future results of operations or financial condition.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, this Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#x201C;believes,&#x201D; &#x201C;hopes,&#x201D; &#x201C;may,&#x201D; &#x201C;anticipates,&#x201D; &#x201C;should,&#x201D; &#x201C;intends,&#x201D; &#x201C;plans,&#x201D; &#x201C;will,&#x201D; &#x201C;expects,&#x201D; &#x201C;estimates,&#x201D; &#x201C;projects,&#x201D; &#x201C;positioned,&#x201D; &#x201C;strategy&#x201D; and similar expressions and are based on assumptions and assessments made in light of management&#x2019;s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are made as of the date of this Quarterly Report on Form 10-Q and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled &#x201C;Risk Factors&#x201D; in our Annual Report, and include the following: our ability to resolve the deficiencies identified by the U.S. Food and Drug Administration, or FDA, in our new drug application, or NDA, for our TX-004HR product candidate and the time frame associated with such resolution; whether we will be able to prepare an amended NDA for our TX-004HR product candidate and, if prepared, whether the FDA will accept and approve the NDA; our ability to maintain or increase sales of our products; our ability to develop and commercialize our hormone therapy drug candidates and obtain additional financing necessary therefor; whether we will be able to prepare an NDA for our TX-001HR product candidate and, if prepared, whether the FDA will accept and approve the NDA; the length, cost and uncertain results of our clinical trials, including any additional clinical trials that the FDA may require in connection with TX-004HR; the potential of adverse side effects or other safety risks that could preclude the approval of our hormone therapy drug candidates; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Throughout this Quarterly Report on Form 10-Q, the terms &#x201C;we,&#x201D; &#x201C;us,&#x201D; &#x201C;our,&#x201D; &#x201C;TherapeuticsMD,&#x201D; or &#x201C;our company&#x201D; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  21; Options:  NewSection; Value:  21; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->21
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>Overview</u></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">We are a women&#x2019;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. With our SYMBODA&#x2122; technology, we are developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, iron supplements.</p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our common stock, par value $0.001 per share, or Common Stock, is traded on the NYSE MKT under the symbol &#x201C;TXMD.&#x201D; We maintain websites at <i>www.therapeuticsmd.com</i>, <i>www.vitamedmd.com</i>, <i>www.vitamedmdrx.com</i>, and <i>www.bocagreenmd.com</i>. The information contained on our websites or that can be accessed through our websites does not constitute part of this Quarterly Report on Form 10-Q.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><i><u>Research and Development</u></i></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have obtained FDA acceptance of our Investigational New Drug, or IND, applications to conduct clinical trials for five of our proposed hormone therapy drug products: TX-001HR, our oral combination of progesterone and estradiol; TX-002HR, our oral progesterone alone; TX-003HR, our oral estradiol alone; and TX-004HR, our applicator-free vaginal estradiol softgel with estradiol alone and TX-006HR our combination estradiol and progesterone product in a topical cream form. Our IND applications for TX-002HR and TX-003HR are currently inactive.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In December 2016, we announced positive top-line results from the recently completed the REPLENISH Trial, our phase 3 clinical trial of TX-001HR, our bio-identical hormone therapy combination of 17&#xDF;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate to severe vasomotor symptoms, or VMS, due to menopause in post-menopausal women with an intact uterus. In December 2015, we completed the REJOICE Trial, our phase 3 clinical of TX-004HR, our applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of vulvar and vaginal atrophy, or VVA, in post-menopausal women with vaginal linings that do not receive enough estrogen. In the fourth quarter of 2016 we submitted an IND application for TX-006HR, our combination estradiol and progesterone drug candidate in a topical cream form, and intend to commence phase 1 clinical trials of this drug candidate as early as the second half of 2017. In July 2014, we suspended enrollment in the SPRY Trial, our phase 3 clinical trial for TX-002HR, our oral progesterone alone drug candidate, and, in October 2014, we stopped the trial in order to update the phase 3 protocol based on discussions with the FDA. We have currently suspended further development of this drug candidate to prioritize our leading drug candidates. We have no current plans to conduct clinical trials for TX-003HR, our oral estradiol alone drug candidate, and the IND application for this drug candidate is currently inactive.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;"><i>TX-001HR</i></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-001HR is our bio-identical hormone therapy combination of 17&#xDF;- estradiol and progesterone in a single, oral softgel drug candidate for the treatment of moderate to severe VMS due to menopause, including hot flashes, night sweats and sleep disturbances in post-menopausal women with an intact uterus. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone bioidentical to the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  22; Value:  21; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->22
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On September 5, 2013, we began enrollment in the REPLENISH Trial, a multicenter, double-blind, placebo-controlled, phase 3 clinical trial of TX-001HR in postmenopausal women with an intact uterus. The trial was designed to evaluate the efficacy of TX-001HR for the treatment of moderate to severe VMS due to menopause and the endometrial safety of TX-001HR. Patients were assigned to one of five arms, four active and one placebo, and received study medication for 12 months. The primary endpoint for the reduction of endometrial hyperplasia was an incidence of endometrial hyperplasia of less than 1% at 12 months, as determined by endometrial biopsy. The primary endpoint for the treatment of moderate to severe VMS was the mean change of frequency and severity of moderate to severe VMS at weeks four and 12 compared to placebo, as measured by the number and severity of hot flashes. Only subjects experiencing a minimum daily frequency of seven moderate to severe hot flashes at screening were included in the VMS analysis, while all subjects were included in the endometrial hyperplasia analysis. The secondary endpoints included reduction in sleep disturbances and improvement in quality of life measures, night sweats and vaginal dryness, measured at 12 weeks, six months and 12 months. The trial evaluated 1,835 patients between 40 and 65 years old at 111 sites. On December 5, 2016, we announced positive topline data for the REPLENISH Trial.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The REPLENISH Trial evaluated four doses of TX-001HR and placebo; the doses studied were:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 48px;">&nbsp;</td>
            <td style="width: 24px; font-size: 10pt;">
                <font style="font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-size: 10pt;">17&#xDF;-estradiol 1 mg/progesterone 100 mg (n = 416) </font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="font-size: 10pt;">&nbsp;</td>
            <td style="text-align: justify; font-size: 10pt;">&nbsp;</td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 48px;">&nbsp;</td>
            <td style="width: 24px; font-size: 10pt;">
                <font style="font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-size: 10pt;">17&#xDF;-estradiol 0.5 mg/progesterone 100 mg (n = 423) </font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="font-size: 10pt;">&nbsp;</td>
            <td style="text-align: justify; font-size: 10pt;">&nbsp;</td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 48px;">&nbsp;</td>
            <td style="width: 24px; font-size: 10pt;">
                <font style="font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-size: 10pt;">17&#xDF;-estradiol 0.5 mg/progesterone 50 mg (n = 421) </font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="font-size: 10pt;">&nbsp;</td>
            <td style="text-align: justify; font-size: 10pt;">&nbsp;</td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 48px;">&nbsp;</td>
            <td style="width: 24px; font-size: 10pt;">
                <font style="font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-size: 10pt;">17&#xDF;-estradiol 0.25 mg/progesterone 50 mg (n = 424) </font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="font-size: 10pt;">&nbsp;</td>
            <td style="text-align: justify; font-size: 10pt;">&nbsp;</td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 48px;">&nbsp;</td>
            <td style="width: 24px; font-size: 10pt;">
                <font style="font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-size: 10pt;">Placebo (n = 151) </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The REPLENISH Trial results demonstrated:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#x25CF; TX-001HR estradiol 1 mg/progesterone 100 mg and TX-001HR estradiol 0.5 mg/progesterone 100 mg both achieved all four of the co-primary efficacy endpoints and the primary safety endpoint.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#x25CF; TX-001HR estradiol 1 mg/progesterone 100 mg and TX-001HR estradiol 0.5 mg/progesterone 100 mg both demonstrated a statistically significant and clinically meaningful reduction from baseline in both the frequency and severity of hot flashes compared to placebo.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#x25CF; TX-001HR estradiol 0.5 mg/progesterone 50 mg and TX-001HR estradiol 0.25 mg/progesterone 50 mg were not statistically significant at all of the co-primary efficacy endpoints. The estradiol 0.25 mg/progesterone 50 mg dose was included in the clinical trial as a non-effective dose to meet the recommendation of the FDA guidance to identify the lowest effective dose.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#x25CF; The incidence of consensus endometrial hyperplasia or malignancy was 0 percent across all four TX-001HR doses, meeting the recommendations established by the FDA&#x2019;s draft guidance.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As outlined in the FDA guidance, the co-primary efficacy endpoints in the REPLENISH Trial were the change from baseline in the number and severity of hot flashes at weeks four and 12 as compared to placebo. The primary safety endpoint was the incidence of endometrial hyperplasia with up to 12 months of treatment. General safety was also evaluated.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  23; Value:  21; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->23
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The results of the REPLENISH Trial are summarized in the table below (p-values of &lt; 0.05 meet FDA guidance and support evidence of efficacy):</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="border-left: black 1pt solid; border-right: black 1pt solid; border-top: black 1pt solid; padding-left: 1pt; padding-right: 1pt; padding-top: 10pt; text-align: center;" colspan="6">
                <font style="font-size: 10pt;">Replenish Trial Co-Primary Efficacy Endpoints: Mean Change in Frequency and Severity of Hot Flashes Per Week Versus Placebo at Weeks 4 and 12, VMS-MITT Population</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt; width: 36%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 12%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 12%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 12%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 12%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; width: 16%; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Estradiol/Progesterone</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">1 mg/100 mg</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.5 mg/100 mg</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.5 mg/50 mg</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.25 mg/50 mg</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">Placebo</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">(n = 141)</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">(n = 149)</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">(n = 147)</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">(n = 154)</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">(n = 135)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">Frequency</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Week 4 P-value versus placebo</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.013</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.141</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.001</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Week 12 P-value versus placebo</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0.002</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">Severity</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Week 4 P-value versus placebo</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.031</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.005</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.401</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.100</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Week 12 P-value versus placebo</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.018</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.096</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-left: black 1pt solid; border-top: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-top: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-top: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-top: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-top: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; border-top: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="border-left: black 1pt solid; border-right: black 1pt solid; padding-left: 1pt; padding-right: 1pt; text-align: center;" colspan="6">
                <font style="font-size: 10pt;">Replenish Trial Primary Safety Endpoint: Incidence of Consensus Endometrial Hyperplasia or Malignancy up to 12 months, Endometrial Safety Population&#x166;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Endometrial Hyperplasia</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/280)</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/303)</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/306)</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/274)</font>
            </td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/92)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">MITT = Modified intent to treat</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 31.55pt 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#x166;Per FDA, consensus hyperplasia refers to the concurrence of two of the three pathologists be accepted as the final diagnosis</p>
    <p style="margin: 0pt 31.55pt 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">We have a pre-NDA meeting for TX-001HR scheduled with the FDA at the end of August 2017.&nbsp; We anticipate that we will submit an NDA for TX-001HR to the FDA in the fourth quarter of 2017. Assuming that the NDA is accepted 60 days thereafter and an FDA review period of ten months from the receipt date to the Prescription Drug User Fee Act, or PDUFA, date for a non-new molecular entity, the NDA for TX-001HR could be approved by the FDA as soon as the third quarter of 2018.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;"><i>TX-002HR</i></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body. We believe it will be similarly effective to traditional treatments, but may demonstrate efficacy at lower dosages. In January 2014, we began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY Trial encountered enrollment challenges because of Institutional Review Board approved clinical trial protocols and FDA inclusion and exclusion criteria. In July 2014, we suspended enrollment and in October 2014 we stopped the SPRY Trial in order to update the phase 3 protocol based on discussions with the FDA. Our IND is currently in inactive status. We are considering updating the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe that the updated phase 3 protocol, if proposed by us and approved by the FDA, would allow us to mitigate the enrollment challenges in, and shorten the duration of, the SPRY Trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol if we propose it. We have currently suspended further development of this drug candidate to prioritize our leading drug candidates.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  24; Value:  21; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->24
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;"><i>TX-004HR</i></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">TX-004HR is our applicator free vaginal estradiol softgel drug candidate for the treatment of VVA in post-menopausal women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset of action with less systemic exposure, inferring a greater probability of dose administration to the target tissue, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments. TX-004HR features our SYMBODA<sup>TM</sup> technology. This allows for the production of cohesive, stable formulations and provides content uniformity and accuracy of dosing strengths for TX-004HR. We initiated the REJOICE Trial, a randomized, multicenter, double-blind, placebo-controlled phase 3 clinical trial during the third quarter of 2014 to assess the safety and efficacy of three doses &#x2013; 25 mcg, 10 mcg and 4 mcg (compared to placebo) &#x2013; of TX-004HR for the treatment of moderate to severe dyspareunia, or painful intercourse, as a symptom of VVA due to menopause.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On December 7, 2015, we announced positive top-line results from the REJOICE Trial. The pre-specified four co-primary efficacy endpoints were the changes from baseline to week 12 versus placebo in the percentage of vaginal superficial cells, percentage of vaginal parabasal cells, vaginal pH and severity of participants&#x2019; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA. The trial enrolled 764 postmenopausal women (40 to 75 years old) experiencing moderate to severe dyspareunia at approximately 89 sites across the United States and Canada. Trial participants were randomized to receive either TX-004HR at 25 mcg (n=190), 10 mcg (n=191), or 4 mcg (n=191) doses or placebo (n=192) for a total of 12 weeks, all administered once daily for two weeks and then twice weekly (approximately three to four days apart) for ten weeks. The 25 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 10 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 4 mcg dose of TX-004HR also demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoints of vaginal superficial cells, vaginal parabasal cells, and vaginal pH; the change from baseline compared to placebo in the severity of dyspareunia was statistically significant at the p = 0.0149 level. The FDA has previously indicated to us that in order to approve the drug based on a single trial, the trial would need to show statistical significance at the 0.01 level or lower for each endpoint, and that a trial that is merely statistically significant at a higher level may not provide sufficient evidence to support an NDA filing or approval of a drug candidate where the NDA relies on a single clinical trial. Statistical improvement over placebo was also observed for all three doses at the first assessment at week two and sustained through week 12. Vaginal dryness was a pre-specified key secondary endpoint. The 25 mcg and 10 mcg doses of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoint of vaginal dryness. The 4 mcg dose of TX-004HR demonstrated statistically significant results at the p = 0.0014 level compared to placebo. The pharmacokinetic data for all three doses demonstrated negligible to very low systemic absorption of 17 beta estradiol, estrone and estrone conjugated, supporting the previous phase 1 trial data. TX-004HR was well tolerated, and there were no clinically significant differences compared to placebo-treated participants with respect to adverse events. There were no drug-related serious adverse events reported.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We submitted the NDA for TX-004HR with the FDA on July 7, 2016. The FDA determined that the NDA was sufficiently complete to permit a substantive review and accepted the NDA for filing with the PDUFA target action date for the completion of the FDA&#x2019;s review of May 7, 2017. The NDA submission was supported by the complete TX-004HR clinical program, including positive results of the phase 3 REJOICE Trial. The NDA submission included all three doses of TX-004HR (4 mcg, 10 mcg and 25 mcg) that were evaluated in the REJOICE Trial. If approved, the 4 mcg formulation would represent a lower effective dose than the currently available VVA therapies approved by the FDA.</p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On May 5, 2017, we received a Complete Response Letter, or CRL, from the FDA regarding the NDA for TX-004HR. In the CRL, the only approvability concern raised by the FDA was the lack of long-term endometrial safety data for TX-004HR beyond the 12-weeks studied in the phase 3 REJOICE Trial. The CRL did not identify any issues related to the efficacy of TX-004HR and did not identify any approvability issues related to chemistry, manufacturing and controls. We believe that the NDA was approvable as filed and have been engaged in discussions with the FDA to address the concerns raised by the FDA in the CRL.</p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  25; Value:  21; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->25
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On June 14, 2017, we participated in a Type A Post-Action Meeting with the Division of Bone, Reproductive, and Urologic Products (DBRUP) of the FDA to discuss the CRL. The meeting enabled us to present new information that we believe could address concerns raised by the FDA in the CRL and positively affect the status of the NDA for TX-004HR. We have received the minutes of the meeting and, per the FDA&#x2019;s request, have formally submitted the new information for consideration related to the NDA for TX-004HR. We continue to have a productive dialogue with the FDA related to its review of this information but have not yet received a formal timeline from the FDA for a conclusion of such review. If we are not able to establish a reasonable timeline with the FDA to address its concerns, we reserve the right to pursue the FDA&#x2019;s formal dispute resolution process regarding the NDA for TX-004HR.</p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As of June 30, 2017, we had 17 issued patents, which included 13 utility patents that relate to our combination progesterone and estradiol formulations, two utility patents that relate to TX-004HR, which establish an important intellectual property foundation for TX-004HR, one utility patent that relates to a pipeline transdermal patch technology, and one utility patent that relates to our OPERA<sup>&#xAE;</sup> information technology platform.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>Research and Development Expenses</i></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A significant portion of our operating expenses to date have been incurred in research and development activities. Research and development expenses relate primarily to the discovery and development of our drug candidates. Our business model is dependent upon our company continuing to conduct a significant amount of research and development. Our research and development expenses consist primarily of expenses incurred under agreements with contract research organizations, or CROs, investigative sites and consultants that conduct our clinical trials and a substantial portion of our preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing and controls capabilities, and acquiring clinical trial materials; and costs associated with other research activities and regulatory approvals. Other research and development costs listed below consist of costs incurred with respect to drug candidates that have not received IND application approval from the FDA.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We make payments to the CROs based on agreed upon terms that may include payments in advance of a study starting date. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed in future research and development activities are capitalized, and were $0 at June 30, 2017 and $228,933 at December 31, 2016 which were included in other current assets on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The following table indicates our research and development expense by project/category for the periods indicated:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Three Months Ended
                <br>June 30,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Six Months Ended
                <br>June 30,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 39%; text-align: justify;">TX 001-HR</td>
            <td style="width: 2%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">5,377</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 2%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">8,324</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 2%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">8,905</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">17,350</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">TX 002-HR</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">TX 004-HR</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2,767</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2,676</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4,712</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5,113</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Other research and development</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">572</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">2,841</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">2,824</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">6,475</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; text-align: justify;">Total</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">8,716</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">13,841</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">16,441</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">28,938</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Research and development expenditures will continue to be incurred as we continue development of our drug candidates and advance the development of our proprietary pipeline of novel drug candidates. We expect to incur ongoing research and development costs as we develop our drug pipeline, continue stability testing and validation on our drug candidates, prepare regulatory submissions and work with regulatory authorities on existing submissions.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  26; Value:  21; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->26
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The costs of clinical trials may vary significantly over the life of a project owing to factors that include, but are not limited to, the following: per patient trial costs; the number of patients that participate in the trials; the number of sites included in the trials; the length of time each patient is enrolled in the trial; the number of doses that patients receive; the drop-out or discontinuation rates of patients; the amount of time required to recruit patients for the trial; the duration of patient follow-up; and the efficacy and safety profile of the drug candidate. We base our expenses related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties. Research and development expenditures for the drug candidates will continue after the trial completes for on-going stability and laboratory testing, regulatory submission and response work.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>Results of Operations</u></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Three months ended June 30, 2017 compared with three months ended June 30, 2016</u></i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Three Months Ended
                <br>June 30,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: justify;" colspan="2">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Change</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 53%; text-align: justify;">Revenues, net</td>
            <td style="width: 2%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">4,250</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">4,403</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">(153</td>
            <td style="width: 1%; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Cost of goods sold</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">682</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,130</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(448</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Operating expenses</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">23,398</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">24,484</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(1,086</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating loss</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(19,830</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(21,211</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(1,381</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Other income, net</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">153</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">117</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">36</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; text-align: justify;">Net loss</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(19,677</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(21,094</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(1,417</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><u>Revenues and Cost of Goods Sold</u></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Revenues for the three months ended June 30, 2017 decreased approximately $153,000, or 3%, to approximately $4,250,000, compared with approximately $4,403,000 for the three months ended June 30, 2016. This decrease was primarily attributable to a decrease in the number of units sold. Cost of goods sold decreased approximately $448,000, or 40%, to approximately $682,000 for the three months ended June 30, 2017, compared with approximately $1,130,000 for the three months ended June 30, 2016. Our gross margin was approximately 84% and 74% for the three months ended June 30, 2017 and 2016, respectively. The increase in gross margin percentage was primarily attributable to the centralization of the distribution channel for both our retail pharmacy distributors and wholesale distributors, which, among other things, lowered the costs to package, prepare and deliver our products to customers.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><u>Operating Expenses</u></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our principal operating costs include the following items as a percentage of total operating expenses.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Three Months Ended
                <br>June 30,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 64%; text-align: justify;">Research and development costs</td>
            <td style="width: 2%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 9%; text-align: right;">37.2</td>
            <td style="width: 1%; text-align: left;">%</td>
            <td style="width: 2%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 9%; text-align: right;">56.5</td>
            <td style="width: 1%; text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Human resource related costs including salaries, benefits and taxes</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">24.7</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">24.8</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Sales and marketing costs, excluding human resource costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">24.5</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">8.1</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Professional fees for legal, accounting and consulting</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5.1</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">3.5</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Other operating expenses</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">8.5</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">7.1</td>
            <td style="text-align: left;">%</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  27; Value:  21; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->27
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Operating expenses decreased by approximately $1,086,000, or 4%, to approximately $23,398,000 for the three months ended June 30, 2017, from approximately $24,484,000 for the three months ended June 30, 2016 as a result of the following items:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Three Months Ended
                <br>June 30,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td colspan="2">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Change</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; width: 53%; text-align: justify; text-indent: -0.125in;">Research and development costs</td>
            <td style="width: 2%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">8,716</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">13,841</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 9%; text-align: right;">(5,125</td>
            <td style="width: 1%; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">Human resources related costs, including salaries, benefits and taxes</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5,785</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">6,074</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(289</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">Sales and marketing, excluding human resource costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5,729</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,976</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">3,753</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">Professional fees for legal, accounting and consulting</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,184</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">864</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">320</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">Other operating expenses</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">1,984</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">1,729</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">255</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">Total operating expenses</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">23,398</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">24,484</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(1,086</td>
            <td style="padding-bottom: 2pt; text-align: left;">)&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Research and development costs for the three months ended June 30, 2017 decreased by approximately $5,125,000, or 37%, to approximately $8,716,000, compared with $13,841,000 for the three months ended June 30, 2016. Research and development costs include costs related to clinical trials as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and development activities. Research and development costs decreased as a direct result of the completion of the REPLENISH Trial for TX-001HR, our combination estradiol and progesterone drug candidate. Research and developments costs during the three months ended June 30, 2017 included the following research and development projects.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the three months ended June 30, 2017 and the period from February 2013 (project inception) through June 30, 2017, we have incurred approximately $5,377,000 and $104,921,000, respectively, in research and development costs with respect to TX-001HR, our combination estradiol and progesterone drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the three months ended June 30, 2017 and the period April 2013 (project inception) through June 30, 2017, we have incurred approximately $0 and $2,525,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the three months ended June 30, 2017 and the period from August 2014 (project inception) through June 30, 2017, we have incurred approximately $2,767,000 and $37,518,000, respectively, in research and development costs with respect to TX-004HR, our applicator-free vaginal estradiol softgel drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">For a discussion of the nature of efforts and steps necessary to complete these projects, see &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation&#x201D; in our Annual Report and &#x201C;Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations &#x2013; Overview &#x2013; Research and Development&#x201D; above. For a discussion of the risks and uncertainties associated with completing development of our products, see &#x201C;Item 1A. Risk Factors &#x2014; Risks Related to Our Business&#x201D; in our Annual Report. For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &#x201C;&#x2014; Liquidity and Capital Resources&#x201D; below. For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &#x201C;Item 1. Business &#x2014; Our Hormone Therapy Drug Candidates,&#x201D; and &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation&#x201D; in our Annual Report. Future milestones, including NDA submission dates and potential approval dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, scale-up and manufacturing activities.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  28; Value:  21; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->28
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Sales and marketing costs for the three months ended June 30, 2017 increased by approximately $3,753,000, or 190%, to approximately $5,729,000, compared with approximately $1,976,000 for the three months ended June 30, 2016, primarily as a result of increased expenses associated with sales and marketing efforts to support commercialization of our hormone therapy drug candidates, including costs related to outsourced sales personnel and their related expenses, coupled with an increase in employee incentives.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Other operating expense for the three months ended June 30, 2017 increased by approximately $255,000, or 15%, to approximately $1,984,000 compared with approximately $1,729,000 for the three months ended June 30, 2016, as a result of increased rent, information technology and other office expenses partially offset by decreased allowance for bad debt expense.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Human resource costs, including salaries, benefits and taxes, for the three months ended June 30, 2017 decreased by approximately $289,000, or 5%, to approximately $5,785,000, compared with approximately $6,074,000 for the three months ended June 30, 2016, primarily as a result of a decrease of approximately $1,816,000 in non-cash compensation expense included in this category related to employee stock option amortization, partially offset by an increase of approximately $1,527,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our hormone therapy drug candidates.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Professional fees for the three months ended June 30, 2017 increased by approximately $320,000, or 37%, to approximately $1,184,000, compared with approximately $864,000 for the three months ended June 30, 2016, primarily as a result of increased legal expenses.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Operating Loss</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the foregoing, our operating loss decreased approximately $1,381,000 to approximately $19,830,000 for the three months ended June 30, 2017, compared with approximately $21,211,000 for the three months ended June 30, 2016, primarily as a result of decreased research and development costs, partially offset by increased personnel costs, sales and marketing expenses to support commercialization of our hormone therapy drug candidates, including costs related to outsourced sales personnel and their related expenses, professional fees and other operating expenses as well a decrease in revenue.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future until our hormone therapy drug candidates are approved by the FDA and brought to market, although there is no assurance that we will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved, will be successful.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Other Income </u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Other non-operating income increased by approximately $36,000, or 31%, to approximately $153,000 for the three months ended June 30, 2017 compared with approximately $117,000 for the comparable period in 2016, primarily as a result of increased interest income.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Net Loss</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the net effects of the foregoing, net loss decreased approximately $1,417,000 to approximately $19,677,000 for the three months ended June 30, 2017, compared with approximately $21,094,000 for the three months ended June 30, 2016. Net loss per share of Common Stock, basic and diluted, was ($0.10) for the three months ended June 30, 2017, compared with ($0.11) for the three months ended June 30, 2016.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  29; Value:  21; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->29
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><i><u>Six months ended June 30, 2017 compared with six months ended June 30, 2016</u></i></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">
                <font style="color: black;">Six Months Ended
                    <br>June 30,</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: justify;" colspan="2">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">2017</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">2016</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">Change</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1px; padding-left: 5.4pt; text-align: justify;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">
                <font style="color: black;">(000s)</font>
            </td>
            <td style="padding-bottom: 1px; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 5.4pt; width: 61%; text-align: justify;">
                <font style="color: black;">Revenues, net</font>
            </td>
            <td style="width: 1%;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="color: black;">8,236</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">9,333</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">(1,097</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 5.4pt; text-align: justify;">
                <font style="color: black;">Cost of goods sold</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">1,341</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">2,239</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">(898</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1px; padding-left: 5.4pt; text-align: justify;">
                <font style="color: black;">Operating expenses</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="color: black;">48,011</font>
            </td>
            <td style="padding-bottom: 1px; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="color: black;">49,279</font>
            </td>
            <td style="padding-bottom: 1px; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="color: black;">(1,268</font>
            </td>
            <td style="padding-bottom: 1px; text-align: left;">
                <font style="color: black;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 5.4pt; text-align: justify;">
                <font style="color: black;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating loss</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">(41,116</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">)</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">(42,185</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">)</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">(1,069</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1px; padding-left: 5.4pt; text-align: justify;">
                <font style="color: black;">Other income, net</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="color: black;">283</font>
            </td>
            <td style="padding-bottom: 1px; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="color: black;">161</font>
            </td>
            <td style="padding-bottom: 1px; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="color: black;">122</font>
            </td>
            <td style="padding-bottom: 1px; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 3px; padding-left: 5.4pt; text-align: justify;">
                <font style="color: black;">Net loss</font>
            </td>
            <td style="padding-bottom: 3px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: right;">
                <font style="color: black;">(40,833</font>
            </td>
            <td style="padding-bottom: 3px; text-align: left;">
                <font style="color: black;">)</font>
            </td>
            <td style="padding-bottom: 3px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: right;">
                <font style="color: black;">(42,024</font>
            </td>
            <td style="padding-bottom: 3px; text-align: left;">
                <font style="color: black;">)</font>
            </td>
            <td style="padding-bottom: 3px;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: right;">
                <font style="color: black;">(1,191</font>
            </td>
            <td style="padding-bottom: 3px; text-align: left;">
                <font style="color: black;">)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><u>Revenues and Cost of Goods Sold</u></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><i>&nbsp;</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Revenues for the six months ended June 30, 2017 decreased approximately $1,097,000 or 12%, to approximately $8,236,000, compared with approximately $9,333,000 for the six months ended June 30, 2016. This decrease was primarily attributable to a decrease in the average net revenue per unit of our products, which was primarily related to higher estimates related to discounts and returns in 2017, partially offset by an increase in the number of units sold. Cost of goods sold decreased approximately $898,000, or 40%, to approximately $1,341,000 for the six months ended June 30, 2017, compared with approximately $2,239,000 for the six months ended June 30, 2016. Our gross margin was approximately 84% and 76% for the six months ended June 30, 2017 and 2016, respectively. The increase in gross margin percentage was primarily attributable to the centralization of the distribution channel for both our retail pharmacy distributors and wholesale distributors, which, among other things, lowered the costs to package, prepare and deliver our products to customers.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><u>Operating Expenses</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><i>&nbsp;</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Our principal operating costs include the following items as a percentage of total operating expenses.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">
                <font style="color: black;">Six Months Ended
                    <br>June 30,</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">2017</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">2016</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 74%; text-align: justify;">
                <font style="color: black;">Research and development costs</font>
            </td>
            <td style="width: 1%;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="color: black;">34.2</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">%</font>
            </td>
            <td style="width: 1%;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="color: black;">58.7</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">%</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">Human resource related costs, including salaries, benefits and taxes</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">23.9</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">%</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">23.0</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">%</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">Sales and marketing costs, excluding human resource costs</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">28.0</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">%</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">7.3</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">%</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">Professional fees for legal, accounting and consulting</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">5.8</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">%</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">4.4</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">%</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">Other operating expenses</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">8.1</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">%</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">6.6</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">%</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  30; Options:  NewSection; Value:  30; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->30
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Operating expenses decreased by approximately $1,268,000, or 3%, to approximately $48,011,000 for the six months ended June 30, 2017, from approximately $49,279,000 for the six months ended June 30, 2016 as a result of the following items:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">
                <font style="color: black;">Six Months Ended
                    <br>June 30,</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td colspan="2">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">2017</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">2016</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">Change</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">
                <font style="color: black;">(000s)</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; width: 61%; text-align: justify; text-indent: -0.125in;">
                <font style="color: black;">Research and development costs</font>
            </td>
            <td style="width: 1%;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="color: black;">16,441</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">28,938</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">(12,497</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">Human resources related costs,
                <font style="color: black;">including salaries, benefits and taxes</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">11,449</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">11,344</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">105</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">
                <font style="color: black;">Sales and marketing costs, excluding human resource costs</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">13,428</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">3,594</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">9,834</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">
                <font style="color: black;">Professional fees for legal, accounting and consulting</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">2,790</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">2,165</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">625</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">
                <font style="color: black;">Other operating expenses</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="color: black;">3,903</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="color: black;">3,238</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="color: black;">665</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in;">
                <font style="color: black;">Total operating expenses</font>
            </td>
            <td style="padding-bottom: 2.5pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: right;">
                <font style="color: black;">48,011</font>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 2.5pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: right;">
                <font style="color: black;">49,279</font>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 2.5pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="border-bottom: Black 3pt double; text-align: right;">
                <font style="color: black;">(1,268</font>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left;">
                <font style="color: black;">)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Research and development costs for the six months ended June 30, 2017 decreased by approximately $12,497,000, or 43%, to approximately $16,441,000, compared with $28,938,000 for the six months ended June 30, 2016. Research and development costs include costs related to clinical trials as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and development activities. Research and development costs decreased as a direct result of the completion of the REPLENISH Trial for TX-001HR, our combination estradiol and progesterone drug candidate. Research and developments costs during the six months ended June 30, 2017 included the following research and development projects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">During the six months ended June 30, 2017 and the period from February 2013 (project inception) through June 30, 2017, we have incurred approximately $8,905,000 and $104,921,000, respectively, in research and development costs with respect to TX-001HR, our combination estradiol and progesterone drug candidate.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">During the six months ended June 30, 2017 and the period April 2013 (project inception) through June 30, 2017, we have incurred approximately $0 and $2,525,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">During the six months ended June 30, 2017 and the period from August 2014 (project inception) through June 30, 2017, we have incurred approximately $4,712,000 and $37,518,000, respectively, in research and development costs with respect to TX-004HR, our applicator-free vaginal estradiol softgel drug candidate.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">For a discussion of the nature of efforts and steps necessary to complete these projects, see &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation&#x201D; in our Annual Report and &#x201C;Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations &#x2013; Overview &#x2013; Research and Development&#x201D; above. For a discussion of the risks and uncertainties associated with completing development of our products, see &#x201C;Item 1A. Risk Factors &#x2014; Risks Related to Our Business&#x201D; in our Annual Report. For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &#x201C;&#x2014; Liquidity and Capital Resources&#x201D; below. For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &#x201C;Item 1. Business &#x2014; Our Hormone Therapy Drug Candidates,&#x201D; and &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation&#x201D; in our Annual Report. Future milestones, including NDA submission dates and potential approval dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, scale-up and manufacturing activities.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Sales and marketing costs for the six months ended June 30, 2017 increased by approximately $9,834,000, or 274%, to approximately $13,428,000, compared with approximately $3,594,000 for the six months ended June 30, 2016, primarily as a result of increased expenses associated with sales and marketing efforts to support commercialization of our hormone therapy drug candidates, including costs related to outsourced sales personnel and their related expenses, coupled with an increase in employee incentives.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  31; Value:  30; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->31
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Other operating expense for the six months ended June 30, 2017 increased by approximately $665,000, or 21%, to approximately $3,903,000, compared with approximately $3,238,000 for the six months ended June 30, 2016, as a result of increased rent, information technology and other office expenses partially offset by decreased investor relations expenses and allowance for bad debt.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Human resource costs, including salaries, benefits and taxes, for the six months ended June 30, 2017 increased by approximately $105,000, or 1%, to approximately $11,449,000, compared with approximately $11,344,000 for the six months ended June 30, 2016, primarily as a result of an increase of approximately $3,593,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our hormone therapy drug candidates partially offset by a decrease of approximately $3,488,000 in non-cash compensation expense included in this category related to employee stock option amortization.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Professional fees for the six months ended June 30, 2017 increased by approximately $625,000, or 29%, to approximately $2,790,000, compared with approximately $2,165,000 for the six months ended June 30, 2016, primarily as a result of increased legal expenses.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><u>Operating Loss</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">As a result of the foregoing, our operating loss decreased approximately $1,069,000 to approximately $41,116,000 for the six months ended June 30, 2017, compared with approximately $42,185,000 for the six months ended June 30, 2016, primarily as a result of decreased research and development costs, partially offset by increased personnel costs, sales and marketing expenses to support commercialization of our hormone therapy drug candidates, including costs related to outsourced sales personnel and their related expenses, professional fees and other operating expenses as well a decrease in revenue.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">As a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future until our hormone therapy drug candidates are approved by the FDA and brought to market, although there is no assurance that we will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved, will be successful.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><u>Other Income </u></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><i>&nbsp;</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Other non-operating income increased by approximately $122,000, or 76%, to approximately $283,000 for the six months ended June 30, 2017 compared with approximately $161,000 for the comparable period in 2016, primarily as a result of increased interest income.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><u>Net Loss</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">As a result of the net effects of the foregoing, net loss decreased approximately $1,191,000 to approximately $40,833,000 for the six months ended June 30, 2017, compared with approximately $42,024,000 for the six months ended June 30, 2016. Net loss per share of Common Stock, basic and diluted, was ($0.20) for the six months ended June 30, 2017, compared with ($0.21) for the six months ended June 30, 2016.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><b><u>Liquidity and Capital Resources</u></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">We have funded our operations primarily through public offerings of our Common Stock and private placements of equity and debt securities. For the year ended December 31, 2016, we received approximately $134,864,000 in net proceeds from the issuance of shares of Common Stock. As of June 30, 2017, we had cash and cash equivalents totaling approximately $96,476,000, however, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  32; Value:  30; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->32
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">During the six months ended June 30, 2017, certain individuals exercised warrants to purchase 2,476,666 shares of Common Stock for $3,798,999 in cash. During the six months ended June 30, 2017, certain individuals exercised stock options to purchase 100,046 shares of Common Stock for $212,360 in cash.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">As a result of developments in the pharmaceutical industry that negatively affected independent pharmacies, including such pharmacies&#x2019; reliance on third party payors, in 2016, we identified that payment periods for our retail pharmacy distributors were becoming longer than in prior years. As a result, during the third quarter of 2016, we centralized the distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies and minimize business risk exposure to any one retail pharmacy. During the third quarter of 2016, we entered into new distribution agreements with our retail pharmacy distributors to effectuate this centralization which were effective September 1, 2016.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">For the three months ended June 30, 2017, our days sales outstanding, or DSO, was 74 days compared to 92 days for the year ended December 31, 2016. This decline in DSO was primarily due to higher collections as well as the paydown of receivables outstanding prior to the centralization of the distribution channel for both our retail pharmacy distributors and wholesale distributors. We anticipate that our DSO will fluctuate in the future based upon a variety of factors, including longer payment terms associated with the centralization of the distribution channel for both our retail pharmacy distributors and wholesale distributors in September 2016, as compared to the terms previously provided to our retail pharmacy distributors, changes in the healthcare industry and specific terms that may be extended in connection with the launch of our hormone therapy drug candidates, if approved.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">We believe that our existing cash will allow us to fund our operating plan through at least the next 12 months from the date of this quarterly report. However, if the commercialization of our hormone therapy drug candidates is delayed, our existing cash may be insufficient to satisfy our liquidity requirements until we are able to commercialize our hormone therapy drug candidates. &nbsp;If our available cash is insufficient to satisfy our liquidity requirements, we may curtail our sales, marketing and other pre-commercialization efforts and&nbsp;we may seek to sell additional equity or debt securities or obtain a credit facility. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing shareholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing shareholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products. Additionally, we may have to grant licenses on terms that may not be favorable to us.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">We need substantial amounts of cash to complete the clinical development of and commercialize of our hormone therapy drug candidates. The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0.7pt 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><u>Summary of (Uses) and Sources of Cash</u></font>
    </p>
    <p style="margin: 0pt 0.7pt 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">
                <font style="color: black;">Six Months Ended
                    <br>June 30,</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">2017</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="color: black;">2016</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center;" colspan="6">
                <font style="color: black;">(000s)</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 74%; text-align: justify;">
                <font style="color: black;">Net cash used in operating activities</font>
            </td>
            <td style="width: 1%;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="color: black;">(38,666</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="color: black;">)</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">(34,725</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">Net cash used in investing activities</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">(403</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">)</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">(663</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="color: black;">Net cash provided by financing activities</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">4,011</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">$</font>
            </td>
            <td style="text-align: right;">
                <font style="color: black;">137,214</font>
            </td>
            <td style="text-align: left;">
                <font style="color: black;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0 0pt 0.25pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  33; Value:  30; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->33
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0 0pt 0.25pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.25pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><i>Operating Activities</i></font>
    </p>
    <p style="margin: 0pt 0 0pt 0.25pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">The principal use of cash in&nbsp;operating activities for the six months ended June 30, 2017 was to fund our current expenses primarily related to supporting clinical development, scale-up and manufacturing activities and future commercial activities, adjusted for non-cash items. The increase of approximately $3,941,000 in cash used in operating activities for the six months ended June 30, 2017 compared with the comparable period in the prior year was due primarily to lower non-cash compensation expense coupled with changes in the components of working capital and decreased net loss.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0.7pt 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><i>Investing Activities</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 5.05pt 0pt 0; text-align: justify; text-indent: 38.45pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">A decrease in spending on patent and trademarks and fixed assets resulted in a decrease in cash used in investing activities for the six months ended June 30, 2017 compared with the same period in 2016.</font>
    </p>
    <p style="margin: 0pt 0.7pt 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><i>&nbsp;</i></font>
    </p>
    <p style="margin: 0pt 0.7pt 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><i>Financing Activities</i></font>
    </p>
    <p style="margin: 0pt 0 0pt 0.25pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0.7pt 0pt 0.5pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Financing activities represent the principal source of our cash flow. Our financing activities for the six months ended June 30, 2017 provided net cash of approximately $4,011,000 which was related to the exercise of warrants and options. The cash provided by financing activities during the six months ended June 30, 2016, included approximately $134,864,000 in proceeds from the sale of Common Stock and approximately $2,351,000 in proceeds from the exercise of options and warrants.</font>
    </p>
    <p style="margin: 0pt 0.7pt 0pt 0.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><b>New Accounting Pronouncements</b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">In May 2017, the Financial Accounting Standards Board, or FASB, issued an Accounting Standards Update, or ASU, that clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. The new guidance will allow companies to make certain changes to awards without accounting for them as modifications. This guidance does not change the accounting for modifications. The guidance will be applied prospectively to awards modified on or after the adoption date and is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including in an interim period. We do not expect that adoption of this guidance will have a material effect on our consolidated financial statements.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted with retrospective application. We are currently evaluating the impact of this guidance on our consolidated financial statements and disclosures.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">In March 2016, the FASB issued ASU 2016-09, Compensation &#x2013; Stock Compensation: Improvements to Employee Share-Based Payment Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&nbsp;ASU&nbsp;2016-09&nbsp;effective January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to recognize the previously unrecognized net operating losses from prior periods, was made to the valuation allowance through retained earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated financial statements.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  34; Value:  30; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->34
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to the accounting for our operating lease.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We have performed a preliminary review of the requirements of the new revenue standard and are monitoring the activity of the FASB and the transition resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied the five-step model of the new standard to our contracts as well as compared the results to our current accounting practices. At this point of our analysis, we do not believe that the adoption of this standard will have a material effect on our financial statements but will potentially expand our disclosures related to contracts with customers.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">
            <font style="font-family: Times New Roman, Times, Serif;"><b><a name="txmda006"></a>Item 3. Quantitative and Qualitative Disclosures about Market Risk</b></font>
        </font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Our market risk has not changed materially from the interest rate risk disclosed in Item 7A of our Annual Report.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">
            <font style="font-family: Times New Roman, Times, Serif;"><b><a name="txmda007"></a>Item 4. Controls and Procedures</b></font>
        </font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><u>Disclosure Controls and Procedures</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported, within the time period specified in the SEC&#x2019;s rules and forms and is accumulated and communicated to our principal executive officer and principal financial officer, as appropriate, in order to allow timely decisions in connection with required disclosure.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  35; Value:  30; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->35
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><u>Evaluation of Disclosure Controls and Procedures</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q were effective in providing reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><u>Changes in Internal Controls</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">During the three months ended June 30, 2017, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">
            <font style="font-family: Times New Roman, Times, Serif;"><b><a name="txmda008"></a>PART II - OTHER INFORMATION</b></font>
        </font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">
            <font style="font-family: Times New Roman, Times, Serif;"><b><a name="txmda009"></a>Item 1. Legal Proceedings</b></font>
        </font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">On April 17, 2017, a securities class action lawsuit was filed against our company and certain of our officers and directors in the U.S. District Court for the Southern District of Florida (Case No. 9:17-cv-80473-RLR) that purports to state a claim for alleged violations of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 thereunder, based on statements made by the defendants concerning the NDA for TX-004HR. The complaint sought unspecified damages, interest, attorneys&#x2019; fees and other costs. On July 18, 2017, the complaint was voluntarily dismissed by the lead plaintiff without prejudice. We and certain of our officers and directors are also subject to two shareholder derivative lawsuits regarding the NDA for TX-004HR, one filed in the U.S. District Court for the Southern District of Florida on May 30, 2017 (Case No. 9:17-cv-80686-RLR) and one filed in Florida state court in Palm Beach County on June 5, 2017 (Case No. 502017CA006289XXXXMB). We believe these lawsuits to be without merit and intend to vigorously defend against them. The derivative lawsuits are in the very early stages and, at this time, no assessment can be made as to their likely outcome or whether the outcome will be material to us.</font>
    </p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">
            <font style="font-family: Times New Roman, Times, Serif;"><b><a name="txmda010"></a>Item 1A. Risk Factors</b></font>
        </font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">There have been no material changes to the risk factors previously disclosed in our Annual Report.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  36; Value:  30; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->36
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><b><a name="txmda011"></a>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">On April 5, 2017, a certain individual exercised warrants to purchase 566,666 shares of Common Stock for $1,138,999 in cash. On April 10, 2017, certain individuals exercised warrants to purchase 6,590,000 shares of Common Stock pursuant to the warrants&#x2019; cashless exercise provisions, wherein 4,762,208 shares of Common Stock were issued. On June 19, 2017, a certain individual exercised warrants to purchase 100,000 shares of Common Stock for $200,000 in cash. Proceeds from these transactions were used in working capital. The shares of Common Stock were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.</font>
        <font style="color: black;">
            <br clear="ALL">
        </font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  37; Value:  30; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->37
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">
            <font style="font-family: Times New Roman, Times, Serif;"><b><a name="txmda012"></a>Item 6. Exhibits</b></font>
        </font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><b>&nbsp;</b></font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 13%; font-family: Times New Roman, Times, Serif;">
                <p style="border-bottom: Black 0.5pt solid; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
                    <font style="color: black; font-family: Times New Roman, Times, Serif;"><b>Exhibit</b></font>
                </p>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 19%; font-family: Times New Roman, Times, Serif;">
                <p style="border-bottom: Black 0.5pt solid; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
                    <font style="color: black; font-family: Times New Roman, Times, Serif;"><b>Date</b></font>
                </p>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 68%; font-family: Times New Roman, Times, Serif;">
                <p style="border-bottom: Black 0.5pt solid; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
                    <font style="color: black; font-family: Times New Roman, Times, Serif;"><b>Description</b></font>
                </p>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ex31-1.htm">31.1*</a></font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">August 3, 2017</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ex31-1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ex31-2.htm">31.2*</a></font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">August 3, 2017</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ex32-1.htm">32.1*</a></font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">August 3, 2017</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ex32-1.htm">Section 1350 Certification of Chief Executive Officer</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ex32-2.htm">32.2*</a></font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">August 3, 2017</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ex32-2.htm">Section 1350 Certification of Chief Financial Officer</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">101.INS*</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">XBRL Instance Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">101.SCH*</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">XBRL Taxonomy Extension Schema Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">101.CAL*</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">101.DEF*</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">XBRL Taxonomy Extension Definition Linkbase Instance Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">101.LAB*</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">XBRL Taxonomy Extension Label Linkbase Instance Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">101.PRE*</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">XBRL Taxonomy Extension Presentation Linkbase Instance Document</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-right: 0; margin-top: 0pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">&nbsp;</font>
    </p>
    <div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 1pt solid; width: 20%; font-size: 1pt;">
            <font style="color: black;">&nbsp;</font>
        </div>
    </div>
    <p style="margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">* Filed herewith.</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  38; Value:  30; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->38
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><b>&nbsp;</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><b>SIGNATURES</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;"><b>&nbsp;</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black; font-family: Times New Roman, Times, Serif;">DATE: August 3, 2017</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td colspan="2">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>THERAPEUTICSMD, INC.</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="width: 50%;">
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="width: 3%;">
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="width: 47%;">
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">By:</font>
            </td>
            <td style="border-bottom: Black 1pt solid;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.125in;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;Robert G. Finizio</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.125in;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;Chief Executive Officer</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.125in;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;(Principal Executive Officer)</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">By:</font>
            </td>
            <td style="border-bottom: Black 1pt solid;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">/<i>s/ Daniel A. Cartwright</i></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.125in;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.125in;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;Chief Financial Officer</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td>
                <font style="color: black; font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="padding-left: 0.125in;">
                <font style="color: black; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;(Principal Financial and Accounting Officer)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  39; Options:  Last; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: normal 10pt Times New Roman, Times, Serif">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 100%; text-align: center">
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->39
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="color: black;">&nbsp;</font>
    </p>
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex31-1.htm</TITLE>
</HEAD>

<BODY style='font: 10pt Times New Roman, Times, Serif'>
    <!-- Edge Version : 1.1 -->
    <div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10q_063017.htm">TherapeuticsMD, Inc. 10-Q</a></p>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.1</b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">I, Robert G. Finizio, certify that:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(1)</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(2)</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(3)</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(4)</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 0.25in; text-align: justify;">&nbsp;</td>
            <td style="width: 0.25in; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(c)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(d)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(5)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 0.25in; text-align: justify;">&nbsp;</td>
            <td style="width: 0.25in; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="padding-left: 12pt; width: 50%; vertical-align: top; text-align: justify; text-indent: -12pt;">
                <font style="font-size: 10pt;">August 3, 2017</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 50%; vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt;">
                <font style="font-size: 10pt;">Robert G. Finizio</font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt;">&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom;">
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">Chief Executive Officer</p>
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">(Principal Executive Officer)</p>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  40; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->40
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex31-2.htm</TITLE>
</HEAD>

<BODY style='font: 10pt Times New Roman, Times, Serif'>
    <!-- Edge Version : 1.1 -->
    <div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10q_063017.htm">TherapeuticsMD, Inc. 10-Q</a></p>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.2</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">I, Daniel A. Cartwright, certify that:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(1)</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(2)</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(3)</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(4)</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="width: 0.25in; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(c)</font>
            </td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(d)</font>
            </td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(5)</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="width: 0.25in; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 12pt; width: 50%; vertical-align: top; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">August 3, 2017</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 50%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;"><i>/s/ Daniel A. Cartwright</i></font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-size: 10pt;">Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">Chief Financial Officer</p>
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">(Principal Financial and Accounting Officer)</p>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="text-transform: uppercase;">&nbsp;&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  41; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->41
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex32-1.htm</TITLE>
</HEAD>

<BODY style='font: 10pt Times New Roman, Times, Serif'>
    <!-- Edge Version : 1.2 -->
    <div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10q_063017.htm">TherapeuticsMD, Inc. 10-Q</a></p>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;"><b>Exhibit 32.1</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">In connection with the quarterly report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-Q for the quarterly period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Robert G. Finizio, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font-family: Times New Roman, Times, Serif;"></td>
            <td style="width: 0.5in; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">(1)</font>
            </td>
            <td style="text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font-family: Times New Roman, Times, Serif;"></td>
            <td style="width: 0.5in; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">(2)</font>
            </td>
            <td style="text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 12pt; width: 50%; vertical-align: top; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">August 3, 2017</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 50%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;"><i>/s/ Robert G. Finizio</i></font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">Robert G. Finizio</font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">
                    <font style="font-family: Times New Roman, Times, Serif;">Chief Executive Officer</font>
                </p>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  42; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->42
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex32-2.htm</TITLE>
</HEAD>

<BODY style='font: 10pt Times New Roman, Times, Serif'>
    <!-- Edge Version : 1.1 -->
    <div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10q_063017.htm">TherapeuticsMD, Inc. 10-Q</a></p>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;"><b>Exhibit 32.2</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">In connection with the quarterly report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-Q for the quarterly period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Daniel A. Cartwright, Chief Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font-family: Times New Roman, Times, Serif;"></td>
            <td style="width: 0.5in; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">(1)</font>
            </td>
            <td style="text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font-family: Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font-family: Times New Roman, Times, Serif;"></td>
            <td style="width: 0.5in; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">(2)</font>
            </td>
            <td style="text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 12pt; width: 50%; vertical-align: top; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">August 3, 2017</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 50%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;"><i>/s/ Daniel A. Cartwright</i></font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">
                    <font style="font-family: Times New Roman, Times, Serif;">Chief Financial Officer</font>
                </p>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  43; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->43
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>txmd-20170630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20170630\txmd_063017.xfr; Date: 2017%2D08%2D02T21:59:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:txmd="http://therapeuticsmd.com/20170630">
    <link:schemaRef xlink:href="txmd-20170630.xsd" xlink:type="simple" />
    <xbrli:context id="From2017-01-01to2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_Patents1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_Patents2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-05to2016-01-06_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-05</xbrli:startDate>
        <xbrli:endDate>2016-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-01-06_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-11to2016-01-12_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-11</xbrli:startDate>
        <xbrli:endDate>2016-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-05-01to2012-05-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-05-01</xbrli:startDate>
        <xbrli:endDate>2012-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-05-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30_us-gaap_WarrantMember_custom_IndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:IndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_us-gaap_WarrantMember_custom_IndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:IndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_WarrantMember_custom_IndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:IndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_WarrantMember_custom_IndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:IndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30_custom_Warrant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_custom_Warrant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_FiveCustomersMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">txmd:FiveCustomersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_FiveCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">txmd:FiveCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">txmd:ThreeCustomersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">txmd:ThreeCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmacyInnovationsTXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:PharmacyInnovationsTXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmacyInnovationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:PharmacyInnovationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_AmerisourceBergenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:AmerisourceBergenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CardinalHealthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CardinalHealthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_McKessonCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:McKessonCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_WoodstockPharmaceuticalAndCompoundingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:WoodstockPharmaceuticalAndCompoundingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_MedicalCenterPharmacyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:MedicalCenterPharmacyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DueWestPharmacyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:DueWestPharmacyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-30to2016-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-30</xbrli:startDate>
        <xbrli:endDate>2016-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>txmd:Number</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>txmd:Segment</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2017-01-01to2017-06-30">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2017-01-01to2017-06-30">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2017-01-01to2017-06-30">10-Q</dei:DocumentType>
    <dei:TradingSymbol contextRef="From2017-01-01to2017-06-30">TXMD</dei:TradingSymbol>
    <dei:DocumentPeriodEndDate contextRef="From2017-01-01to2017-06-30">2017-06-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2017-01-01to2017-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2017-01-01to2017-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2017-01-01to2017-06-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2017-01-01to2017-06-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2017-01-01to2017-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2017-01-01to2017-06-30">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2017-01-01to2017-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2017-01-01to2017-06-30">2017</dei:DocumentFiscalYearFocus>
    <us-gaap:Cash contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">96476483</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">131534101</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">64706355</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-06-30" unitRef="USD" decimals="0">166532446</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">3396419</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">4500699</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1414015</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1076321</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2228755</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2299052</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">103515672</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">139410173</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">483688</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">516839</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2739686</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2405972</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">139036</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">139036</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2878722</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2545008</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">106878082</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">142472020</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">8108034</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">7358514</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">5180218</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">7624085</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">13288252</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">14982599</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">204027</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">196688</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">443952952</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">436995052</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">-350567149</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">-309702319</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">93589830</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">127489421</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">106878082</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">142472020</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">358268</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">376374</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">204027142</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">196688222</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">204027142</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">196688222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">8235897</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">4250433</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">4403247</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">9333338</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmacyInnovationsTXMember" unitRef="USD" decimals="0">834000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmacyInnovationsMember" unitRef="USD" decimals="0">1863000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_AmerisourceBergenMember" unitRef="USD" decimals="0">1053000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CardinalHealthMember" unitRef="USD" decimals="0">1119000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_McKessonCorporationMember" unitRef="USD" decimals="0">907000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_WoodstockPharmaceuticalAndCompoundingMember" unitRef="USD" decimals="0">2237000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_MedicalCenterPharmacyMember" unitRef="USD" decimals="0">1540000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DueWestPharmacyMember" unitRef="USD" decimals="0">1863000</us-gaap:SalesRevenueNet>
    <us-gaap:CostOfGoodsSold contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">1341360</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">681725</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">1130108</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">2238551</us-gaap:CostOfGoodsSold>
    <us-gaap:GrossProfit contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">6894537</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">3568708</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">3273139</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">7094787</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">31466544</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">14628927</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">10619006</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">20297558</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">16441235</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">8716395</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">13841193</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">28938210</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">102888</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">53189</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">24262</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">43859</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">48010667</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">23398511</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">24484461</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">49279627</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">-41116130</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">-19829803</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-21211322</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">-42184840</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">275022</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">149054</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">114320</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">155937</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InvestmentIncomeInterest contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">7699</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">3832</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">2863</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">5399</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">282721</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">152886</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">117183</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">161336</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">-40833409</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">-19676917</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-21094139</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">-42023504</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">-40833409</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">-19676917</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-21094139</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">-42023504</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-01to2017-06-30" unitRef="USDPShares" decimals="INF">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-04-01to2017-06-30" unitRef="USDPShares" decimals="INF">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-04-01to2016-06-30" unitRef="USDPShares" decimals="INF">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-01-01to2016-06-30" unitRef="USDPShares" decimals="INF">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-01-01to2017-06-30" unitRef="Shares" decimals="INF">200602778</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-04-01to2017-06-30" unitRef="Shares" decimals="INF">203384610</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-04-01to2016-06-30" unitRef="Shares" decimals="INF">196325715</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-01-01to2016-06-30" unitRef="Shares" decimals="INF">195613639</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:Depreciation contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">69000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">35400</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">10853</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">19216</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">33888</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">17789</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">13409</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">24643</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">-18106</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">447388</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">3051357</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">9200844</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">115774</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">683590</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-04-01to2017-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">68089</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-04-01to2016-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">556125</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">-1122386</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">1874980</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">337694</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">193503</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">58601</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">-1001120</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">749520</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">-86786</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">-2443867</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">-1239743</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">-38665526</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">-34725305</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">367602</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">393221</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">35849</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">265036</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2017-01-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">4864</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">-403451</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">-663121</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-01-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">134863475</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">3798999</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">1373000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">212360</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">978042</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">4011359</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">137214517</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">-35057618</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">101826091</us-gaap:CashPeriodIncreaseDecrease>
    <txmd:AmountOfAdjustmentForProvisionsRelatedToForfeitureRates contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">31000</txmd:AmountOfAdjustmentForProvisionsRelatedToForfeitureRates>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2017-06-30_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">0</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2016-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">228933</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1399979</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1062285</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">14036</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">14036</us-gaap:InventoryRawMaterials>
    <txmd:PrepaidManufacturingCostsCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">999508</txmd:PrepaidManufacturingCostsCurrent>
    <txmd:PrepaidManufacturingCostsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">991809</txmd:PrepaidManufacturingCostsCurrent>
    <txmd:PrepaidMarketingCostsCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">535936</txmd:PrepaidMarketingCostsCurrent>
    <us-gaap:PrepaidInsurance contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">350571</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">628039</us-gaap:PrepaidInsurance>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">100035</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">128898</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidVendorDepositsCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">5000</txmd:PrepaidVendorDepositsCurrent>
    <txmd:PrepaidVendorDepositsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">44311</txmd:PrepaidVendorDepositsCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">337740</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">405960</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">783305</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">747456</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-06-30_us-gaap_EquipmentMember" unitRef="USD" decimals="0">247568</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-06-30_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-06-30_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">116542</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-06-30_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">37888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_EquipmentMember" unitRef="USD" decimals="0">215182</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">113079</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">37888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">299617</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">230617</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2017-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2017-06-30_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2017-06-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1207267</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2017-06-30_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1444581</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-12-31_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1093452</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1203987</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">234513</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">200626</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">7488</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-06-30_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-06-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">135282</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">6490</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-12-31_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">102393</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">24463</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-06-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1071985</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-06-30_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1444581</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">25461</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">991059</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1203987</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2017-01-01to2017-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember">P12Y3M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2017-01-01to2017-06-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P15Y6M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2016-01-01to2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P12Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2016-01-01to2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P16Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2017-06-30_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">198657</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2016-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">185465</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2017-06-30_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">198657</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2016-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">185465</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">2974199</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2606598</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">35579</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">71157</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">71157</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">71157</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">71157</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">776241</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2017-01-01to2017-06-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-06-30" unitRef="N" decimals="INF">17</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="N" decimals="INF">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-06-30_custom_Patents1Member" unitRef="N" decimals="INF">13</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-06-30_us-gaap_PatentsMember" unitRef="N" decimals="INF">2</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-06-30_custom_Patents2Member" unitRef="N" decimals="INF">1</txmd:NumberOfIssuedPatents>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">527979</txmd:AccruedClinicalTrialCostsCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1281080</txmd:AccruedClinicalTrialCostsCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1738495</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">3531440</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">934370</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">665561</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">263375</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">176518</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">100821</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">665773</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">171487</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">224865</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">98729</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">76510</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">71775</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">26507</us-gaap:AccruedRoyaltiesCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1019853</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">794816</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">253334</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">181015</us-gaap:AccruedRentCurrent>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-06-30" unitRef="Shares" decimals="INF">26518005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-06-30" unitRef="Shares" decimals="INF">32729228</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">23402100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3115905</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">20668657</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">12060571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NatureOfOperations contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;1 &amp;#8211; THE COMPANY&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TherapeuticsMD,&#13;Inc., a Nevada corporation, or TherapeuticsMD, or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware&#13;limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,&#13;Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare&#13;collectively are sometimes referred to as &amp;#8220;our company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;our,&amp;#8221; or &amp;#8220;us.&amp;#8221;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Nature&#13;of Business&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;are a women&amp;#8217;s health care company focused on creating and commercializing products targeted exclusively for women. Currently,&#13;we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our&#13;advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate&#13;the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis&#13;and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone&#13;or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile&#13;compared with competing products. With our SYMBODA&amp;#8482; technology, we are developing advanced hormone therapy pharmaceutical&#13;products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition,&#13;we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, iron supplements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;2 &amp;#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Interim&#13;Financial Statements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #252525"&gt;The&#13;accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,&#13;should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report&#13;on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission, or the SEC, from which&#13;we derived the accompanying consolidated balance sheet as of December 31, 2016. The accompanying unaudited interim consolidated&#13;financial statements have been prepared in accordance &lt;/font&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;with&#13;accounting principles generally accepted in the United States of America, or GAAP&lt;font style="color: #252525"&gt;, for interim financial&#13;information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements,&#13;the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required&#13;by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments,&#13;consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results&#13;for the interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim&#13;period in the future.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Recently&#13;Issued Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2017, the Financial Accounting Standards Board, or FASB, issued an Accounting Standards Update, or ASU, that clarifies when&#13;changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will&#13;reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. The new&#13;guidance will allow companies to make certain changes to awards without accounting for them as modifications. This guidance does&#13;not change the accounting for modifications. The guidance will be applied prospectively to awards modified on or after the adoption&#13;date and is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017.&#13;Early adoption is permitted, including in an interim period. We do not expect that adoption of this guidance will have a material&#13;effect on our consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity&#13;in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for&#13;public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years.&#13;Early adoption is permitted with retrospective application. We are currently evaluating the impact of this guidance on our consolidated&#13;financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2016, the FASB issued ASU 2016-09, Compensation &amp;#8211; Stock Compensation: Improvements to Employee Share-Based Payment&#13;Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both&#13;public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,&#13;as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years&#13;beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&amp;#160;ASU&amp;#160;2016-09&amp;#160;effective&#13;January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture&#13;rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of&#13;approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies&#13;in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full&#13;valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to&#13;recognize the previously unrecognized net operating losses from prior periods was made to the valuation allowance through retained&#13;earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets&#13;but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current&#13;real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting&#13;for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning&#13;after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process&#13;of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing&#13;to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to&#13;the accounting for our operating lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&amp;#8217;s core principle&#13;is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects&#13;the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies&#13;will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance&#13;obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating&#13;the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective&#13;date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for&#13;public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB&#13;issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting&#13;for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical&#13;expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We&#13;have performed a preliminary review of the requirements of the new revenue standard and are monitoring the activity of the FASB&#13;and the transition resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied&#13;the five-step model of the new standard to our contracts as well as compared the results to our current accounting practices.&#13;At this point of our analysis, we do not believe that the adoption of this standard will have a material effect on our financial&#13;statements but will potentially expand our disclosures related to contracts with customers.&lt;/font&gt;&lt;/p&gt;</txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;3 &amp;#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fair&#13;Value of Financial Instruments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount&#13;of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity&#13;of such instruments, which are considered Level 1 assets under the fair value hierarchy.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy&#13;as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements&lt;i&gt;. &lt;/i&gt;The fair value hierarchy gives the&#13;highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable&#13;inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy&#13;of inputs, as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 0.85in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted&#13;    prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 0.85in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for&#13;    similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly&#13;    or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 0.85in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;unobservable inputs&#13;    for the asset or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;June 30, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of&#13;indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level&#13;3) in connection with our impairment test. There was no impairment of intangible assets or long-lived assets during the three&#13;and six months ended June 30, 2017 and 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Trade&#13;Accounts Receivable and Allowance for Doubtful Accounts&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade&#13;accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts&#13;and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,&#13;historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than&#13;90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual&#13;credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts&#13;previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate&#13;these estimates does not accurately reflect bad debts, adjustments to these reserves may be required.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Revenue&#13;Recognition&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is&#13;fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably&#13;assured.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation&#13;and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers&#13;of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products&#13;pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing&#13;support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product&#13;lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales. The revenue that is generated&#13;by us from major customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note&#13;13. There are no major customers for our OTC prenatal vitamin or other products.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,&#13;when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if&#13;any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC&#13;customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit&#13;card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back&#13;return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC&#13;sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product&#13;lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Prescription&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy distributors.&#13;We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees, customer rebates and&#13;estimated returns.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped&#13;to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products&#13;sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration.&#13;Our prescription products currently have a shelf life of 24 months from the date of manufacture.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prior&#13;to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the&#13;product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were&#13;known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the&#13;distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader&#13;population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription&#13;products are distributed under the wholesale distributor model described above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer&#13;loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry&#13;averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated&#13;in contracts and estimate chargebacks based on the number of units sold each period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Share-Based&#13;Compensation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the&#13;costs in the financial statements over the period during which employees are required to provide services. Share-based&#13;compensation arrangements may include options, restricted stock, restricted stock units, performance-based awards, and share&#13;appreciation rights. We amortize such compensation amounts, if any, over the respective service periods of the award. We use&#13;the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,&#13;Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the&#13;expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected&#13;dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury&#13;bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by&#13;which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected&#13;volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were&#13;publicly available that were similar to our company with respect to industry, stage of life cycle, market capitalization, and&#13;financial leverage. On January 1, 2017, we started using our own stock price in our volatility calculation along with two&#13;other peer entities whose stock prices were publicly available that were similar to our company. Our calculation of estimated&#13;volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected&#13;life of warrants is based on the contractual terms of the awards. The average expected life of options is based on the&#13;contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that&#13;we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based&#13;compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the&#13;share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of&#13;share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of&#13;management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense&#13;could be materially different in the future.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Equity&#13;instruments (&amp;#8220;instruments&amp;#8221;) issued to non-employees are recorded on the basis of the fair value of the instruments,&#13;as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition&#13;period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached&#13;or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is&#13;recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees&#13;can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value&#13;related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined&#13;in ASC 505.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance&#13;with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&amp;#8217;s requisite service&#13;period. &lt;font style="color: #252525"&gt;We adopted ASU 2016-09, effective January 1, 2017, electing to account for forfeitures when&#13;they occur. Prior to that, &lt;/font&gt;we estimated the forfeiture rate based on our historical experience of forfeitures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Research&#13;and Development Expenses&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations,&#13;or CROs, costs of their clinical research sites, manufacturing, laboratory supplies, scale-up and validation costs, and other&#13;activities. Internal R&amp;#38;D activity expenses include salaries, benefits, and non-cash share-based compensation expenses. Advance&#13;payments to be expensed in future research and development activities are capitalized, and were $0 at June 30, 2017 and $228,933&#13;at December 31, 2016, all of which were included in other current assets on the accompanying consolidated balance sheets. CRO&#13;activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory&#13;consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;#38;D expenses&#13;include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration,&#13;or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and&#13;FDA submissions. Legal activities include professional research and advice regarding R&amp;#38;D, patents and regulatory matters.&#13;These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical&#13;trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity expenses to operations as incurred. We&#13;make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable&#13;advance payments for goods and services that will be used in future R&amp;#38;D activities when the activity has been performed or&#13;when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study&#13;expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided&#13;by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense&#13;in the period in which the facts that give rise to the revision become known.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Segment&#13;Reporting&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.&#13;Our business operations are managed by a single management team that reports to the President of our company. We do not operate&#13;separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect&#13;to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one&#13;reportable operating segment.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;4 &amp;#8211; INVENTORY&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, &lt;br /&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; width: 68%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    product&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,399,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,062,285&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw&#13;    material&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,036&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,036&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TOTAL&#13;    INVENTORY&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,414,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,076,321&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-06-30_us-gaap_EmployeeStockOptionMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-01-01to2016-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">21767854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">23402100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-06-30_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">18611959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-06-30_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">4790141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">2184500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-06-30" unitRef="Shares" decimals="INF">100046</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-04-01to2017-06-30" unitRef="Shares" decimals="INF">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-04-01to2016-06-30" unitRef="Shares" decimals="INF">77123</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-06-30" unitRef="Shares" decimals="INF">417168</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">100046</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">450208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">18731808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">4670292</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">8.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">6.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">6.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">6.43</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember">P8Y9M18D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">60495730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">52165428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">437667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">51750547</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue contextRef="AsOf2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">414881</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">212360</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">20050</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">191592</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">978042</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">15151515</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-11to2016-01-12_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">17424242</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="AsOf2016-01-06_custom_GoldmanSachsMember" unitRef="USDPShares" decimals="INF">8.25</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember" unitRef="USD" decimals="0">134864000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">2272727</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">3115905</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2017-01-01to2017-06-30">P2Y3M</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-06-30_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-06-30_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">8.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-06-30_custom_OutsideConsultant2Member" unitRef="USDPShares" decimals="INF">6.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USDPShares" decimals="INF">2.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-05-31_custom_Warrant1Member" unitRef="USDPShares" decimals="INF">2.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2017-06-30" unitRef="USDPShares" decimals="INF">2.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2016-06-30_custom_OutsideConsultant2Member" unitRef="USDPShares" decimals="INF">7.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member" unitRef="Shares" decimals="INF">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member" unitRef="Shares" decimals="INF">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Shares" decimals="INF">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" unitRef="Shares" decimals="INF">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member" unitRef="USDPShares" decimals="INF">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member" unitRef="USDPShares" decimals="INF">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member">2022-03-15</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member">2021-01-21</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheOneMember">2021-04-21</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">2021-04-21</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">2021-01-21</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-06-30_custom_LongTermIncentiveCompensationPlan2009Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-06-30_custom_NonQualified2012StockIncentivePlanMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheOneMember">2016-04-21</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">2013-06-30</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member" unitRef="Pure" decimals="INF">0.6324</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.7410</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.7415</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" decimals="INF">0.4589</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" decimals="INF">0.4584</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Pure" decimals="INF">0.4471</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member" unitRef="Pure" decimals="INF">0.0147</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0104</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0128</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" decimals="INF">0.0112</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" decimals="INF">0.0141</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Pure" decimals="INF">0.0074</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2017-01-01to2017-06-30_custom_OutsideConsultant2Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2016-01-01to2016-06-30_custom_OutsideConsultant2Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2017-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">420000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="USD" decimals="0">405066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="USD" decimals="0">462196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="USD" decimals="0">1532228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">850000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Shares" decimals="INF">1300000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="USD" decimals="0">405066</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-01-01to2017-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2016-01-01to2016-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">77026</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-01-01to2017-06-30_custom_Warrant1Member" unitRef="USD" decimals="0">128898</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2016-01-01to2016-06-30_custom_Warrant1Member" unitRef="USD" decimals="0">128898</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-04-01to2017-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2016-04-01to2016-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">38509</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-04-01to2017-06-30_custom_Warrant1Member" unitRef="USD" decimals="0">64449</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2016-04-01to2016-06-30_custom_Warrant1Member" unitRef="USD" decimals="0">64449</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights contextRef="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">833000</txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <txmd:DescriptionOfSharesToBeVested contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">&lt;p style="font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,334&#13;shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated&#13;that this event will occur in the near future.&lt;/font&gt;&lt;/p&gt;</txmd:DescriptionOfSharesToBeVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-06-30_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-06-30_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-06-30_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">2139503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-06-30_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">5128333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">2806685</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">1505625</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">4160071</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">8311330</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">14365000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2017-01-01to2017-06-30">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-04-01to2017-06-30_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="USD" decimals="0">1338999</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-04-01to2016-06-30_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="USD" decimals="0">63000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-01-01to2017-06-30_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="USD" decimals="0">3798999</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-06-30_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="USD" decimals="0">1373000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-04-01to2017-06-30_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="Shares" decimals="INF">666666</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2016-04-01to2016-06-30_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="Shares" decimals="INF">161372</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-01-01to2017-06-30_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="Shares" decimals="INF">2476666</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2016-01-01to2016-06-30_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="Shares" decimals="INF">722744</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-04-01to2017-06-30_custom_Warrant2Member" unitRef="Shares" decimals="INF">4762208</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-01-01to2017-06-30_custom_Warrant2Member" unitRef="Shares" decimals="INF">4762208</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-06-30" unitRef="USDPShares" decimals="INF">3.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-01-01to2016-06-30" unitRef="USDPShares" decimals="INF">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2017-01-01to2017-06-30_custom_LongTermIncentiveCompensationPlan2009Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2017-01-01to2017-06-30_custom_NonQualified2012StockIncentivePlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2017-01-01to2017-06-30_us-gaap_DirectorMember" unitRef="USD" decimals="0">2460000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2016-01-01to2016-06-30_us-gaap_DirectorMember" unitRef="USD" decimals="0">2079000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2017-04-01to2017-06-30_us-gaap_DirectorMember" unitRef="USD" decimals="0">1754000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2016-04-01to2016-06-30_us-gaap_DirectorMember" unitRef="USD" decimals="0">614000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2017-06-30_us-gaap_DirectorMember" unitRef="USD" decimals="0">1132000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2016-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">57000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-06-30_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">1.00</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-06-30_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_FiveCustomersMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_FiveCustomersMember" unitRef="Pure" decimals="INF">0.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember" unitRef="Pure" decimals="INF">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-04-01to2017-06-30_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">1.00</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-04-01to2016-06-30_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">449264</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">951194</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1094116</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1113069</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">943127</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">4550770</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <txmd:CapitalLeaseObligationsTerm contextRef="From2017-01-01to2017-06-30">P63M</txmd:CapitalLeaseObligationsTerm>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-01-01to2017-06-30" unitRef="USD" decimals="0">515000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">265000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">182000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2016-01-01to2016-06-30" unitRef="USD" decimals="0">300000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseExpirationDate1 contextRef="From2016-04-30to2016-05-01">2021-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;5 &amp;#8211; OTHER CURRENT ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current assets consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, &lt;br /&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    manufacturing costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;999,508&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;991,809&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid marketing&#13;    costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;535,936&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,571&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;628,039&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research&#13;    and development costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,035&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;128,898&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,311&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    prepaid costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;337,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;405,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TOTAL&#13;    OTHER CURRENT ASSETS&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,228,755&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,299,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;6 &amp;#8211; FIXED ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed&#13;assets consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, &lt;br /&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounting&#13;    system&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;301,096&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;301,096&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;247,568&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;215,182&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computer hardware&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;80,211&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;80,211&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;116,542&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;113,079&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,888&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,888&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;783,305&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;747,456&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&#13;    depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(299,617&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(230,617&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL&#13;    FIXED ASSETS&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;483,688&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;516,839&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&#13;expense for the three months ended June 30, 2017 and 2016 was $35,400 and $10,853 respectively, and $69,000 and $19,216 for the&#13;six months ended June 30, 2017 and 2016, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;7 &amp;#8211; INTANGIBLE ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of June 30, 2017&#13;and December 31, 2016:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&#13;    &lt;br /&gt;Carrying &lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-&lt;br /&gt;Average&#13;    &lt;br /&gt;Remaining&lt;br /&gt;Amortization &lt;br /&gt;Period (yrs.)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&#13;    &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,488&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;24,463&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Development&#13;    costs of &amp;#160;corporate website&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Approved&#13;    hormone&amp;#160;therapy drug&amp;#160;candidate patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,207,267&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(135,282&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,071,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Hormone&#13;    therapy drug&amp;#160;candidate patents&amp;#160;(pending)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,444,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,444,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Multiple&#13;    trademarks&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;198,657&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;198,657&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,974,199&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(234,513&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,739,686&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&#13;    &lt;br /&gt;Carrying &lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    &lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-&#13;    &lt;br /&gt;Average &lt;br /&gt;Remaining &lt;br /&gt;Amortization &lt;br /&gt;Period (yrs.)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&#13;    &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,490&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,461&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Development&#13;    costs of corporate website&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Approved&#13;    hormone&amp;#160;therapy drug&amp;#160;candidate patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,093,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(102,393&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;991,059&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Hormone&#13;    therapy drug&amp;#160;candidate patents&amp;#160;(pending)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,203,987&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,203,987&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Multiple&#13;    trademarks&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;185,465&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;185,465&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,606,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(200,626&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,405,972&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent&#13;is granted, we amortize the approved hormone therapy drug candidate patents using the straight line method over the estimated&#13;useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off&#13;any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the six months ended June 30,&#13;2017 and year ended December 31, 2016, there was no impairment recognized related to intangible assets.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;addition to numerous pending patent applications, as of June 30, 2017, we had 17 issued patents, including:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13 utility patents&#13;    that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction&#13;    patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina,&#13;    Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;two utility patent&#13;    that relates to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establishes an important&#13;    intellectual property foundation for TX-004HR, which are owned by us and are U.S. jurisdiction patents with an expiration&#13;    date in 2033.&amp;#160; We have pending patent applications with respect to certain of these patents in Argentina, Australia,&#13;    Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;one utility patent&#13;    that relates to a pipeline transdermal patch technology, which is owned by us and is a U.S. jurisdiction patent with an expiration&#13;    in 2032. We have pending patent application with respect to this patent in Australia, Brazil, Canada, Europe, Mexico, and&#13;    Japan.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;one utility patent&#13;    that relates to our OPERA&amp;#174; information technology platform, which is owned by us and is a U.S. jurisdiction patent with&#13;    an expiration date in 2029.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization&#13;expense was $17,789 and $13,409 for the three months ended June 30, 2017 and 2016, respectively, and $33,888 and $24,643 for the&#13;six months ended June 30, 2017 and 2016, respectively. Estimated amortization expense for the next five years for the patent cost&#13;currently being amortized is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&#13;    Ending &lt;br /&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    &lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 2%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 46%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017(6&#13;    months)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 44%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,579&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;776,241&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;8 &amp;#8211; OTHER CURRENT LIABILITIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current liabilities consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, &lt;br /&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 66%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued&#13;    clinical trial costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;527,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,281,080&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll,&#13;    bonuses and commission costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,738,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,531,440&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated&#13;    absences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;934,370&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;665,561&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and&#13;    accounting expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;263,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;176,518&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued sales and&#13;    marketing costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;665,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;171,487&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;224,865&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale&#13;    distributor fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;98,729&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;76,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,775&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,507&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons&#13;    and returns&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,019,853&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;794,816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued&#13;    rent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,334&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;181,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL&#13;    OTHER CURRENT LIABILITIES&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,180,218&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,624,085&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;9 &amp;#8211; NET LOSS PER SHARE&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure&#13;of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par&#13;value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number&#13;of shares of Common Stock outstanding plus all potentially dilutive shares of Common Stock outstanding during the period. Such&#13;potentially dilutive shares of Common Stock consist of options and warrants and were excluded from the calculation of diluted&#13;earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table below presents&#13;potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders&#13;for the periods presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Three&#13;    and Six months ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,402,100&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,668,657&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,115,905&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,060,571&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,518,005&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;32,729,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;10 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Preferred&#13;Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;June 30, 2017, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred&#13;stock were issued or outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Common&#13;Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;June 30, 2017, we had 350,000,000 shares of Common Stock authorized for issuance, of which 204,027,142 shares of Common Stock&#13;were issued and outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Issuances&#13;During 2017&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended June 30, 2017, certain individuals exercised stock options to purchase 5,000 shares of Common Stock for&#13;$20,050 in cash. During the six months ended June 30, 2017, certain individuals exercised stock options to purchase 100,046 shares&#13;of Common Stock for $212,360 in cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Issuances&#13;During 2016&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 6, 2016, we entered into an underwriting agreement with Goldman Sachs &amp;#38; Co. and Cowen and Company, LLC, as the representatives&#13;of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of Common Stock&#13;at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day&#13;option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full. The&#13;net proceeds to us from the offering were approximately $134,864,000, after deducting underwriting discounts and commissions and&#13;other estimated offering expenses payable by us. The offering closed on January 12, 2016 and we issued 17,424,242 shares of Common&#13;Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended June 30, 2016, certain individuals exercised stock options to purchase 77,123 shares of Common Stock for&#13;$191,592 in cash. During the six months ended June 30, 2016, certain individuals exercised stock options to purchase 417,168 shares&#13;of Common Stock for $978,042 in cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrants&#13;to Purchase Common Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of June 30, 2017, we had warrants outstanding to purchase an aggregate of 3,115,905 shares of Common Stock with a weighted-average&#13;contractual remaining life of approximately 2.3 years, and exercise prices ranging from $0.24 to $8.20 per share, resulting in&#13;a weighted average exercise price of $2.58 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;valuation methodology used to determine the fair value of our warrants is the Black-Scholes&#13;Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free&#13;interest rate and the term of the warrant. During the six months ended June 30, 2017, we granted warrants to purchase 125,000&#13;shares of Common Stock to outside consultants at an exercise price of $6.83 per share. The fair value for these warrants was determined&#13;by using the Black-Scholes Model on the date of the grant using a term of five years; volatility of 63.24%; risk free rate of&#13;1.47%; and dividend yield of 0%. The grant date fair value of the warrants was $3.67 per share. The warrants are vesting ratably&#13;over a 12-month period and have an expiration date of March 15, 2022. During the six months ended June 30, 2016, we granted warrants&#13;to purchase 245,000 shares of Common Stock to outside consultants at a weighted average exercise price of $7.90 per share. The&#13;weighted average grant date fair value of these warrants was $4.78 per share. The fair value for these warrants was determined&#13;by using the Black-Scholes Model on the date of the grant using a term of five years; volatility of 74.10%-74.15%; risk free rate&#13;of 1.04%- 1.28%; and dividend yield of 0%. These warrants vest and have expiration dates as follows: warrants to purchase 75,000&#13;shares of Common Stock vested on April 21, 2016 and have an expiration date of April 21, 2021, warrants to purchase 50,000 shares&#13;of Common Stock vest ratably over a 24-month period and have an expiration date of April 21, 2021, and warrants to purchase 120,000&#13;shares of Common Stock vest ratable over a 12-month period and have an expiration date of January 21, 2021.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended June 30, 2017 and 2016, we recorded $68,089 and $556,125, respectively, and during the six months ended&#13;June 30, 2017 and 2016 we recorded $115,774 and $683,590, respectively, as share-based compensation expense in the accompanying&#13;consolidated financial statements related to warrants. As of June 30, 2017, unamortized costs associated with these warrants totaled&#13;approximately $420,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2013, we entered into a consulting agreement with Sancilio and Company, Inc., or SCI, to develop drug platforms to be used&#13;in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain FDA approval&#13;for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with&#13;the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of Common Stock that were to be&#13;granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed&#13;to issue to SCI a warrant to purchase 850,000 shares of Common Stock at $2.01 per share that has vested or will vest, as applicable,&#13;as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,333 shares were&#13;    earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol based drug candidate&#13;    in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares&#13;    did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using&#13;    the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and&#13;    a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,333 shares vested&#13;    on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date&#13;    of vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the&#13;    three months ended June 30, 2017 and 2016, we recorded $0 and $38,509, respectively, as non-cash compensation in the accompanying&#13;    consolidated financial statements related to this warrant. During the six months ended June 30, 2017 and 2016, we recorded&#13;    $0 and $77,026, respectively, as non-cash compensation in the accompanying consolidated financial statements related to this&#13;    warrant. As of June 30, 2016, this warrant was fully amortized; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,334 shares will&#13;    vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that&#13;    this event will occur in the near future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to SCI for services to be rendered over&#13;approximately five years beginning in May 2012. The warrants vested upon issuance. Services provided are to include (a) services&#13;in support of our drug development efforts, including services in support of our ongoing and future drug development and commercialization&#13;efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing&#13;and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated&#13;therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services&#13;as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228&#13;on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of&#13;0.74%; and a dividend yield of 0%. During both the three months ended June 30, 2017 and 2016 and both the six months ended June&#13;30, 2017 and 2016, we recorded $64,449 and $128,898, respectively, as non-cash compensation expense with respect to these warrants&#13;in the accompanying consolidated statements of operations. The contract will expire upon the commercial manufacture of a drug&#13;product. As of June 30, 2017, the SCI warrants issued in 2013 and 2012 were fully amortized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended June 30, 2017, certain individuals exercised warrants to purchase 666,666 shares of Common Stock for $1,338,999&#13;in cash. In addition, during the three months ended June 30, 2017, certain individuals exercised warrants to purchase 6,590,000&#13;shares of Common Stock pursuant to the warrants&amp;#8217; cashless exercise provisions, wherein 4,762,208 shares of Common Stock&#13;were issued. During the three months ended June 30, 2016, certain individuals exercised warrants to purchase 161,372 shares of&#13;Common Stock for $63,000 in cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the six months ended June 30, 2017, certain individuals exercised warrants to purchase 2,476,666 shares of Common Stock for $3,798,999&#13;in cash. In addition, during the six months ended June 30, 2017, certain individuals exercised warrants to purchase 6,590,000&#13;shares of Common Stock pursuant to the warrants&amp;#8217; cashless exercise provisions, wherein 4,762,208 shares of Common Stock&#13;were issued. During the six months ended June 30, 2016, certain individuals exercised warrants to purchase 722,744 shares of Common&#13;Stock for $1,373,000 in cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Options&#13;to Purchase Common Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to&#13;employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have&#13;created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards&#13;available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units,&#13;performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000&#13;shares authorized for issuance thereunder. Generally, the options vest annually over four years or as determined by our board&#13;of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis&#13;after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if&#13;any. The expiration date is generally ten years from the date the option is issued. As of June 30, 2017, there were&#13;non-qualified stock options to purchase 18,611,959 shares of Common Stock outstanding under the 2009 Plan. As of June 30,&#13;2017, there were 2,139,503 shares of Common Stock available to be issued under the 2009 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012&#13;Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain&#13;consultants and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation&#13;rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described&#13;in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option&#13;grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior&#13;to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally&#13;ten years from the date the option is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder.&#13;As of June 30, 2017, there were non-qualified stock options to purchase 4,790,141 shares of Common Stock outstanding under the&#13;2012 Plan. As of June 30, 2017, there were 5,128,333 shares of Common Stock available to be issued under the 2012 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires&#13;the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life&#13;of the stock options. The assumptions used in the Black-Scholes Model for options granted during the six months ended June 30,&#13;2017 and 2016 are set forth in the table below.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Six&#13;    Months Ended&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 46%; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 26%; border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 26%; border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest&#13;    rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.84-2.01%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.26-1.70%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: white"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;61.56-63.95%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70.44-71.22%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.5-6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.25&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: white"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of activity under the 2009 and 2012 Plans and related information follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares Underlying Stock Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    &lt;br /&gt;Average &lt;br /&gt;Remaining &lt;br /&gt;Contractual &lt;br /&gt;Life in Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    Intrinsic Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21,767,854&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.56&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,495,730&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,184,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(100,046&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;437,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired/Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(450,208&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at June&#13;    30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,402,100&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;52,165,428&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&#13;    and Exercisable at June 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18,731,808&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;51,750,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unvested at June 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,670,292&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;414,881&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;June 30, 2017, our outstanding stock options had exercise prices ranging from $0.10 to $8.92 per share. The weighted average grant&#13;date fair value per share of options granted was $3.82 and $5.08 during the six months ended June 30, 2017 and 2016, respectively.&#13;Share-based compensation expense for options recognized in our results of operations is based on vested awards. Share-based compensation&#13;expense related to options for the three months ended June 30, 2017 and 2016 was $1,505,625 and $4,160,071, respectively, and&#13;for the six months ended June 30, 2017 and 2016 was $2,806,685 and $8,311,330, respectively. At June 30, 2017, total unrecognized&#13;estimated compensation expense related to unvested options granted prior to that date was approximately $14,365,000 which may&#13;be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 2.4 years.&#13;No tax benefit was realized due to a continued pattern of operating losses.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;11 &amp;#8211; INCOME TAXES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred&#13;income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets&#13;and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected&#13;to reverse. We do not expect to pay any significant federal or state income tax for 2017 as a result of (a) the losses recorded&#13;during the six months ended June 30, 2017, (b) additional losses expected for the remainder of 2017, and/or (c) net operating&#13;loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax&#13;assets if it is &amp;#8220;more likely than not&amp;#8221; that some component or all of the benefits of deferred tax assets will not&#13;be realized. As of June 30, 2017, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,&#13;no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the&#13;reporting period.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;12 &amp;#8211; RELATED PARTIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to&#13;time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements&#13;with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of&#13;our company since July 2015. During the three months ended June 30, 2017 and 2016, we were billed by Catalent approximately $1,754,000&#13;and $614,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability&#13;and validation testing. During the six months ended June 30, 2017 and 2016, we were billed by Catalent approximately $2,460,000&#13;and $2,079,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability&#13;and validation testing. As of June 30, 2017 and December 31, 2016, there were amounts due to Catalent of approximately $1,132,000&#13;and $57,000, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;13 - BUSINESS CONCENTRATIONS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;purchase our products from several suppliers with approximately 100% and 96% of our purchases supplied from one vendor for both&#13;the three and six months ended June 30, 2017 and 2016, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain&#13;drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. As a result of developments&#13;in the pharmaceutical industry that negatively affected independent pharmacies, including such pharmacies&amp;#8217; reliance on third-party&#13;payors, in 2016, we identified that payment periods for our retail pharmacy distributors were becoming longer than in prior years.&#13;As a result, during the third quarter of 2016, we centralized the distribution channel for both our retail pharmacy distributors&#13;and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies and minimize business risk&#13;exposure to any one retail pharmacy. During the third quarter of 2016, we entered into new distribution agreements with our retail&#13;pharmacy distributors to effectuate this centralization which were effective September 1, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the six months ended June 30, 2017, five customers each generated more than 10% of our total revenues and during the six months&#13;ended June 30, 2016 three customers each generated more than 10% of our total revenues. Revenue generated from five major customers&#13;combined accounted for approximately 70% of our recognized revenue for the six months ended June 30, 2017 and revenue generated&#13;from three major customers combined accounted for approximately 60% of our recognized revenue for the six months ended June 30,&#13;2016. During the six months ended June 30, 2017, Pharmacy Innovations TX generated approximately $834,000 of our revenue, Pharmacy&#13;Innovations PA generated approximately $1,863,000 of our revenue, AmerisourceBergen generated approximately $1,053,000 of our&#13;revenue, Cardinal Health generated approximately $1,119,000 of our revenue and McKesson Corporation generated approximately $907,000&#13;of our revenue. During the six months ended June 30, 2016, Woodstock Pharmaceutical and Compounding generated approximately $2,237,000&#13;of our revenue; Medical Center Pharmacy generated approximately $1,540,000 of our revenue and Due West Pharmacy generated approximately&#13;$1,863,000 of our revenue.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fair&#13;Value of Financial Instruments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount&#13;of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity&#13;of such instruments, which are considered Level 1 assets under the fair value hierarchy.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy&#13;as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements&lt;i&gt;. &lt;/i&gt;The fair value hierarchy gives the&#13;highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable&#13;inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy&#13;of inputs, as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 0.85in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted&#13;    prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 0.85in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for&#13;    similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly&#13;    or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 0.85in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;unobservable inputs&#13;    for the asset or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;June 30, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of&#13;indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level&#13;3) in connection with our impairment test. There was no impairment of intangible assets or long-lived assets during the three&#13;and six months ended June 30, 2017 and 2016.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Revenue&#13;Recognition&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is&#13;fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably&#13;assured.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation&#13;and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers&#13;of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products&#13;pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing&#13;support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product&#13;lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales. The revenue that is generated&#13;by us from major customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note&#13;13. There are no major customers for our OTC prenatal vitamin or other products.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Research&#13;and Development Expenses&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations,&#13;or CROs, costs of their clinical research sites, manufacturing, laboratory supplies, scale-up and validation costs, and other&#13;activities. Internal R&amp;#38;D activity expenses include salaries, benefits, and non-cash share-based compensation expenses. Advance&#13;payments to be expensed in future research and development activities are capitalized, and were $0 at June 30, 2017 and $228,933&#13;at December 31, 2016, all of which were included in other current assets on the accompanying consolidated balance sheets. CRO&#13;activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory&#13;consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;#38;D expenses&#13;include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration,&#13;or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and&#13;FDA submissions. Legal activities include professional research and advice regarding R&amp;#38;D, patents and regulatory matters.&#13;These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical&#13;trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity expenses to operations as incurred. We&#13;make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable&#13;advance payments for goods and services that will be used in future R&amp;#38;D activities when the activity has been performed or&#13;when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study&#13;expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided&#13;by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense&#13;in the period in which the facts that give rise to the revision become known.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Segment&#13;Reporting&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.&#13;Our business operations are managed by a single management team that reports to the President of our company. We do not operate&#13;separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect&#13;to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one&#13;reportable operating segment.&lt;/font&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, &lt;br /&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    product&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,399,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,062,285&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw&#13;    material&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,036&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,036&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TOTAL&#13;    INVENTORY&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,414,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,076,321&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current assets consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, &lt;br /&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    manufacturing costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;999,508&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;991,809&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid marketing&#13;    costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;535,936&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,571&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;628,039&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research&#13;    and development costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,035&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;128,898&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,311&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    prepaid costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;337,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;405,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TOTAL&#13;    OTHER CURRENT ASSETS&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,228,755&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,299,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed&#13;assets consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, &lt;br /&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounting&#13;    system&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;301,096&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;301,096&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;247,568&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;215,182&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computer hardware&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;80,211&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;80,211&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;116,542&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;113,079&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,888&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,888&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;783,305&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;747,456&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&#13;    depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(299,617&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(230,617&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL&#13;    FIXED ASSETS&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;483,688&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;516,839&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <txmd:ScheduleOfIntangibleAssetsTableTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of June 30, 2017&#13;and December 31, 2016:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&#13;    &lt;br /&gt;Carrying &lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-&lt;br /&gt;Average&#13;    &lt;br /&gt;Remaining&lt;br /&gt;Amortization &lt;br /&gt;Period (yrs.)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&#13;    &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,488&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;24,463&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Development&#13;    costs of &amp;#160;corporate website&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Approved&#13;    hormone&amp;#160;therapy drug&amp;#160;candidate patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,207,267&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(135,282&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,071,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Hormone&#13;    therapy drug&amp;#160;candidate patents&amp;#160;(pending)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,444,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,444,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Multiple&#13;    trademarks&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;198,657&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;198,657&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,974,199&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(234,513&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,739,686&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&#13;    &lt;br /&gt;Carrying &lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    &lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-&#13;    &lt;br /&gt;Average &lt;br /&gt;Remaining &lt;br /&gt;Amortization &lt;br /&gt;Period (yrs.)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&#13;    &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,490&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,461&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Development&#13;    costs of corporate website&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Approved&#13;    hormone&amp;#160;therapy drug&amp;#160;candidate patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,093,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(102,393&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;991,059&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Hormone&#13;    therapy drug&amp;#160;candidate patents&amp;#160;(pending)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,203,987&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,203,987&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Multiple&#13;    trademarks&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;185,465&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;185,465&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,606,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(200,626&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,405,972&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</txmd:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;amortization expense for the next five years for the patent cost currently being amortized is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&#13;    Ending &lt;br /&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    &lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 2%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 46%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017(6&#13;    months)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 44%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,579&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;776,241&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current liabilities consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 83%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, &lt;br /&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    31, &lt;br /&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 66%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued&#13;    clinical trial costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;527,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,281,080&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll,&#13;    bonuses and commission costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,738,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,531,440&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated&#13;    absences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;934,370&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;665,561&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and&#13;    accounting expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;263,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;176,518&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued sales and&#13;    marketing costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;665,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;171,487&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;224,865&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale&#13;    distributor fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;98,729&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;76,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,775&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,507&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons&#13;    and returns&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,019,853&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;794,816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued&#13;    rent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,334&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;181,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL&#13;    OTHER CURRENT LIABILITIES&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,180,218&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,624,085&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable&#13;to common stockholders for the periods presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Three&#13;    and Six months ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,402,100&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,668,657&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,115,905&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,060,571&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,518,005&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;32,729,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;assumptions used in the Black-Scholes Model for options granted during the six months ended June 30, 2017 and 2016 are set forth&#13;in the table below.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Six&#13;    Months Ended&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 46%; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 26%; border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 26%; border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest&#13;    rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.84-2.01%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.26-1.70%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: white"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;61.56-63.95%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70.44-71.22%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.5-6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.25&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: white"&gt;&#13;    &lt;td style="padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of activity under the 2009 and 2012 Plans and related information follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares Underlying Stock Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    &lt;br /&gt;Average &lt;br /&gt;Remaining &lt;br /&gt;Contractual &lt;br /&gt;Life in Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    Intrinsic Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21,767,854&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.56&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,495,730&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,184,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(100,046&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;437,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired/Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(450,208&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at June&#13;    30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,402,100&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2pt; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;52,165,428&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&#13;    and Exercisable at June 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18,731,808&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;51,750,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unvested at June 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,670,292&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;414,881&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of June 30, 2017, future minimum rental payments on non-cancelable operating leases are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Years&#13;    Ending December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 74%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017 (6&#13;    months)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;449,264&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;951,194&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,094,116&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,113,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;943,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,550,770&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="From2017-01-01to2017-06-30" unitRef="Segment" decimals="INF">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Trade&#13;Accounts Receivable and Allowance for Doubtful Accounts&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade&#13;accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts&#13;and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,&#13;historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than&#13;90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual&#13;credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts&#13;previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate&#13;these estimates does not accurately reflect bad debts, adjustments to these reserves may be required.&lt;/font&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Share-Based&#13;Compensation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the&#13;costs in the financial statements over the period during which employees are required to provide services. Share-based&#13;compensation arrangements may include options, restricted stock, restricted stock units, performance-based awards, and share&#13;appreciation rights. We amortize such compensation amounts, if any, over the respective service periods of the award. We use&#13;the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,&#13;Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the&#13;expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected&#13;dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury&#13;bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by&#13;which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected&#13;volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were&#13;publicly available that were similar to our company with respect to industry, stage of life cycle, market capitalization, and&#13;financial leverage. On January 1, 2017, we started using our own stock price in our volatility calculation along with two&#13;other peer entities whose stock prices were publicly available that were similar to our company. Our calculation of estimated&#13;volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected&#13;life of warrants is based on the contractual terms of the awards. The average expected life of options is based on the&#13;contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that&#13;we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based&#13;compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the&#13;share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of&#13;share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of&#13;management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense&#13;could be materially different in the future.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Equity&#13;instruments (&amp;#8220;instruments&amp;#8221;) issued to non-employees are recorded on the basis of the fair value of the instruments,&#13;as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition&#13;period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached&#13;or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is&#13;recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees&#13;can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value&#13;related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined&#13;in ASC 505.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance&#13;with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&amp;#8217;s requisite service&#13;period. &lt;font style="color: #252525"&gt;We adopted ASU 2016-09, effective January 1, 2017, electing to account for forfeitures when&#13;they occur. Prior to that, &lt;/font&gt;we estimated the forfeiture rate based on our historical experience of forfeitures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2016-01-01to2016-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2016-01-01to2016-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.6395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2016-01-01to2016-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.7122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2017-01-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.6156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2016-01-01to2016-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.7044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <txmd:PrescriptionProductsPolicyTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Prescription&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy distributors.&#13;We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees, customer rebates and&#13;estimated returns.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped&#13;to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products&#13;sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration.&#13;Our prescription products currently have a shelf life of 24 months from the date of manufacture.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prior&#13;to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the&#13;product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were&#13;known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the&#13;distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader&#13;population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription&#13;products are distributed under the wholesale distributor model described above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer&#13;loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry&#13;averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated&#13;in contracts and estimate chargebacks based on the number of units sold each period.&lt;/font&gt;&lt;/p&gt;</txmd:PrescriptionProductsPolicyTextBlock>
    <txmd:OverTheCounterProductsPolicyTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,&#13;when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if&#13;any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC&#13;customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit&#13;card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back&#13;return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC&#13;sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product&#13;lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales.&lt;/font&gt;&lt;/p&gt;</txmd:OverTheCounterProductsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2017-04-01to2017-06-30_custom_Warrant2Member" unitRef="Shares" decimals="INF">6590000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2017-01-01to2017-06-30_custom_Warrant2Member" unitRef="Shares" decimals="INF">6590000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2017-07-31" unitRef="Shares" decimals="INF">204027142</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2017-01-01to2017-06-30">&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 14&amp;#x2013; COMMITMENTS AND CONTINGENCIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Operating Lease&lt;/u&gt;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016.&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;The rental expense related to our current lease during the three months ended June 30, 2017 and 2016 was approximately $265,000 and $182,000, respectively. The rental expense related to our current lease during the six months ended June 30, 2017 and 2016 was approximately $515,000 and $300,000, respectively.&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;As of June 30, 2017, future minimum rental payments on non-cancelable operating leases are as follows:&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;    &lt;table align="center" cellpadding="0" cellspacing="0" style="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;        &lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Years Ending December 31,&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="width: 73%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;                &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017 (6 months)&lt;/font&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 4%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;            &lt;td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;449,264&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;951,194&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,094,116&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,113,069&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;943,127&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;                &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,550,770&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;    &lt;/table&gt;&#13;    &lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;    &lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="text-decoration: underline"&gt;Legal Proceedings&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;On April&#13;17, 2017, a securities class action lawsuit was filed against our company and certain of our officers and directors in the U.S.&#13;District Court for the Southern District of Florida (Case No. 9:17-cv-80473-RLR) that purports to state a claim for alleged violations&#13;of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, based on statements&#13;made by the defendants concerning the NDA for TX-004HR. The complaint sought unspecified damages, interest, attorneys&amp;#x2019;&#13;fees and other costs. On July 18, 2017, the complaint was voluntarily dismissed by the lead plaintiff without prejudice. We and&#13;certain of our officers and directors are also subject to two shareholder derivative lawsuits regarding the NDA for TX-004HR,&#13;one filed in the U.S. District Court for the Southern District of Florida on May 30, 2017 (Case No. 9:17-cv-80686-RLR) and one&#13;filed in Florida state court in Palm Beach County on June 5, 2017 (Case No. 502017CA006289XXXXMB). We believe these lawsuits to&#13;be without merit and intend to vigorously defend against them. The derivative lawsuits are in the very early stages and, at this&#13;time, no assessment can be made as to their likely outcome or whether the outcome will be material to us.&lt;/p&gt;&#13;    &lt;p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>txmd-20170630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20170630\txmd_063017.xfr; Date: 2017%2D08%2D02T21:59:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSamIqbP9w5dzaelBtm99Hek63yYoOvRZ1SJaQg520U8P -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:txmd="http://therapeuticsmd.com/20170630" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20170630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
	  <link:definition>00000006 - Disclosure - THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" id="BasisOfPresentationAndRecentlyIssuedAccountingPronouncements">
	  <link:definition>00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssets" id="FixedAssets">
	  <link:definition>00000011 - Disclosure - FIXED ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000012 - Disclosure - INTANGIBLE ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000013 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShare" id="NetLossPerShare">
	  <link:definition>00000014 - Disclosure - NET LOSS PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000015 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000016 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000017 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
	  <link:definition>00000018 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000021 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000022 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" id="FixedAssetsTables">
	  <link:definition>00000023 - Disclosure - FIXED ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000024 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000025 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
	  <link:definition>00000026 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" id="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative">
	  <link:definition>00000029 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryDetails" id="InventoryDetails">
	  <link:definition>00000031 - Disclosure - INVENTORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" id="OtherCurrentAssetsDetails">
	  <link:definition>00000032 - Disclosure - OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" id="FixedAssetsDetails">
	  <link:definition>00000033 - Disclosure - FIXED ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" id="FixedAssetsDetailsNarrative">
	  <link:definition>00000034 - Disclosure - FIXED ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
	  <link:definition>00000035 - Disclosure - INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
	  <link:definition>00000036 - Disclosure - INTANGIBLE ASSETS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000038 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" id="NetLossPerShareDetails">
	  <link:definition>00000039 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetailsNarrtaive" id="NetLossPerShareDetailsNarrtaive">
	  <link:definition>00000040 - Disclosure - NET LOSS PER SHARE (Details Narrtaive)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" id="StockholdersEquityDetailsNarrative1">
	  <link:definition>00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" id="StockholdersEquityDetailsNarrative2">
	  <link:definition>00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" id="StockholdersEquityDetailsNarrative3">
	  <link:definition>00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000047 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20170630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20170630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20170630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20170630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates" name="AmountOfAdjustmentForProvisionsRelatedToForfeitureRates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturingCostsCurrent" name="PrepaidManufacturingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidMarketingCostsCurrent" name="PrepaidMarketingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidConsultingCurrent" name="PrepaidConsultingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidVendorDepositsCurrent" name="PrepaidVendorDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatents" name="NumberOfIssuedPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalPeriodForPurchaseShare" name="AdditionalPeriodForPurchaseShare" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" name="ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" name="ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DescriptionOfSharesToBeVested" name="DescriptionOfSharesToBeVested" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfIntangibleAssetsTableTextBlock" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrescriptionProductsPolicyTextBlock" name="PrescriptionProductsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OverTheCounterProductsPolicyTextBlock" name="OverTheCounterProductsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Patents1Member" name="Patents1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Patents2Member" name="Patents2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_GoldmanSachsMember" name="GoldmanSachsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultant2Member" name="OutsideConsultant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrantsMember" name="SancilioAndCompanyWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Warrant1Member" name="Warrant1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndividualsMember" name="IndividualsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Warrant2Member" name="Warrant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FiveCustomersMember" name="FiveCustomersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ThreeCustomersMember" name="ThreeCustomersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PharmacyInnovationsTXMember" name="PharmacyInnovationsTXMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PharmacyInnovationsMember" name="PharmacyInnovationsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AmerisourceBergenMember" name="AmerisourceBergenMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CardinalHealthMember" name="CardinalHealthMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_McKessonCorporationMember" name="McKessonCorporationMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WoodstockPharmaceuticalAndCompoundingMember" name="WoodstockPharmaceuticalAndCompoundingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MedicalCenterPharmacyMember" name="MedicalCenterPharmacyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DueWestPharmacyMember" name="DueWestPharmacyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EntityCommonStockHeldByNonaffiliates" name="EntityCommonStockHeldByNonaffiliates" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" name="SummaryOfActivityUnder2009And2012PlansAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAbstract" name="WarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>txmd-20170630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20170630\txmd_063017.xfr; Date: 2017%2D08%2D02T21:59:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20170630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20170630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20170630.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20170630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20170630.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20170630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20170630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20170630.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20170630.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20170630.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20170630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20170630.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShare" xlink:href="txmd-20170630.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20170630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20170630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20170630.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20170630.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20170630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20170630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20170630.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20170630.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20170630.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20170630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20170630.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:href="txmd-20170630.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20170630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20170630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:href="txmd-20170630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20170630.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20170630.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20170630.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20170630.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20170630.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20170630.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20170630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20170630.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20170630.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetailsNarrtaive" xlink:href="txmd-20170630.xsd#NetLossPerShareDetailsNarrtaive" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20170630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20170630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20170630.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20170630.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20170630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20170630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000006 - Disclosure - THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare" xlink:title="00000014 - Disclosure - NET LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000017 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000018 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000021 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000022 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000023 - Disclosure - FIXED ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000024 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000025 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:title="00000026 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:title="00000029 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000031 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000032 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidManufacturingCostsCurrent" xlink:label="loc_txmdPrepaidManufacturingCostsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidManufacturingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidVendorDepositsCurrent" xlink:label="loc_txmdPrepaidVendorDepositsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidVendorDepositsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidMarketingCostsCurrent" xlink:label="loc_txmdPrepaidMarketingCostsCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidMarketingCostsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000033 - Disclosure - FIXED ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000034 - Disclosure - FIXED ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000035 - Disclosure - INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000036 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000038 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000039 - Disclosure - NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetailsNarrtaive" xlink:title="00000040 - Disclosure - NET LOSS PER SHARE (Details Narrtaive)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000047 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>txmd-20170630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20170630\txmd_063017.xfr; Date: 2017%2D08%2D02T21:59:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20170630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20170630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20170630.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20170630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20170630.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20170630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20170630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20170630.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20170630.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20170630.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20170630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20170630.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShare" xlink:href="txmd-20170630.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20170630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20170630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20170630.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20170630.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20170630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20170630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20170630.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20170630.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20170630.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20170630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20170630.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:href="txmd-20170630.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20170630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20170630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:href="txmd-20170630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20170630.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20170630.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20170630.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20170630.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20170630.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20170630.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20170630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20170630.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20170630.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetailsNarrtaive" xlink:href="txmd-20170630.xsd#NetLossPerShareDetailsNarrtaive" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20170630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20170630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20170630.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20170630.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20170630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20170630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000006 - Disclosure - THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare" xlink:title="00000014 - Disclosure - NET LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000017 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000018 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000021 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000022 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000023 - Disclosure - FIXED ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000024 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000025 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:title="00000026 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:title="00000029 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMajorCustomersAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000031 - Disclosure - INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000032 - Disclosure - OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000033 - Disclosure - FIXED ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000034 - Disclosure - FIXED ASSETS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000035 - Disclosure - INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000036 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Patents1Member" xlink:label="loc_txmdPatents1Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents1Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Patents2Member" xlink:label="loc_txmdPatents2Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents2Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000038 - Disclosure - OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000039 - Disclosure - NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetailsNarrtaive" xlink:title="00000040 - Disclosure - NET LOSS PER SHARE (Details Narrtaive)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_30" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdGoldmanSachsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare_90" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedCompensation_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_190" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Warrant1Member" xlink:label="loc_txmdWarrant1Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant1Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_DescriptionOfSharesToBeVested" xlink:label="loc_txmdDescriptionOfSharesToBeVested_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdDescriptionOfSharesToBeVested_180" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Warrant2Member" xlink:label="loc_txmdWarrant2Member_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant2Member_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_IndividualsMember" xlink:label="loc_txmdIndividualsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdIndividualsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_180" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000047 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_FiveCustomersMember" xlink:label="loc_txmdFiveCustomersMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdFiveCustomersMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ThreeCustomersMember" xlink:label="loc_txmdThreeCustomersMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdThreeCustomersMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PharmacyInnovationsTXMember" xlink:label="loc_txmdPharmacyInnovationsTXMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdPharmacyInnovationsTXMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PharmacyInnovationsMember" xlink:label="loc_txmdPharmacyInnovationsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdPharmacyInnovationsMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AmerisourceBergenMember" xlink:label="loc_txmdAmerisourceBergenMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdAmerisourceBergenMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_CardinalHealthMember" xlink:label="loc_txmdCardinalHealthMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCardinalHealthMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_McKessonCorporationMember" xlink:label="loc_txmdMcKessonCorporationMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMcKessonCorporationMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:label="loc_txmdWoodstockPharmaceuticalAndCompoundingMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdWoodstockPharmaceuticalAndCompoundingMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_MedicalCenterPharmacyMember" xlink:label="loc_txmdMedicalCenterPharmacyMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMedicalCenterPharmacyMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_DueWestPharmacyMember" xlink:label="loc_txmdDueWestPharmacyMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdDueWestPharmacyMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet_170" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>txmd-20170630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20170630\txmd_063017.xfr; Date: 2017%2D08%2D02T21:59:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Related to Research and Development Activities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Accounting System [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Hardware [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_2_lbl" xml:lang="en-US">Leasehold improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Opera Software Patent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="us-gaap_InternetDomainNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternetDomainNamesMember" xlink:to="us-gaap_InternetDomainNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternetDomainNamesMember_lbl" xml:lang="en-US">Development Costs Of Corporate Website [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Patents1Member" xlink:label="txmd_Patents1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents1Member" xlink:to="txmd_Patents1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Patents1Member_lbl" xml:lang="en-US">Utility Patent Progesterone and Estradiol Products [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Utility Patent TX-004HR [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Patents2Member" xlink:label="txmd_Patents2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents2Member" xlink:to="txmd_Patents2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Patents2Member_lbl" xml:lang="en-US">Utility Patent Pipeline Transdermal Patch Technology [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_GoldmanSachsMember" xlink:label="txmd_GoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_GoldmanSachsMember_lbl" xml:lang="en-US">Underwriting Agreement - Goldman And Cowen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_OutsideConsultant2Member" xlink:label="txmd_OutsideConsultant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultant2Member_lbl" xml:lang="en-US">Outside Consultant Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_OutsideConsultant2Member_2_lbl" xml:lang="en-US">Outside Consultant Warrants #3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="txmd_SancilioAndCompanyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrantsMember_lbl" xml:lang="en-US">SCI - Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Warrant1Member" xlink:label="txmd_Warrant1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant1Member" xlink:to="txmd_Warrant1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Warrant1Member_lbl" xml:lang="en-US">Warrants - Unaffiliated Entity [Member] [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_IndividualsMember" xlink:label="txmd_IndividualsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualsMember" xlink:to="txmd_IndividualsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndividualsMember_lbl" xml:lang="en-US">Individuals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Warrant2Member" xlink:label="txmd_Warrant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant2Member" xlink:to="txmd_Warrant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Warrant2Member_lbl" xml:lang="en-US">Warrants - Cashless Exercise [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Catalent Inc.[Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_FiveCustomersMember" xlink:label="txmd_FiveCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FiveCustomersMember" xlink:to="txmd_FiveCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FiveCustomersMember_lbl" xml:lang="en-US">Five Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ThreeCustomersMember" xlink:label="txmd_ThreeCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersMember" xlink:to="txmd_ThreeCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ThreeCustomersMember_lbl" xml:lang="en-US">Three Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PharmacyInnovationsTXMember" xlink:label="txmd_PharmacyInnovationsTXMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PharmacyInnovationsTXMember" xlink:to="txmd_PharmacyInnovationsTXMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PharmacyInnovationsTXMember_lbl" xml:lang="en-US">Pharmacy Innovations TX [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PharmacyInnovationsMember" xlink:label="txmd_PharmacyInnovationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PharmacyInnovationsMember" xlink:to="txmd_PharmacyInnovationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PharmacyInnovationsMember_lbl" xml:lang="en-US">Pharmacy Innovations PA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AmerisourceBergenMember" xlink:label="txmd_AmerisourceBergenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmerisourceBergenMember" xlink:to="txmd_AmerisourceBergenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmerisourceBergenMember_lbl" xml:lang="en-US">AmerisourceBergen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_CardinalHealthMember" xlink:label="txmd_CardinalHealthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CardinalHealthMember" xlink:to="txmd_CardinalHealthMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CardinalHealthMember_lbl" xml:lang="en-US">Cardinal Health [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_McKessonCorporationMember" xlink:label="txmd_McKessonCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_McKessonCorporationMember" xlink:to="txmd_McKessonCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_McKessonCorporationMember_lbl" xml:lang="en-US">McKesson Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:label="txmd_WoodstockPharmaceuticalAndCompoundingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:to="txmd_WoodstockPharmaceuticalAndCompoundingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WoodstockPharmaceuticalAndCompoundingMember_lbl" xml:lang="en-US">Woodstock Pharmaceutical and Compounding [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_MedicalCenterPharmacyMember" xlink:label="txmd_MedicalCenterPharmacyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MedicalCenterPharmacyMember" xlink:to="txmd_MedicalCenterPharmacyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MedicalCenterPharmacyMember_lbl" xml:lang="en-US">Medical Center Pharmacy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_DueWestPharmacyMember" xlink:label="txmd_DueWestPharmacyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DueWestPharmacyMember" xlink:to="txmd_DueWestPharmacyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DueWestPharmacyMember_lbl" xml:lang="en-US">Due West Pharmacy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="txmd_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DocumentAndEntityInformationAbstract" xlink:to="txmd_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity a Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity a Voluntary Filer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity's Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xml:lang="en-US">Entity Common Stock, Held by non-affiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $358,268 and $376,374, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - See Note 14</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 350,000,000 shares authorized 204,027,142 and 196,688,222 issued and outstanding,respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other income:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Accreted interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">(Recovery of) provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Payment of security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">(Decrease) increase in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:to="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_lbl" xml:lang="en-US">Basis Of Presentation And Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:to="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_OverTheCounterProductsPolicyTextBlock" xlink:label="txmd_OverTheCounterProductsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OverTheCounterProductsPolicyTextBlock" xlink:to="txmd_OverTheCounterProductsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OverTheCounterProductsPolicyTextBlock_lbl" xml:lang="en-US">Over-the-Counter Products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrescriptionProductsPolicyTextBlock" xlink:label="txmd_PrescriptionProductsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionProductsPolicyTextBlock" xlink:to="txmd_PrescriptionProductsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrescriptionProductsPolicyTextBlock_lbl" xml:lang="en-US">Prescription Products</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="txmd_ScheduleOfIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of plan activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum rental payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" xlink:to="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract_lbl" xml:lang="en-US">Basis Of Presentation And Recently Issued Accounting Pronouncements Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates" xlink:label="txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates" xlink:to="txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates_lbl" xml:lang="en-US">Amount of adjustment for provisions related to forfeiture rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Advance payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw material</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="txmd_OtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherCurrentAssetsAbstract" xlink:to="txmd_OtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidManufacturingCostsCurrent" xlink:label="txmd_PrepaidManufacturingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsCurrent" xlink:to="txmd_PrepaidManufacturingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturingCostsCurrent_lbl" xml:lang="en-US">Prepaid manufacturing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidMarketingCostsCurrent" xlink:label="txmd_PrepaidMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidMarketingCostsCurrent" xlink:to="txmd_PrepaidMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidMarketingCostsCurrent_lbl" xml:lang="en-US">Prepaid marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidConsultingCurrent" xlink:label="txmd_PrepaidConsultingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidConsultingCurrent_lbl" xml:lang="en-US">Prepaid consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidVendorDepositsCurrent" xlink:label="txmd_PrepaidVendorDepositsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDepositsCurrent" xlink:to="txmd_PrepaidVendorDepositsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidVendorDepositsCurrent_lbl" xml:lang="en-US">Prepaid vendor deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Weighted average remaining amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Estimated amortization expense for the year:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2017(6 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_NumberOfIssuedPatents" xlink:label="txmd_NumberOfIssuedPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatents_lbl" xml:lang="en-US">Number of issued patents</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="txmd_AccruedClinicalTrialCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US">Accrued clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xml:lang="en-US">Accrued sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US">Accrued rent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares excluded from earnings per share calculation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:to="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xml:lang="en-US">Summary of Activity under 2009 and 2012 Plans:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Options, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options Expired/Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Options, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired/Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_lbl" xml:lang="en-US">Options, Weighted Average Remaining Contractual Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Options outstanding, Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Value of common stock issued during period for stock options exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Additional common stock issued under offering</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="txmd_AdditionalPeriodForPurchaseShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalPeriodForPurchaseShare_lbl" xml:lang="en-US">Number of days of the option to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_WarrantsAbstract" xlink:label="txmd_WarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAbstract" xlink:to="txmd_WarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAbstract_lbl" xml:lang="en-US">Warrants:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants granted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xml:lang="en-US">Expiration date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xml:lang="en-US">Vesting date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unamortized costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xml:lang="en-US">Warrants granted to purchase common stock (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_2_lbl" xml:lang="en-US">Prepaid expenses - current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Non-cash compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unamortized costs of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xml:lang="en-US">Forfeited warrants granted to purchase common stock (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested warrants granted to purchase common stock (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Recognition period of unamortized costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_DescriptionOfSharesToBeVested" xlink:label="txmd_DescriptionOfSharesToBeVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DescriptionOfSharesToBeVested" xlink:to="txmd_DescriptionOfSharesToBeVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DescriptionOfSharesToBeVested_lbl" xml:lang="en-US">Description of shares to be vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of shares available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Option exercise prices (in dollars per shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized estimated compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2_lbl" xml:lang="en-US">Recognized weighted-average period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued for exercise of warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued for exercise of warrants, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Manufacturing activities billed from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNet_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xml:lang="en-US">Future minimum rental payments, year ending December 31,</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2017 (6 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rental expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xml:lang="en-US">Rental income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_doc" xml:lang="en-US">Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates" xlink:to="txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates_doc" xml:lang="en-US">It refers to the amount of adjustment for provisions related to forfeiture rates during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsCurrent" xlink:to="txmd_PrepaidManufacturingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturingCostsCurrent_doc" xml:lang="en-US">It represents amount of prepaid manufacturing costs current during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidMarketingCostsCurrent" xlink:to="txmd_PrepaidMarketingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidMarketingCostsCurrent_doc" xml:lang="en-US">It refers to the amount of prepaid marketing costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidConsultingCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDepositsCurrent" xlink:to="txmd_PrepaidVendorDepositsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidVendorDepositsCurrent_doc" xml:lang="en-US">It represents amount prepaid vendor deposits current during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xml:lang="en-US">Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents1Member" xlink:to="txmd_Patents1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Patents1Member_doc" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents2Member" xlink:to="txmd_Patents2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Patents2Member_doc" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatents_doc" xml:lang="en-US">Number of issued patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:to="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_doc" xml:lang="en-US">The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire unvested shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_GoldmanSachsMember_doc" xml:lang="en-US">Goldman Sachs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalPeriodForPurchaseShare_doc" xml:lang="en-US">Refers to additonal period for purchase of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultant2Member_doc" xml:lang="en-US">A person who provides professional services to the Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are expired in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are vesting date in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrantsMember_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant1Member" xlink:to="txmd_Warrant1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Warrant1Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xml:lang="en-US">Refer to numbers of shares forfeit during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DescriptionOfSharesToBeVested" xlink:to="txmd_DescriptionOfSharesToBeVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DescriptionOfSharesToBeVested_doc" xml:lang="en-US">General descriptive information regarding shares to be vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualsMember" xlink:to="txmd_IndividualsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndividualsMember_doc" xml:lang="en-US">It refers name of the related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant2Member" xlink:to="txmd_Warrant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Warrant2Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FiveCustomersMember" xlink:to="txmd_FiveCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FiveCustomersMember_doc" xml:lang="en-US">Represent number of major customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersMember" xlink:to="txmd_ThreeCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ThreeCustomersMember_doc" xml:lang="en-US">Represent number of major customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PharmacyInnovationsTXMember" xlink:to="txmd_PharmacyInnovationsTXMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PharmacyInnovationsTXMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PharmacyInnovationsMember" xlink:to="txmd_PharmacyInnovationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PharmacyInnovationsMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmerisourceBergenMember" xlink:to="txmd_AmerisourceBergenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmerisourceBergenMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CardinalHealthMember" xlink:to="txmd_CardinalHealthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CardinalHealthMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_McKessonCorporationMember" xlink:to="txmd_McKessonCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_McKessonCorporationMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:to="txmd_WoodstockPharmaceuticalAndCompoundingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WoodstockPharmaceuticalAndCompoundingMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MedicalCenterPharmacyMember" xlink:to="txmd_MedicalCenterPharmacyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MedicalCenterPharmacyMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DueWestPharmacyMember" xlink:to="txmd_DueWestPharmacyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DueWestPharmacyMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of intangible assets, which may be broken down by major class.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionProductsPolicyTextBlock" xlink:to="txmd_PrescriptionProductsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrescriptionProductsPolicyTextBlock_doc" xml:lang="en-US">Disclosure of policy related to prescription products.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OverTheCounterProductsPolicyTextBlock" xlink:to="txmd_OverTheCounterProductsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OverTheCounterProductsPolicyTextBlock_doc" xml:lang="en-US">Disclosure of policy related to over-the-counter products.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_3_lbl" xml:lang="en-US">SCI - Warrants [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_2_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>txmd-20170630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20170630\txmd_063017.xfr; Date: 2017%2D08%2D02T21:59:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20170630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20170630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20170630.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20170630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20170630.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20170630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20170630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20170630.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20170630.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20170630.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20170630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20170630.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShare" xlink:href="txmd-20170630.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20170630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20170630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20170630.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20170630.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20170630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20170630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20170630.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20170630.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20170630.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20170630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20170630.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:href="txmd-20170630.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20170630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20170630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:href="txmd-20170630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20170630.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20170630.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20170630.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20170630.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20170630.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20170630.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20170630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20170630.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20170630.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetailsNarrtaive" xlink:href="txmd-20170630.xsd#NetLossPerShareDetailsNarrtaive" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20170630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20170630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:href="txmd-20170630.xsd#StockholdersEquityDetailsNarrative3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20170630.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20170630.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20170630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20170630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="loc_txmdDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="loc_txmdEntityCommonStockHeldByNonaffiliates" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_txmdEntityCommonStockHeldByNonaffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaapOtherExpensesAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000006 - Disclosure - THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS">
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:label="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:label="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:to="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare" xlink:title="00000014 - Disclosure - NET LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000017 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000018 - Disclosure - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_OverTheCounterProductsPolicyTextBlock" xlink:label="loc_txmdOverTheCounterProductsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdOverTheCounterProductsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrescriptionProductsPolicyTextBlock" xlink:label="loc_txmdPrescriptionProductsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdPrescriptionProductsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000021 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000022 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000023 - Disclosure - FIXED ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000024 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="loc_txmdScheduleOfIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_txmdScheduleOfIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000025 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:title="00000026 - Disclosure - NET LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:title="00000029 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" xlink:label="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates" xlink:label="loc_txmdAmountOfAdjustmentForProvisionsRelatedToForfeitureRates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" xlink:to="loc_txmdAmountOfAdjustmentForProvisionsRelatedToForfeitureRates" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMajorCustomersAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000031 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaapInventoryNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNetAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000032 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="loc_txmdOtherCurrentAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdOtherCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidManufacturingCostsCurrent" xlink:label="loc_txmdPrepaidManufacturingCostsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidManufacturingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidMarketingCostsCurrent" xlink:label="loc_txmdPrepaidMarketingCostsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PrepaidVendorDepositsCurrent" xlink:label="loc_txmdPrepaidVendorDepositsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidVendorDepositsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000033 - Disclosure - FIXED ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000034 - Disclosure - FIXED ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000035 - Disclosure - INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000036 - Disclosure - INTANGIBLE ASSETS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Patents1Member" xlink:label="loc_txmdPatents1Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Patents2Member" xlink:label="loc_txmdPatents2Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000038 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000039 - Disclosure - NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetailsNarrtaive" xlink:title="00000040 - Disclosure - NET LOSS PER SHARE (Details Narrtaive)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdGoldmanSachsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Warrant1Member" xlink:label="loc_txmdWarrant1Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_DescriptionOfSharesToBeVested" xlink:label="loc_txmdDescriptionOfSharesToBeVested" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdDescriptionOfSharesToBeVested" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_Warrant2Member" xlink:label="loc_txmdWarrant2Member" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_IndividualsMember" xlink:label="loc_txmdIndividualsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdIndividualsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000047 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_FiveCustomersMember" xlink:label="loc_txmdFiveCustomersMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdFiveCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_ThreeCustomersMember" xlink:label="loc_txmdThreeCustomersMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdThreeCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PharmacyInnovationsTXMember" xlink:label="loc_txmdPharmacyInnovationsTXMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdPharmacyInnovationsTXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_PharmacyInnovationsMember" xlink:label="loc_txmdPharmacyInnovationsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdPharmacyInnovationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_AmerisourceBergenMember" xlink:label="loc_txmdAmerisourceBergenMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdAmerisourceBergenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_CardinalHealthMember" xlink:label="loc_txmdCardinalHealthMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCardinalHealthMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_McKessonCorporationMember" xlink:label="loc_txmdMcKessonCorporationMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMcKessonCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:label="loc_txmdWoodstockPharmaceuticalAndCompoundingMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdWoodstockPharmaceuticalAndCompoundingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_MedicalCenterPharmacyMember" xlink:label="loc_txmdMedicalCenterPharmacyMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMedicalCenterPharmacyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_DueWestPharmacyMember" xlink:label="loc_txmdDueWestPharmacyMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdDueWestPharmacyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20170630.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748145152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TherapeuticsMD, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity a Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity a Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,027,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751087744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 96,476,483<span></span>
</td>
<td class="nump">$ 131,534,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $358,268 and $376,374, respectively</a></td>
<td class="nump">3,396,419<span></span>
</td>
<td class="nump">4,500,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,414,015<span></span>
</td>
<td class="nump">1,076,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,228,755<span></span>
</td>
<td class="nump">2,299,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">103,515,672<span></span>
</td>
<td class="nump">139,410,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">483,688<span></span>
</td>
<td class="nump">516,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,739,686<span></span>
</td>
<td class="nump">2,405,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
<td class="nump">139,036<span></span>
</td>
<td class="nump">139,036<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">2,878,722<span></span>
</td>
<td class="nump">2,545,008<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">106,878,082<span></span>
</td>
<td class="nump">142,472,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,108,034<span></span>
</td>
<td class="nump">7,358,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">5,180,218<span></span>
</td>
<td class="nump">7,624,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,288,252<span></span>
</td>
<td class="nump">14,982,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies - See Note 14</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 350,000,000 shares authorized 204,027,142 and 196,688,222 issued and outstanding,respectively</a></td>
<td class="nump">204,027<span></span>
</td>
<td class="nump">196,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">443,952,952<span></span>
</td>
<td class="nump">436,995,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(350,567,149)<span></span>
</td>
<td class="num">(309,702,319)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">93,589,830<span></span>
</td>
<td class="nump">127,489,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 106,878,082<span></span>
</td>
<td class="nump">$ 142,472,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6738351872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 358,268<span></span>
</td>
<td class="nump">$ 376,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">204,027,142<span></span>
</td>
<td class="nump">196,688,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">204,027,142<span></span>
</td>
<td class="nump">196,688,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748725888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues, net</a></td>
<td class="nump">$ 4,250,433<span></span>
</td>
<td class="nump">$ 4,403,247<span></span>
</td>
<td class="nump">$ 8,235,897<span></span>
</td>
<td class="nump">$ 9,333,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">681,725<span></span>
</td>
<td class="nump">1,130,108<span></span>
</td>
<td class="nump">1,341,360<span></span>
</td>
<td class="nump">2,238,551<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,568,708<span></span>
</td>
<td class="nump">3,273,139<span></span>
</td>
<td class="nump">6,894,537<span></span>
</td>
<td class="nump">7,094,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administration</a></td>
<td class="nump">14,628,927<span></span>
</td>
<td class="nump">10,619,006<span></span>
</td>
<td class="nump">31,466,544<span></span>
</td>
<td class="nump">20,297,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,716,395<span></span>
</td>
<td class="nump">13,841,193<span></span>
</td>
<td class="nump">16,441,235<span></span>
</td>
<td class="nump">28,938,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">53,189<span></span>
</td>
<td class="nump">24,262<span></span>
</td>
<td class="nump">102,888<span></span>
</td>
<td class="nump">43,859<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">23,398,511<span></span>
</td>
<td class="nump">24,484,461<span></span>
</td>
<td class="nump">48,010,667<span></span>
</td>
<td class="nump">49,279,627<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(19,829,803)<span></span>
</td>
<td class="num">(21,211,322)<span></span>
</td>
<td class="num">(41,116,130)<span></span>
</td>
<td class="num">(42,184,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">149,054<span></span>
</td>
<td class="nump">114,320<span></span>
</td>
<td class="nump">275,022<span></span>
</td>
<td class="nump">155,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Accreted interest</a></td>
<td class="nump">3,832<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">7,699<span></span>
</td>
<td class="nump">5,399<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">152,886<span></span>
</td>
<td class="nump">117,183<span></span>
</td>
<td class="nump">282,721<span></span>
</td>
<td class="nump">161,336<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(19,676,917)<span></span>
</td>
<td class="num">(21,094,139)<span></span>
</td>
<td class="num">(40,833,409)<span></span>
</td>
<td class="num">(42,023,504)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,676,917)<span></span>
</td>
<td class="num">$ (21,094,139)<span></span>
</td>
<td class="num">$ (40,833,409)<span></span>
</td>
<td class="num">$ (42,023,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">203,384,610<span></span>
</td>
<td class="nump">196,325,715<span></span>
</td>
<td class="nump">200,602,778<span></span>
</td>
<td class="nump">195,613,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748126336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,833,409)<span></span>
</td>
<td class="num">$ (42,023,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">69,000<span></span>
</td>
<td class="nump">19,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">33,888<span></span>
</td>
<td class="nump">24,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">(Recovery of) provision for doubtful accounts</a></td>
<td class="num">(18,106)<span></span>
</td>
<td class="nump">447,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,051,357<span></span>
</td>
<td class="nump">9,200,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,122,386<span></span>
</td>
<td class="num">(1,874,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(337,694)<span></span>
</td>
<td class="num">(193,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(58,601)<span></span>
</td>
<td class="nump">1,001,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">749,520<span></span>
</td>
<td class="num">(86,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(2,443,867)<span></span>
</td>
<td class="num">(1,239,743)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(38,665,526)<span></span>
</td>
<td class="num">(34,725,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(367,602)<span></span>
</td>
<td class="num">(393,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(35,849)<span></span>
</td>
<td class="num">(265,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Payment of security deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,864)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(403,451)<span></span>
</td>
<td class="num">(663,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">134,863,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">3,798,999<span></span>
</td>
<td class="nump">1,373,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">212,360<span></span>
</td>
<td class="nump">978,042<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,011,359<span></span>
</td>
<td class="nump">137,214,517<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">(Decrease) increase in cash</a></td>
<td class="num">(35,057,618)<span></span>
</td>
<td class="nump">101,826,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">131,534,101<span></span>
</td>
<td class="nump">64,706,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">$ 96,476,483<span></span>
</td>
<td class="nump">$ 166,532,446<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744142432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">THE COMPANY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
1 &#8211; THE COMPANY</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD, or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Nature
of Business</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
are a women&#8217;s health care company focused on creating and commercializing products targeted exclusively for women. Currently,
we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our
advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate
the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis
and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone
or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile
compared with competing products. With our SYMBODA&#8482; technology, we are developing advanced hormone therapy pharmaceutical
products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition,
we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, iron supplements.</font></p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908385280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract', window );"><strong>Basis Of Presentation And Recently Issued Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock', window );">BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Interim
Financial Statements</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #252525">The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2016. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance </font><font style="font: 10pt Times New Roman, Times, Serif">with
accounting principles generally accepted in the United States of America, or GAAP<font style="color: #252525">, for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements,
the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required
by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments,
consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results
for the interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim
period in the future.</font></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recently
Issued Accounting Pronouncements</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2017, the Financial Accounting Standards Board, or FASB, issued an Accounting Standards Update, or ASU, that clarifies when
changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will
reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. The new
guidance will allow companies to make certain changes to awards without accounting for them as modifications. This guidance does
not change the accounting for modifications. The guidance will be applied prospectively to awards modified on or after the adoption
date and is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017.
Early adoption is permitted, including in an interim period. We do not expect that adoption of this guidance will have a material
effect on our consolidated financial statements.</font></p>

<p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity
in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for
public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years.
Early adoption is permitted with retrospective application. We are currently evaluating the impact of this guidance on our consolidated
financial statements and disclosures.</font></p>

<p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
March 2016, the FASB issued ASU 2016-09, Compensation &#8211; Stock Compensation: Improvements to Employee Share-Based Payment
Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both
public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,
as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years
beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&#160;ASU&#160;2016-09&#160;effective
January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture
rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of
approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies
in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full
valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to
recognize the previously unrecognized net operating losses from prior periods was made to the valuation allowance through retained
earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated
financial statements.</font></p>

<p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets
but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current
real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting
for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning
after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process
of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing
to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to
the accounting for our operating lease.</font></p>

<p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="color: #252525; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#8217;s core principle
is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects
the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies
will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance
obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating
the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective
date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for
public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB
issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting
for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical
expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We
have performed a preliminary review of the requirements of the new revenue standard and are monitoring the activity of the FASB
and the transition resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied
the five-step model of the new standard to our contracts as well as compared the results to our current accounting practices.
At this point of our analysis, we do not believe that the adoption of this standard will have a material effect on our financial
statements but will potentially expand our disclosures related to contracts with customers.</font></p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744139824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair
Value of Financial Instruments</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount
of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity
of such instruments, which are considered Level 1 assets under the fair value hierarchy.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements<i>. </i>The fair value hierarchy gives the
highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable
inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy
of inputs, as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 0.85in"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    1</b></font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">unadjusted quoted
    prices in active markets for identical assets or liabilities;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 0.85in"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    2</b></font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">quoted prices for
    similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
    or indirectly through market corroboration, for substantially the full term of the financial instrument; and</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 0.85in"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    3</b></font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">unobservable inputs
    for the asset or liability.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of
indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level
3) in connection with our impairment test. There was no impairment of intangible assets or long-lived assets during the three
and six months ended June 30, 2017 and 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Trade
Accounts Receivable and Allowance for Doubtful Accounts</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than
90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual
credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts
previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate
these estimates does not accurately reflect bad debts, adjustments to these reserves may be required.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenue
Recognition</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is
fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably
assured.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Our
OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation
and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers
of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products
pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing
support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product
lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales. The revenue that is generated
by us from major customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note
13. There are no major customers for our OTC prenatal vitamin or other products.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Over-the-Counter
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,
when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if
any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC
customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit
card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back
return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC
sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product
lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Prescription
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy distributors.
We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees, customer rebates and
estimated returns.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Revenue
related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped
to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products
sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration.
Our prescription products currently have a shelf life of 24 months from the date of manufacture.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Prior
to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the
product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were
known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the
distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader
population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription
products are distributed under the wholesale distributor model described above.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer
loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry
averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated
in contracts and estimate chargebacks based on the number of units sold each period.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Share-Based
Compensation</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the
costs in the financial statements over the period during which employees are required to provide services. Share-based
compensation arrangements may include options, restricted stock, restricted stock units, performance-based awards, and share
appreciation rights. We amortize such compensation amounts, if any, over the respective service periods of the award. We use
the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,
Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the
expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected
dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury
bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by
which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected
volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were
publicly available that were similar to our company with respect to industry, stage of life cycle, market capitalization, and
financial leverage. On January 1, 2017, we started using our own stock price in our volatility calculation along with two
other peer entities whose stock prices were publicly available that were similar to our company. Our calculation of estimated
volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected
life of warrants is based on the contractual terms of the awards. The average expected life of options is based on the
contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that
we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based
compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the
share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of
share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of
management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense
could be materially different in the future.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Equity
instruments (&#8220;instruments&#8221;) issued to non-employees are recorded on the basis of the fair value of the instruments,
as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition
period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached
or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is
recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees
can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value
related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined
in ASC 505.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance
with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service
period. <font style="color: #252525">We adopted ASU 2016-09, effective January 1, 2017, electing to account for forfeitures when
they occur. Prior to that, </font>we estimated the forfeiture rate based on our historical experience of forfeitures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Research
and Development Expenses</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, laboratory supplies, scale-up and validation costs, and other
activities. Internal R&#38;D activity expenses include salaries, benefits, and non-cash share-based compensation expenses. Advance
payments to be expensed in future research and development activities are capitalized, and were $0 at June 30, 2017 and $228,933
at December 31, 2016, all of which were included in other current assets on the accompanying consolidated balance sheets. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses
include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration,
or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and
FDA submissions. Legal activities include professional research and advice regarding R&#38;D, patents and regulatory matters.
These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical
trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We
make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable
advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or
when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study
expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided
by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense
in the period in which the facts that give rise to the revision become known.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Segment
Reporting</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</font></p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908042528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
4 &#8211; INVENTORY</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, <br />2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, <br />2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; width: 68%"><font style="font: 10pt Times New Roman, Times, Serif">Finished
    product</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 13%"><font style="font: 10pt Times New Roman, Times, Serif">1,399,979</font></td>
    <td style="text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 13%"><font style="font: 10pt Times New Roman, Times, Serif">1,062,285</font></td>
    <td style="text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Raw
    material</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">14,036</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">14,036</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">TOTAL
    INVENTORY</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,414,015</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,076,321</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744213840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
5 &#8211; OTHER CURRENT ASSETS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, <br />2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, <br />2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid
    manufacturing costs</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">999,508</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">991,809</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid marketing
    costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">535,936</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid insurance</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,571</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">628,039</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid research
    and development costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,035</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid consulting</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">128,898</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44,311</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
    prepaid costs</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">337,740</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">405,960</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">TOTAL
    OTHER CURRENT ASSETS</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,228,755</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,299,052</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744190048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
6 &#8211; FIXED ASSETS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Fixed
assets consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, <br />2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, <br />2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accounting
    system</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">301,096</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">301,096</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Equipment</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">247,568</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">215,182</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Computer hardware</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">80,211</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">80,211</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">116,542</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">113,079</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold
    improvements</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,888</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,888</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">783,305</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">747,456</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated
    depreciation</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(299,617</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(230,617</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL
    FIXED ASSETS</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">483,688</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">516,839</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the three months ended June 30, 2017 and 2016 was $35,400 and $10,853 respectively, and $69,000 and $19,216 for the
six months ended June 30, 2017 and 2016, respectively.</font></p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744093584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
7 &#8211; INTANGIBLE ASSETS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of June 30, 2017
and December 31, 2016:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Gross
    <br />Carrying <br />Amount</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated<br />Amortization</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Net<br />Amount</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-<br />Average
    <br />Remaining<br />Amortization <br />Period (yrs.)</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Amortizing
    intangible assets:</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;
    </sup>software patent</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">31,951</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(7,488</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">24,463</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12.25</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Development
    costs of &#160;corporate website</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">91,743</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(91,743</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Approved
    hormone&#160;therapy drug&#160;candidate patents</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,207,267</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(135,282</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,071,985</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15.5</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Hormone
    therapy drug&#160;candidate patents&#160;(pending)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,444,581</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,444,581</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Non-amortizing
    intangible assets:</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Multiple
    trademarks</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">198,657</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">198,657</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,974,199</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(234,513</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,739,686</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, 2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Gross
    <br />Carrying <br />Amount</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated<br />Amortization</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Net
    <br />Amount</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-
    <br />Average <br />Remaining <br />Amortization <br />Period (yrs.)</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Amortizing
    intangible assets:</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;
    </sup>software patent</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">31,951</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,490</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">25,461</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12.75</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Development
    costs of corporate website</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">91,743</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(91,743</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Approved
    hormone&#160;therapy drug&#160;candidate patents</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,093,452</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(102,393</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">991,059</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Hormone
    therapy drug&#160;candidate patents&#160;(pending)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,203,987</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,203,987</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Non-amortizing
    intangible assets:</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Multiple
    trademarks</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">185,465</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">185,465</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,606,598</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(200,626</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,405,972</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent
is granted, we amortize the approved hormone therapy drug candidate patents using the straight line method over the estimated
useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off
any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the six months ended June 30,
2017 and year ended December 31, 2016, there was no impairment recognized related to intangible assets.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In
addition to numerous pending patent applications, as of June 30, 2017, we had 17 issued patents, including:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">13 utility patents
    that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction
    patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina,
    Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">two utility patent
    that relates to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establishes an important
    intellectual property foundation for TX-004HR, which are owned by us and are U.S. jurisdiction patents with an expiration
    date in 2033.&#160; We have pending patent applications with respect to certain of these patents in Argentina, Australia,
    Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">one utility patent
    that relates to a pipeline transdermal patch technology, which is owned by us and is a U.S. jurisdiction patent with an expiration
    in 2032. We have pending patent application with respect to this patent in Australia, Brazil, Canada, Europe, Mexico, and
    Japan.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">one utility patent
    that relates to our OPERA&#174; information technology platform, which is owned by us and is a U.S. jurisdiction patent with
    an expiration date in 2029.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Amortization
expense was $17,789 and $13,409 for the three months ended June 30, 2017 and 2016, respectively, and $33,888 and $24,643 for the
six months ended June 30, 2017 and 2016, respectively. Estimated amortization expense for the next five years for the patent cost
currently being amortized is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Year
    Ending <br />December 31,</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Estimated
    <br />Amortization</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 2%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 46%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2017(6
    months)</font></td>
    <td style="width: 2%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 44%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">35,579</font></td>
    <td style="width: 2%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,157</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,157</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,157</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,157</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">776,241</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6607370368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
8 &#8211; OTHER CURRENT LIABILITIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, <br />2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, <br />2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued
    clinical trial costs</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">527,979</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,281,080</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued payroll,
    bonuses and commission costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,738,495</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,531,440</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued compensated
    absences</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">934,370</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">665,561</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued legal and
    accounting expense</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">263,375</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">176,518</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued sales and
    marketing costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,821</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">665,773</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">171,487</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">224,865</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for wholesale
    distributor fees</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">98,729</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">76,510</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued royalties</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,775</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">26,507</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for coupons
    and returns</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,019,853</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">794,816</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued
    rent</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">253,334</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">181,015</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL
    OTHER CURRENT LIABILITIES</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,180,218</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7,624,085</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908375472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
9 &#8211; NET LOSS PER SHARE</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure
of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par
value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number
of shares of Common Stock outstanding plus all potentially dilutive shares of Common Stock outstanding during the period. Such
potentially dilutive shares of Common Stock consist of options and warrants and were excluded from the calculation of diluted
earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table below presents
potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders
for the periods presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Three
    and Six months ended</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Stock
    options</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23,402,100</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">20,668,657</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,115,905</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,060,571</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">26,518,005</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">32,729,228</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6607370368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
10 &#8211; STOCKHOLDERS&#8217; EQUITY</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Preferred
Stock</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2017, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred
stock were issued or outstanding.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Common
Stock</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2017, we had 350,000,000 shares of Common Stock authorized for issuance, of which 204,027,142 shares of Common Stock
were issued and outstanding.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Issuances
During 2017</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended June 30, 2017, certain individuals exercised stock options to purchase 5,000 shares of Common Stock for
$20,050 in cash. During the six months ended June 30, 2017, certain individuals exercised stock options to purchase 100,046 shares
of Common Stock for $212,360 in cash.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Issuances
During 2016</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">On
January 6, 2016, we entered into an underwriting agreement with Goldman Sachs &#38; Co. and Cowen and Company, LLC, as the representatives
of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of Common Stock
at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day
option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full. The
net proceeds to us from the offering were approximately $134,864,000, after deducting underwriting discounts and commissions and
other estimated offering expenses payable by us. The offering closed on January 12, 2016 and we issued 17,424,242 shares of Common
Stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended June 30, 2016, certain individuals exercised stock options to purchase 77,123 shares of Common Stock for
$191,592 in cash. During the six months ended June 30, 2016, certain individuals exercised stock options to purchase 417,168 shares
of Common Stock for $978,042 in cash.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Warrants
to Purchase Common Stock</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2017, we had warrants outstanding to purchase an aggregate of 3,115,905 shares of Common Stock with a weighted-average
contractual remaining life of approximately 2.3 years, and exercise prices ranging from $0.24 to $8.20 per share, resulting in
a weighted average exercise price of $2.58 per share.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of our warrants is the Black-Scholes
Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free
interest rate and the term of the warrant. During the six months ended June 30, 2017, we granted warrants to purchase 125,000
shares of Common Stock to outside consultants at an exercise price of $6.83 per share. The fair value for these warrants was determined
by using the Black-Scholes Model on the date of the grant using a term of five years; volatility of 63.24%; risk free rate of
1.47%; and dividend yield of 0%. The grant date fair value of the warrants was $3.67 per share. The warrants are vesting ratably
over a 12-month period and have an expiration date of March 15, 2022. During the six months ended June 30, 2016, we granted warrants
to purchase 245,000 shares of Common Stock to outside consultants at a weighted average exercise price of $7.90 per share. The
weighted average grant date fair value of these warrants was $4.78 per share. The fair value for these warrants was determined
by using the Black-Scholes Model on the date of the grant using a term of five years; volatility of 74.10%-74.15%; risk free rate
of 1.04%- 1.28%; and dividend yield of 0%. These warrants vest and have expiration dates as follows: warrants to purchase 75,000
shares of Common Stock vested on April 21, 2016 and have an expiration date of April 21, 2021, warrants to purchase 50,000 shares
of Common Stock vest ratably over a 24-month period and have an expiration date of April 21, 2021, and warrants to purchase 120,000
shares of Common Stock vest ratable over a 12-month period and have an expiration date of January 21, 2021.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended June 30, 2017 and 2016, we recorded $68,089 and $556,125, respectively, and during the six months ended
June 30, 2017 and 2016 we recorded $115,774 and $683,590, respectively, as share-based compensation expense in the accompanying
consolidated financial statements related to warrants. As of June 30, 2017, unamortized costs associated with these warrants totaled
approximately $420,000.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2013, we entered into a consulting agreement with Sancilio and Company, Inc., or SCI, to develop drug platforms to be used
in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain FDA approval
for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with
the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of Common Stock that were to be
granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed
to issue to SCI a warrant to purchase 850,000 shares of Common Stock at $2.01 per share that has vested or will vest, as applicable,
as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">283,333 shares were
    earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol based drug candidate
    in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares
    did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using
    the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and
    a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">283,333 shares vested
    on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date
    of vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the
    three months ended June 30, 2017 and 2016, we recorded $0 and $38,509, respectively, as non-cash compensation in the accompanying
    consolidated financial statements related to this warrant. During the six months ended June 30, 2017 and 2016, we recorded
    $0 and $77,026, respectively, as non-cash compensation in the accompanying consolidated financial statements related to this
    warrant. As of June 30, 2016, this warrant was fully amortized; and</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">3.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">283,334 shares will
    vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that
    this event will occur in the near future.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to SCI for services to be rendered over
approximately five years beginning in May 2012. The warrants vested upon issuance. Services provided are to include (a) services
in support of our drug development efforts, including services in support of our ongoing and future drug development and commercialization
efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing
and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated
therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services
as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228
on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of
0.74%; and a dividend yield of 0%. During both the three months ended June 30, 2017 and 2016 and both the six months ended June
30, 2017 and 2016, we recorded $64,449 and $128,898, respectively, as non-cash compensation expense with respect to these warrants
in the accompanying consolidated statements of operations. The contract will expire upon the commercial manufacture of a drug
product. As of June 30, 2017, the SCI warrants issued in 2013 and 2012 were fully amortized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended June 30, 2017, certain individuals exercised warrants to purchase 666,666 shares of Common Stock for $1,338,999
in cash. In addition, during the three months ended June 30, 2017, certain individuals exercised warrants to purchase 6,590,000
shares of Common Stock pursuant to the warrants&#8217; cashless exercise provisions, wherein 4,762,208 shares of Common Stock
were issued. During the three months ended June 30, 2016, certain individuals exercised warrants to purchase 161,372 shares of
Common Stock for $63,000 in cash.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2017, certain individuals exercised warrants to purchase 2,476,666 shares of Common Stock for $3,798,999
in cash. In addition, during the six months ended June 30, 2017, certain individuals exercised warrants to purchase 6,590,000
shares of Common Stock pursuant to the warrants&#8217; cashless exercise provisions, wherein 4,762,208 shares of Common Stock
were issued. During the six months ended June 30, 2016, certain individuals exercised warrants to purchase 722,744 shares of Common
Stock for $1,373,000 in cash.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Options
to Purchase Common Stock</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to
employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have
created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards
available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units,
performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000
shares authorized for issuance thereunder. Generally, the options vest annually over four years or as determined by our board
of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if
any. The expiration date is generally ten years from the date the option is issued. As of June 30, 2017, there were
non-qualified stock options to purchase 18,611,959 shares of Common Stock outstanding under the 2009 Plan. As of June 30,
2017, there were 2,139,503 shares of Common Stock available to be issued under the 2009 Plan.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012
Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
consultants and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described
in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option
grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior
to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally
ten years from the date the option is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder.
As of June 30, 2017, there were non-qualified stock options to purchase 4,790,141 shares of Common Stock outstanding under the
2012 Plan. As of June 30, 2017, there were 5,128,333 shares of Common Stock available to be issued under the 2012 Plan.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. The assumptions used in the Black-Scholes Model for options granted during the six months ended June 30,
2017 and 2016 are set forth in the table below.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Six
    Months Ended</font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 46%; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 26%; border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2017</font></td>
    <td style="width: 2%; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 26%; border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2016</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest
    rate</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">1.84-2.01%</font></td>
    <td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">1.26-1.70%</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Volatility</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">61.56-63.95%</font></td>
    <td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">70.44-71.22%</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Term (in years)</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">5.5-6.25</font></td>
    <td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">6.25</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of activity under the 2009 and 2012 Plans and related information follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares Underlying Stock Options</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    <br />Average <br />Remaining <br />Contractual <br />Life in Years</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate
    Intrinsic Value</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21,767,854</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.56</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.8</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">60,495,730</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,184,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.61</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(100,046</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.12</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">437,667</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Expired/Forfeited</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(450,208</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.54</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Balance at June
    30, 2017</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23,402,100</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="padding-bottom: 2pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.79</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.6</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="padding-bottom: 2pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">52,165,428</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Vested
    and Exercisable at June 30, 2017</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">18,731,808</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.13</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.9</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">51,750,547</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Unvested at June 30, 2017</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,670,292</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.43</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.8</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">414,881</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2017, our outstanding stock options had exercise prices ranging from $0.10 to $8.92 per share. The weighted average grant
date fair value per share of options granted was $3.82 and $5.08 during the six months ended June 30, 2017 and 2016, respectively.
Share-based compensation expense for options recognized in our results of operations is based on vested awards. Share-based compensation
expense related to options for the three months ended June 30, 2017 and 2016 was $1,505,625 and $4,160,071, respectively, and
for the six months ended June 30, 2017 and 2016 was $2,806,685 and $8,311,330, respectively. At June 30, 2017, total unrecognized
estimated compensation expense related to unvested options granted prior to that date was approximately $14,365,000 which may
be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 2.4 years.
No tax benefit was realized due to a continued pattern of operating losses.</font></p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633433264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
11 &#8211; INCOME TAXES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We do not expect to pay any significant federal or state income tax for 2017 as a result of (a) the losses recorded
during the six months ended June 30, 2017, (b) additional losses expected for the remainder of 2017, and/or (c) net operating
loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax
assets if it is &#8220;more likely than not&#8221; that some component or all of the benefits of deferred tax assets will not
be realized. As of June 30, 2017, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,
no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the
reporting period.</font></p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744219232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
12 &#8211; RELATED PARTIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">In
July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to
time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements
with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of
our company since July 2015. During the three months ended June 30, 2017 and 2016, we were billed by Catalent approximately $1,754,000
and $614,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability
and validation testing. During the six months ended June 30, 2017 and 2016, we were billed by Catalent approximately $2,460,000
and $2,079,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability
and validation testing. As of June 30, 2017 and December 31, 2016, there were amounts due to Catalent of approximately $1,132,000
and $57,000, respectively.</font></p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908159056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
13 - BUSINESS CONCENTRATIONS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
purchase our products from several suppliers with approximately 100% and 96% of our purchases supplied from one vendor for both
the three and six months ended June 30, 2017 and 2016, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain
drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. As a result of developments
in the pharmaceutical industry that negatively affected independent pharmacies, including such pharmacies&#8217; reliance on third-party
payors, in 2016, we identified that payment periods for our retail pharmacy distributors were becoming longer than in prior years.
As a result, during the third quarter of 2016, we centralized the distribution channel for both our retail pharmacy distributors
and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies and minimize business risk
exposure to any one retail pharmacy. During the third quarter of 2016, we entered into new distribution agreements with our retail
pharmacy distributors to effectuate this centralization which were effective September 1, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2017, five customers each generated more than 10% of our total revenues and during the six months
ended June 30, 2016 three customers each generated more than 10% of our total revenues. Revenue generated from five major customers
combined accounted for approximately 70% of our recognized revenue for the six months ended June 30, 2017 and revenue generated
from three major customers combined accounted for approximately 60% of our recognized revenue for the six months ended June 30,
2016. During the six months ended June 30, 2017, Pharmacy Innovations TX generated approximately $834,000 of our revenue, Pharmacy
Innovations PA generated approximately $1,863,000 of our revenue, AmerisourceBergen generated approximately $1,053,000 of our
revenue, Cardinal Health generated approximately $1,119,000 of our revenue and McKesson Corporation generated approximately $907,000
of our revenue. During the six months ended June 30, 2016, Woodstock Pharmaceutical and Compounding generated approximately $2,237,000
of our revenue; Medical Center Pharmacy generated approximately $1,540,000 of our revenue and Due West Pharmacy generated approximately
$1,863,000 of our revenue.</font></p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744149792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 14&#x2013; COMMITMENTS AND CONTINGENCIES</u></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Operating Lease</u></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">The rental expense related to our current lease during the three months ended June 30, 2017 and 2016 was approximately $265,000 and $182,000, respectively. The rental expense related to our current lease during the six months ended June 30, 2017 and 2016 was approximately $515,000 and $300,000, respectively.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">As of June 30, 2017, future minimum rental payments on non-cancelable operating leases are as follows:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table align="center" cellpadding="0" cellspacing="0" style="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Years Ending December 31,</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="width: 73%; text-align: left; font: 10pt Times New Roman, Times, Serif">
                <font style="font: 10pt Times New Roman, Times, Serif">2017 (6 months)</font>
            </td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
            <td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif">449,264</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">951,194</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2019</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,094,116</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2020</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,113,069</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">2021</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">943,127</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">
                <font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
            <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,550,770</td>
            <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
    </table>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">
        <font style="text-decoration: underline">Legal Proceedings</font>
    </p>
    <p style="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">On April
17, 2017, a securities class action lawsuit was filed against our company and certain of our officers and directors in the U.S.
District Court for the Southern District of Florida (Case No. 9:17-cv-80473-RLR) that purports to state a claim for alleged violations
of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, based on statements
made by the defendants concerning the NDA for TX-004HR. The complaint sought unspecified damages, interest, attorneys&#x2019;
fees and other costs. On July 18, 2017, the complaint was voluntarily dismissed by the lead plaintiff without prejudice. We and
certain of our officers and directors are also subject to two shareholder derivative lawsuits regarding the NDA for TX-004HR,
one filed in the U.S. District Court for the Southern District of Florida on May 30, 2017 (Case No. 9:17-cv-80686-RLR) and one
filed in Florida state court in Palm Beach County on June 5, 2017 (Case No. 502017CA006289XXXXMB). We believe these lawsuits to
be without merit and intend to vigorously defend against them. The derivative lawsuits are in the very early stages and, at this
time, no assessment can be made as to their likely outcome or whether the outcome will be material to us.</p>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">&#160;</p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748789456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair
Value of Financial Instruments</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount
of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity
of such instruments, which are considered Level 1 assets under the fair value hierarchy.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements<i>. </i>The fair value hierarchy gives the
highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable
inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy
of inputs, as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 0.85in"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    1</b></font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">unadjusted quoted
    prices in active markets for identical assets or liabilities;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 0.85in"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    2</b></font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">quoted prices for
    similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
    or indirectly through market corroboration, for substantially the full term of the financial instrument; and</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 0.85in"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    3</b></font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">unobservable inputs
    for the asset or liability.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of
indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level
3) in connection with our impairment test. There was no impairment of intangible assets or long-lived assets during the three
and six months ended June 30, 2017 and 2016.</font></p><span></span></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Trade
Accounts Receivable and Allowance for Doubtful Accounts</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than
90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual
credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts
previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate
these estimates does not accurately reflect bad debts, adjustments to these reserves may be required.</font></p><span></span></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenue
Recognition</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is
fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably
assured.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Our
OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation
and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers
of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products
pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing
support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product
lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales. The revenue that is generated
by us from major customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note
13. There are no major customers for our OTC prenatal vitamin or other products.</font></p><span></span></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OverTheCounterProductsPolicyTextBlock', window );">Over-the-Counter Products</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Over-the-Counter
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,
when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if
any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC
customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit
card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back
return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC
sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product
lines, except for Iron 21/7, which have declined steadily over time resulting in immaterial sales.</font></p><span></span></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrescriptionProductsPolicyTextBlock', window );">Prescription Products</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Prescription
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy distributors.
We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees, customer rebates and
estimated returns.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Revenue
related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped
to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products
sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration.
Our prescription products currently have a shelf life of 24 months from the date of manufacture.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Prior
to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the
product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were
known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the
distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader
population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription
products are distributed under the wholesale distributor model described above.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer
loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry
averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated
in contracts and estimate chargebacks based on the number of units sold each period.</font></p><span></span></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Share-Based
Compensation</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the
costs in the financial statements over the period during which employees are required to provide services. Share-based
compensation arrangements may include options, restricted stock, restricted stock units, performance-based awards, and share
appreciation rights. We amortize such compensation amounts, if any, over the respective service periods of the award. We use
the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,
Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the
expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected
dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury
bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by
which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected
volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were
publicly available that were similar to our company with respect to industry, stage of life cycle, market capitalization, and
financial leverage. On January 1, 2017, we started using our own stock price in our volatility calculation along with two
other peer entities whose stock prices were publicly available that were similar to our company. Our calculation of estimated
volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected
life of warrants is based on the contractual terms of the awards. The average expected life of options is based on the
contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that
we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based
compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the
share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of
share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of
management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense
could be materially different in the future.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Equity
instruments (&#8220;instruments&#8221;) issued to non-employees are recorded on the basis of the fair value of the instruments,
as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition
period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached
or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is
recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees
can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value
related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined
in ASC 505.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance
with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service
period. <font style="color: #252525">We adopted ASU 2016-09, effective January 1, 2017, electing to account for forfeitures when
they occur. Prior to that, </font>we estimated the forfeiture rate based on our historical experience of forfeitures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p><span></span></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Research
and Development Expenses</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, laboratory supplies, scale-up and validation costs, and other
activities. Internal R&#38;D activity expenses include salaries, benefits, and non-cash share-based compensation expenses. Advance
payments to be expensed in future research and development activities are capitalized, and were $0 at June 30, 2017 and $228,933
at December 31, 2016, all of which were included in other current assets on the accompanying consolidated balance sheets. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses
include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration,
or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and
FDA submissions. Legal activities include professional research and advice regarding R&#38;D, patents and regulatory matters.
These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical
trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We
make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable
advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or
when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study
expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided
by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense
in the period in which the facts that give rise to the revision become known.</font></p><span></span></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Segment
Reporting</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</font></p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OverTheCounterProductsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of policy related to over-the-counter products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OverTheCounterProductsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrescriptionProductsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of policy related to prescription products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrescriptionProductsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5144-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6621206064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, <br />2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, <br />2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Finished
    product</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,399,979</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,062,285</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Raw
    material</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">14,036</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">14,036</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">TOTAL
    INVENTORY</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,414,015</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,076,321</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748915200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other current assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, <br />2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, <br />2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid
    manufacturing costs</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">999,508</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">991,809</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid marketing
    costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">535,936</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid insurance</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,571</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">628,039</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid research
    and development costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,035</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid consulting</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">128,898</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44,311</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
    prepaid costs</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">337,740</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">405,960</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">TOTAL
    OTHER CURRENT ASSETS</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,228,755</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,299,052</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633406464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Fixed
assets consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 92%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, <br />2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, <br />2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accounting
    system</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">301,096</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">301,096</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Equipment</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">247,568</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">215,182</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Computer hardware</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">80,211</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">80,211</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">116,542</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">113,079</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold
    improvements</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,888</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,888</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">783,305</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">747,456</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated
    depreciation</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(299,617</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(230,617</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL
    FIXED ASSETS</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">483,688</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">516,839</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630431568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of June 30, 2017
and December 31, 2016:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Gross
    <br />Carrying <br />Amount</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated<br />Amortization</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Net<br />Amount</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-<br />Average
    <br />Remaining<br />Amortization <br />Period (yrs.)</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Amortizing
    intangible assets:</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;
    </sup>software patent</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">31,951</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(7,488</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">24,463</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12.25</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Development
    costs of &#160;corporate website</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">91,743</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(91,743</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Approved
    hormone&#160;therapy drug&#160;candidate patents</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,207,267</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(135,282</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,071,985</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15.5</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Hormone
    therapy drug&#160;candidate patents&#160;(pending)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,444,581</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,444,581</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Non-amortizing
    intangible assets:</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Multiple
    trademarks</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">198,657</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">198,657</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,974,199</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(234,513</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,739,686</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, 2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Gross
    <br />Carrying <br />Amount</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated<br />Amortization</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Net
    <br />Amount</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-
    <br />Average <br />Remaining <br />Amortization <br />Period (yrs.)</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Amortizing
    intangible assets:</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;
    </sup>software patent</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">31,951</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,490</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">25,461</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12.75</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Development
    costs of corporate website</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">91,743</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(91,743</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Approved
    hormone&#160;therapy drug&#160;candidate patents</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,093,452</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(102,393</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">991,059</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Hormone
    therapy drug&#160;candidate patents&#160;(pending)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,203,987</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,203,987</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Non-amortizing
    intangible assets:</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Multiple
    trademarks</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">185,465</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">185,465</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,606,598</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(200,626</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,405,972</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr></table><span></span></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Estimated
amortization expense for the next five years for the patent cost currently being amortized is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Year
    Ending <br />December 31,</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Estimated
    <br />Amortization</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 2%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 46%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2017(6
    months)</font></td>
    <td style="width: 2%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 44%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">35,579</font></td>
    <td style="width: 2%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,157</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,157</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,157</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,157</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">776,241</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of intangible assets, which may be broken down by major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6595430320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 83%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, <br />2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December
    31, <br />2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued
    clinical trial costs</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">527,979</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,281,080</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued payroll,
    bonuses and commission costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,738,495</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,531,440</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued compensated
    absences</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">934,370</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">665,561</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued legal and
    accounting expense</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">263,375</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">176,518</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued sales and
    marketing costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,821</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">665,773</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">171,487</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">224,865</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for wholesale
    distributor fees</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">98,729</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">76,510</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued royalties</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,775</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">26,507</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for coupons
    and returns</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,019,853</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">794,816</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued
    rent</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">253,334</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">181,015</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL
    OTHER CURRENT LIABILITIES</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,180,218</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7,624,085</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744198976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable
to common stockholders for the periods presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Three
    and Six months ended</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2017</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2016</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Stock
    options</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23,402,100</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">20,668,657</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,115,905</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,060,571</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">26,518,005</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">32,729,228</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630431568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of stock options</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
assumptions used in the Black-Scholes Model for options granted during the six months ended June 30, 2017 and 2016 are set forth
in the table below.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Six
    Months Ended</font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 46%; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 26%; border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2017</font></td>
    <td style="width: 2%; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 26%; border-bottom: black 1pt solid; text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2016</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest
    rate</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">1.84-2.01%</font></td>
    <td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">1.26-1.70%</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Volatility</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">61.56-63.95%</font></td>
    <td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">70.44-71.22%</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Term (in years)</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">5.5-6.25</font></td>
    <td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">6.25</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td style="padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="text-align: right; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center; padding-left: 5.4pt; padding-right: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td></tr>
</table><span></span></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of plan activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of activity under the 2009 and 2012 Plans and related information follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares Underlying Stock Options</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    <br />Average <br />Remaining <br />Contractual <br />Life in Years</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate
    Intrinsic Value</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21,767,854</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.56</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.8</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">60,495,730</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,184,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.61</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(100,046</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.12</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">437,667</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Expired/Forfeited</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(450,208</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.54</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Balance at June
    30, 2017</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23,402,100</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="padding-bottom: 2pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.79</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.6</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="padding-bottom: 2pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">52,165,428</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Vested
    and Exercisable at June 30, 2017</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">18,731,808</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.13</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.9</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">51,750,547</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Unvested at June 30, 2017</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,670,292</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.43</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.8</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">414,881</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617565536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum rental payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2017, future minimum rental payments on non-cancelable operating leases are as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Years
    Ending December 31,</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2017 (6
    months)</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 3%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">449,264</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">951,194</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,094,116</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,113,069</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">943,127</font></td>
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Total
    minimum lease payments</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,550,770</font></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908351776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract', window );"><strong>Basis Of Presentation And Recently Issued Accounting Pronouncements Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates', window );">Amount of adjustment for provisions related to forfeiture rates</a></td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to the amount of adjustment for provisions related to forfeiture rates during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AmountOfAdjustmentForProvisionsRelatedToForfeitureRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748447168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Related to Research and Development Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Advance payments | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 228,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908265712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished product</a></td>
<td class="nump">$ 1,399,979<span></span>
</td>
<td class="nump">$ 1,062,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
<td class="nump">14,036<span></span>
</td>
<td class="nump">14,036<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 1,414,015<span></span>
</td>
<td class="nump">$ 1,076,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748344992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturingCostsCurrent', window );">Prepaid manufacturing costs</a></td>
<td class="nump">$ 999,508<span></span>
</td>
<td class="nump">$ 991,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidMarketingCostsCurrent', window );">Prepaid marketing costs</a></td>
<td class="nump">535,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">350,571<span></span>
</td>
<td class="nump">628,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidConsultingCurrent', window );">Prepaid consulting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidVendorDepositsCurrent', window );">Prepaid vendor deposits</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">44,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">337,740<span></span>
</td>
<td class="nump">405,960<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 2,228,755<span></span>
</td>
<td class="nump">$ 2,299,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidConsultingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidConsultingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents amount of prepaid manufacturing costs current during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to the amount of prepaid marketing costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidVendorDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents amount prepaid vendor deposits current during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidVendorDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749080800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FIXED ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 783,305<span></span>
</td>
<td class="nump">$ 747,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(299,617)<span></span>
</td>
<td class="num">(230,617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">483,688<span></span>
</td>
<td class="nump">516,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Accounting System [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">301,096<span></span>
</td>
<td class="nump">301,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">247,568<span></span>
</td>
<td class="nump">215,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">80,211<span></span>
</td>
<td class="nump">80,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">116,542<span></span>
</td>
<td class="nump">113,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 37,888<span></span>
</td>
<td class="nump">$ 37,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630389040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="nump">$ 10,853<span></span>
</td>
<td class="nump">$ 69,000<span></span>
</td>
<td class="nump">$ 19,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754073056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (234,513)<span></span>
</td>
<td class="num">$ (200,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">2,974,199<span></span>
</td>
<td class="nump">2,606,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Amount</a></td>
<td class="nump">2,739,686<span></span>
</td>
<td class="nump">2,405,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,444,581<span></span>
</td>
<td class="nump">1,203,987<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">1,444,581<span></span>
</td>
<td class="nump">1,203,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">198,657<span></span>
</td>
<td class="nump">185,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
<td class="nump">198,657<span></span>
</td>
<td class="nump">185,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Opera Software Patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">31,951<span></span>
</td>
<td class="nump">31,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(7,488)<span></span>
</td>
<td class="num">(6,490)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 24,463<span></span>
</td>
<td class="nump">$ 25,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">12 years 3 months<span></span>
</td>
<td class="text">12 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Development Costs Of Corporate Website [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 91,743<span></span>
</td>
<td class="nump">$ 91,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(91,743)<span></span>
</td>
<td class="num">(91,743)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,207,267<span></span>
</td>
<td class="nump">1,093,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(135,282)<span></span>
</td>
<td class="num">(102,393)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 1,071,985<span></span>
</td>
<td class="nump">$ 991,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">15 years 6 months<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908082528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated amortization expense for the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2017(6 months)</a></td>
<td class="nump">$ 35,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2018</a></td>
<td class="nump">71,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2019</a></td>
<td class="nump">71,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2020</a></td>
<td class="nump">71,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2021</a></td>
<td class="nump">71,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 776,241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748604112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense | $</a></td>
<td class="nump">$ 17,789<span></span>
</td>
<td class="nump">$ 13,409<span></span>
</td>
<td class="nump">$ 33,888<span></span>
</td>
<td class="nump">$ 24,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member', window );">Utility Patent Progesterone and Estradiol Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Utility Patent TX-004HR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member', window );">Utility Patent Pipeline Transdermal Patch Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Opera Software Patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748977056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedClinicalTrialCostsCurrent', window );">Accrued clinical trial costs</a></td>
<td class="nump">$ 527,979<span></span>
</td>
<td class="nump">$ 1,281,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">1,738,495<span></span>
</td>
<td class="nump">3,531,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">934,370<span></span>
</td>
<td class="nump">665,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">263,375<span></span>
</td>
<td class="nump">176,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">100,821<span></span>
</td>
<td class="nump">665,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">171,487<span></span>
</td>
<td class="nump">224,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="nump">98,729<span></span>
</td>
<td class="nump">76,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">71,775<span></span>
</td>
<td class="nump">26,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">1,019,853<span></span>
</td>
<td class="nump">794,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="nump">253,334<span></span>
</td>
<td class="nump">181,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 5,180,218<span></span>
</td>
<td class="nump">$ 7,624,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6742690624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">26,518,005<span></span>
</td>
<td class="nump">32,729,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">3,115,905<span></span>
</td>
<td class="nump">12,060,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">23,402,100<span></span>
</td>
<td class="nump">20,668,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908366944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details Narrtaive) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6742650256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate - minimum</a></td>
<td class="nump">1.84%<span></span>
</td>
<td class="nump">1.26%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate - maximum</a></td>
<td class="nump">2.01%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility - minimum</a></td>
<td class="nump">61.56%<span></span>
</td>
<td class="nump">70.44%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility - maximum</a></td>
<td class="nump">63.95%<span></span>
</td>
<td class="nump">71.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754496816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options, Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(77,123)<span></span>
</td>
<td class="num">(100,046)<span></span>
</td>
<td class="num">(417,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options, Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,767,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options Expired/Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(450,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">23,402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,767,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Exercisable</a></td>
<td class="nump">18,731,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,731,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested</a></td>
<td class="nump">4,670,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,670,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending</a></td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and Exercisable</a></td>
<td class="nump">3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice', window );">Unvested</a></td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract', window );"><strong>Options, Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options outstanding, Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,495,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, ending</a></td>
<td class="nump">$ 52,165,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,165,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,495,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and Exercisable</a></td>
<td class="nump">51,750,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,750,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue', window );">Unvested</a></td>
<td class="nump">$ 414,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire unvested shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748334752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Jan. 06, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,027,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,027,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,688,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,027,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,027,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,688,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,050<span></span>
</td>
<td class="nump">$ 191,592<span></span>
</td>
<td class="nump">$ 212,360<span></span>
</td>
<td class="nump">$ 978,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">77,123<span></span>
</td>
<td class="nump">100,046<span></span>
</td>
<td class="nump">417,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=txmd_GoldmanSachsMember', window );">Underwriting Agreement - Goldman And Cowen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
<td class="nump">17,424,242<span></span>
</td>
<td class="nump">15,151,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,272,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalPeriodForPurchaseShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to additonal period for purchase of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalPeriodForPurchaseShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=txmd_GoldmanSachsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=txmd_GoldmanSachsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754865568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 3,115,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,115,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,051,357<span></span>
</td>
<td class="nump">$ 9,200,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2022<span></span>
</td>
<td class="text">Jan. 21,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultant Warrants [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 21,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultant Warrants [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultant Warrants [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="nump">$ 68,089<span></span>
</td>
<td class="nump">$ 556,125<span></span>
</td>
<td class="nump">$ 115,774<span></span>
</td>
<td class="nump">$ 683,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized costs</a></td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Outside Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.04%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Outside Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are expired in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are vesting date in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755328784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>May 11, 2013</div></th>
<th class="th"><div>May 31, 2013</div></th>
<th class="th"><div>May 31, 2012</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 405,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period of unamortized costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">SCI - Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 38,509<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 77,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights', window );">Forfeited warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">SCI - Warrants [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="nump">$ 405,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation</a></td>
<td class="nump">405,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">SCI - Warrants [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="nump">$ 462,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">45.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">1.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested warrants granted to purchase common stock (shares)</a></td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">SCI - Warrants [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DescriptionOfSharesToBeVested', window );">Description of shares to be vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">283,334
shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated
that this event will occur in the near future.</font></p><span></span></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant1Member', window );">Warrants - Unaffiliated Entity [Member] [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,532,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,449<span></span>
</td>
<td class="nump">$ 64,449<span></span>
</td>
<td class="nump">$ 128,898<span></span>
</td>
<td class="nump">$ 128,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refer to numbers of shares forfeit during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are vesting date in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DescriptionOfSharesToBeVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General descriptive information regarding shares to be vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DescriptionOfSharesToBeVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6742956576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,505,625<span></span>
</td>
<td class="nump">$ 4,160,071<span></span>
</td>
<td class="nump">$ 2,806,685<span></span>
</td>
<td class="nump">$ 8,311,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized estimated compensation expense</a></td>
<td class="nump">$ 14,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.82<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">23,402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,767,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">18,611,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,611,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="nump">2,139,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,139,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">4,790,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,790,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="nump">5,128,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,128,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Individuals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="nump">$ 1,338,999<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="nump">$ 3,798,999<span></span>
</td>
<td class="nump">$ 1,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of warrants, net (in shares)</a></td>
<td class="nump">666,666<span></span>
</td>
<td class="nump">161,372<span></span>
</td>
<td class="nump">2,476,666<span></span>
</td>
<td class="nump">722,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant2Member', window );">Warrants - Cashless Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of warrants, net (in shares)</a></td>
<td class="nump">4,762,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,762,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="nump">6,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_IndividualsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_IndividualsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744226768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - Catalent Inc.[Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Manufacturing activities billed from related party</a></td>
<td class="nump">$ 1,754,000<span></span>
</td>
<td class="nump">$ 614,000<span></span>
</td>
<td class="nump">$ 2,460,000<span></span>
</td>
<td class="nump">$ 2,079,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable - related party</a></td>
<td class="nump">$ 1,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754154368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 4,250,433<span></span>
</td>
<td class="nump">$ 4,403,247<span></span>
</td>
<td class="nump">$ 8,235,897<span></span>
</td>
<td class="nump">$ 9,333,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Pharmacy Innovations TX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 834,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Pharmacy Innovations PA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | AmerisourceBergen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Cardinal Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | McKesson Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 907,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Woodstock Pharmaceutical and Compounding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,237,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Medical Center Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Due West Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,863,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Five Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Five Customers [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Three Customers [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_PharmacyInnovationsTXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_PharmacyInnovationsTXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_PharmacyInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_PharmacyInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_AmerisourceBergenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_AmerisourceBergenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_CardinalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_CardinalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_WoodstockPharmaceuticalAndCompoundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_WoodstockPharmaceuticalAndCompoundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_MedicalCenterPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_MedicalCenterPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_DueWestPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_DueWestPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=txmd_FiveCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=txmd_FiveCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=txmd_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=txmd_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633385648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract', window );"><strong>Future minimum rental payments, year ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017 (6 months)</a></td>
<td class="nump">$ 449,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">951,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">1,094,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">1,113,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2021</a></td>
<td class="nump">943,127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 4,550,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633760896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 01, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
<td class="nump">$ 515,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">Oct. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total term (in months) of the company's outstanding lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_A=A=UH[-[^8^.+H.S@UUW(+U!+ P04    " ";BP-+F5R<(Q &  "<)P
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M3!U&K\HT,]T6P\D^=!3OQEM+,%V=BC]02P,$%     @ FXL#2RMTJ2:N P
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MU B:#V&-H!_3A%5A\Q@YC% )[<S,5X<9_ 'QI$3L";C/*>+YL?EOW;TCGH6
MU!'$CI F;XTU2,#,"/5 C[DOQ_,5*&!5#-A)<[\\\N!*6.**D2I4!@7.;!O
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M_9'3'RE_//7G1A%:DBE)IQ&3'*:&;..096F4Q6Z:V$D3VS0+@T9+\DD:\ )
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M#R;#35N=QX]!V?6+U/(_4$L#!!0    ( )N+ TOEZS7E-00  (H1   8
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MI@>--XVQBGLT;<M<;X'7$:0D2W>[]TQQH6F91]_9EKD9O!0:SI:X02EN?Y]
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M,"YX;6Q]4V%OVR 0_2N('U 2XC959%MJ6DV;M$E1IZV?B7VV4<&X@./NW^_
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MOFSJ?V-M $QE=X<CU.$'6PP%38C'(Y[=-&:3$6P__R"V?./R#U!+ P04
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M_VMC/& JNQL<H18_V&(HJ'TX'O!LIS&;#&_Z^0>QY1L7?P!02P,$%     @
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MC?/F#FT35RTZ3@_3*V+S4R[_ %!+ P04    " ";BP-+_.Z?Y.$!  "Q!
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M>Q6F*!A&]N,#0:97*O\/4$L#!!0    ( )N+ TLZ9BXZZ $  /4$   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;(54T8Z;,!#\%>0/.!L,(8D J4E5
MM5(K15>U?79@">@,IK83KG]?VQ!$"&I?L'<]LSL#9I->R#=5 6COO>&M2E&E
M=;?'6.45-$R]B Y:<U(*V3!M0GG!JI/ "D=J. X(V>"&U2W*$I<[R2P15\WK
M%D[24]>F8?+/ ;CH4^2C>^*UOE3:)G"6=.P"WT'_Z$[21'BJ4M0-M*H6K2>A
M3-$'?W^,+-X!?M;0J]G>LT[.0KS9X$N1(F(% 8=<VPK,+#<X N>VD)'Q>ZR)
MII:6.-_?JW]RWHV7,U-P%/Q77>@J15OD%5"R*]>OHO\,HY\(>:/YKW #;N!6
MB>F1"Z[<T\NO2HMFK&*D-.Q]6.O6K?UP0N^T=4(P$H*)X(?_)-"10!<$/"AS
M5C\RS;)$BMZ3P\?JF+T3_IZ:EYG;I'MW[LRX529[RP(2)_AF"XV8PX )YIA'
MQ/$90<D$P4; I")851$X/IWSPW4^7>53QP\?7&P7+@9,[#"MP_ATM]O%NX67
M%1S9!,$V6A<4K@H*5P0M&AT&3#1O%!*Z6<CY'^I!3+0J)GH6XY.%F.C9=6@:
M^=%"S@J.Q!L:^ M!>'8![4#XQN2E;I5W%MK<97?C2B$TF)KDQ12MS R: @ZE
MMMO8[.7P)PZ!%MTX9/ TZ;*_4$L#!!0    ( )N+ TNVGP_E5 (  $X'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;'U5;X^;(!S^*L8/<"*(2F--
MUB[+EFQ)<\MNKVE+JSD5![3>OOT /6.1VQL%?'[/']$?Q<#%JZP84\%;VW1R
M&U9*]9LHDJ>*M50^\9YU^LF%BY8J/1772/:"T;,M:IL( I!&+:V[L"SLVD&4
M!;^IIN[8003RUK94_-VQA@_;, [?%Y[K:Z7,0E06/;VRGTS]Z@]"SZ*9Y5RW
MK),U[P+!+MOP4[S9Q\ 46,1+S0:Y& <FRI'S5S/Y=MZ&P#AB#3LI0T'U[<[V
MK&D,D_;Q9R(-9TU3N!R_LW^QX768(Y5LSYO?]5E5VS /@S.[T%NCGOGPE4V!
M<!A,Z;^S.VLTW#C1&B?>2'L-3C>I>#NQ:"LM?1OO=6?OP_@DB:<R?P&<"N!<
M$"?_+4!3 7(*HM&9C?J9*EH6@@^!&'>KI^:CB#=(O\R36;3OSC[3::5>O9<P
MCHOH;H@FS&[$P"7F$;%?(Q"8(9$V,+N 7A?0UJ,'%]!/@+P$R!(D#P3(B3%B
M,HOI+(80@D'N9/'!XAP0OYW$:R?QV$D<.R,&+W0PP@2E?AWLU<$>'>SHX)4.
MP@!GSB;OU[ 4Y@!]$#OUVDD]=E)')UWIQ   A/TZF5<G\^ADCDZVUH%Y3G*_
M3N[5R3TZSN>RR]?;J/,X9M:@)$&+_^S!"_%Z(1XOQ/%"UEN-LBQQW:QA"< D
M_>"/U4W:VSC VA $;N< JY\)0IAG&+L-Q <D!&"W"T2+QF9.FA]47.M.!D>N
M=(^TG>S"N6*:%#SIB)4^W.9)PR[*##,]%F.''R>*]]/I%<U':/D/4$L#!!0
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M2 Q>SH#5\R@QXT*-"048YN4MV+T@O)P!J^>)"@2\!"%\1UKP(H1H3EJBD5^
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M,E["3V:H#BK;7AX*M6N[V\3<U_TQN']H]7$XX@>7_QE6_P%02P,$%     @
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M2<0P00P2Q)8@OB)8.*L 81(G$0B3PD(6H) %0) Y0B#,TA$"8)8!+"0!A20
M 7:$0!AW:R%,! M)02$I0! [0B",LWT;")/ 0C)02 80I$X0")/!099@D"5
MX.QM>8N)@L 1\C[F2@@.X,(0 !1WSCV^4UOPOY]+#-:.-0[_ONHE (J"\$X<
MN(+@"*"X\Y]BN(;@^#^RA4\_AH[M3;80R/W)T$7];ZDXVE8IO8J?.F4J[85U
M;L?KT/0/QUZ:-FW[RA^:L<=_)>+8=-+;<:6[D^TA!\X5U1J#!ZVQUM>*><+H
M09EAJL=B[*WC1/%^NC>@^?)2_ 902P,$%     @ FXL#2W*7""3^ P  CQ(
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M+_LCDOZA+L[F^">XGD&M_@=02P,$%     @ FXL#2V3S\@,N P  X T  !D
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M *%8;R.Y_#T!NDT!8VKG\D',RA-=O77JM<_WO-D5=1N\"JE>8+O7S*T0DJN
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M:S\#.*(D4$H"H<2M2!##PXD@$@TBD2"^%:3%1(-T^"*TBQ""Q(*$.)4 I1(
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MJ#[OKLYN(%G3OPIH>)JR_U!+ P04    " ";BP-+\*])5Z4#   R$@  &0
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MSMZ,BG,%VC-XTF77^NF; P:5,M-$S\7X (R!XOWTMJ'Y@2W_ U!+ P04
M" ";BP-+ "BK:P("  #J!0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6R-5.UNFS 4?17$ ]1\F70106K31INT25&G;K\=N FH!E/;"=W;SS8.2\#*
M^@?[7I]S['-]<=8S_B8J .E]-+05*[^2LELB)(H*&B+N6 >M6MDSWA"I0GY
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MA;TNSG;%,@&)>$=_[M#US)&W@3P!1#UEMLEBEB[!P20TM>/YFENSR! [[>T
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MC _ $8[09X H19&5N(AB2\YJ"P/U7XM82H08YOR(,1E!3\-268*@B^<F?$B
M9N?SAV<B3'-.^4,QC&Y$8SRK]9#Q$ N,1/%&)%W?^=9(O4>J@0XR"JT[6M*Z
MFA:!)B\T0:0<#-GH)3KQ7 SB*SH)@VF_&Q(B!8Q(GT#DW2K=[!@"A>FA5Y&4
M?QC_;]L,=5P20EAF9"X-2/1K+!XU%W\BH"#F92'Q5L;MRV"!#(:,7G7,QA<;
MIB/3RGJ[\<";W:)$2:BDZC^-Y@_V#));0OH]:W[+9XXMTK^L28'G(9:6W=J
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M+\!I@L4Z KZ(P&37;$YR3&IFW6 1/:MVBS%WZ=^V@% T[!/:FV #=]X/_@9
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MQ%0> 9Y&XZ#?E4?):Q7.%-;8!N@F.+_@[M0@S#66A%RGP0%71$&';A&"YHO
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M3FHE<JVOZS%*^Y"4DLJ\E, ^([9&ZPB5@0LX!(FWWT"3F"AV7D!AQE]_F2=
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M03/1TFCF4F4J7]Z)K'M]'JT!&EY@)V9,:-W^Q^WR$9M#4(HF/Q]M\FS]\$P
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MW0%!XQA7+#%@G])(F(SJ#\&]REG/TPK3@(EV!E.:H514GIO/HA4$KSI6%J)
M47^#OB<!$53:-&WBV*^EE]VUCF#\$0JTNP7V8%[B-:SXTPEC@=PO>?UV>U7F
M#Z(SY40:CA;O28)D62+"BU(NENP5[_<%-*]M M=I\1J^4,2+;6H!'&HS?Z"&
M,!MF2\^&PXUM1Y@-A^M]=03:@2#HA\-QUX&@C^5X_P<"H8%T!HUE6TN6&^UP
M+ *3A4$MCQ PH3?H.S",)G48U C7N\_79^>GU]?!R<7YR>GYS=7QS=G%>9V
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MFL-B2ZEV-66C[8\F?6<C%K)&2$@*5%5(-26*8+<3^S40&K>+6EV\].H@1;?
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MB:I^7<W'V&_3J<9N/FE;2HBND]JO_&)P6M"UE$%NVG>!IC"KH6AEH*\J_R,
MXP1VL4+B$DQ#235FXE*=DREM>8DKD8.X9$WHH.*B?JR-2M,,1(:@!= $VR*N
M%Y4_^A3G&[Q@RN@2JAE,Y,96E&JH*!*2N8Q[ " _8?K48LV;]*9A"?&.N/B%
M_Q75\!/_C58YX>(87IHGS5).=R7'2Z4@BY_0@6A6JJA2*LQ2.24RP5K!T2O=
MXA5V>6$5%U.NG2L&D>:WO3U4' 3L:>+0/O<\Q6S]/<XSH:(<S7&3TY5^QG[F
M"Q1$LB*V'F:]1XDXJ]=H5_0Z*7A^0><-[+@N]GZ%&QQ#/6<6W0A50;PQTJIQ
MFY?@6$G\OUMN)3N"B!^FM)3\6=YR!)$O5>"L*7<EJ)<+\4AU#"E\0-&:=D..
MJ@>>A\5[/P*U^%GRY-<Q=G5,-^RL9-!ZVY.^&=QY$Q./7,$CZ]=4"Y]&"&I]
MR8J\I>PMY#@2LJ\@]LZ?YVC#5H]O1!E5DDXB12DL'5W&S!HYOJE!&8:AJ5DS
M.S<I'NDI+9\7\UX/''X+Y@B]D1)<^I1)T\N#8!1\!8S(CEYM 6T/TI0QTQZK
M=ZBE54B5";D/,9;04H.5P] J_FGI)=L(3=!-"8O?G+#$$?UFC:4>)+N&M?3*
M*V3ECVI:1_7+T'A%&P"N:RD4QA6UF#&0]3ENK/--U*6T$U2OZ*B,2FLIHAGH
MJ(D4)M51"C'I/9)E54-A*=R*DU:YHD/YG4YPH@>,YO VKNWB;;V&CI87/ !;
MQ0@L#IY#[OC7[>+>UL8OL0KG3$-L:N 4QA> Z+C"%M9@K:$-M'U'T:ZYM^%*
M!$]V5Y^=FJQSQV$NX8=3V%V$ 4BL0=5/F*2PRD=<$NI\%+S@I]@JT_);]<#4
M(,A$X@U3^)7R,DD@07Q 54V"1*W]T]7YV)0!3BQA3_T@PYW?O;BVY;,WGDJ,
MTKWB%'!@\VS\P+'74K["^TZJ5KS1LG.8X@>B2%6(E-(-@NVV0DKM8"H\LJ".
M2E8&Q0 GD'RPE) L#[.4:;^7&K0,"SB'!9QZ!3%S?:NC'R1DBA%\Y0*?V.3A
MB=2L7S(UX\B?<AP995.(1S%L'BT1LX4$'6$X<%2J7SFW^3AAX**Y0G%[SA^P
M=4].M5&(C$8Y9E53Q96$O_(!7AJ9"@/!#_&&(AU?)_*"?Z;:9U,*;G@\W/:B
M*XQGU?'TJ0HQ%E)4/T\1,DHX[HDU0B$J@?YR*ZOX9#"PTPDX7N@0XK(3<O3,
MJK8LJTA9@Y-J2<O:T3% ;!03[<F4NMR405FV7I9988W:BZ)>#9U@\&(]$*1>
MN:S5H07JQ1:;2\$ -5W3KQJ&II-6\J UJ^K:9JVMJ,..DE9B?*V$V)_SLA^P
M0I(3,3L&%;<CM/4KB5"53,]? LZ%)A08'",JFMQ2UOJDM._Q]6<R'1UA:727
M&5,3VF**;Y%6\>P&XLI;KLX6W6'4])ZYX8\G,R/;#FNAP5? *ZCQ+!>*<'U+
M3L5GUO:":7LA*#WAI>X3B;OZUVBU?OL^]'URK'(3QT3\ED=*+65L"QBZA?*@
M;;*1ZR:R_#Y*12 &HHP%7ZXNT$N@]@R.R[6U-^R+>$1%I0].&(!HB@&5V']'
M:CUX=3J"2AD.FL.K;F#<^I'\-F_NN0X'--[G-),6#.)!;3N3??P376"+1\+W
MM<=N;F-]@&Z%) 3E_OF76A.YRB44<J?*AAK62%;'QEW5,HI<(J4_#6>#@6FJ
M1VDMI%X"O&R>BP1R<H;0:8U^W->/17R@Z"Z@<D]P\*8=R&B&423P3IG-C"[G
MM%RD!>[^=D''>4%+;!_>-6XR7H<A"K>F!"6;B"(I*"0=.H"307@3_1JG6JK9
MZP3EU\5V6A.E,4G9[<)BF2[,Z,+P(8H0#/W61T@6U5R*-;!$'TS2HX=L2QI<
M)'DMOI:J9F<R/'S(I&,NMUOR$@E!-35B8?CP_CA$P1S39\2U@A99\N.5(>W]
M0M:S><)U->84?4=6*BKF5S+WP*$"2Q*7$PCIV+X*E6+LKN9F!7!SEI@'<(<6
MV5U,3_G$00$SC[T<&TO(L.>:XHMW3+*^CKDA<;P1#2S>T!%R@%-+GUN[MU ,
MW/21'&^"+'206?ZKC510D!JN,"2&<]NH\Y'[D4E<*!FK=]%@+V^JCO=4>=/6
M\HP(H'A_B<^!*O&KEZZ'-8: *'NV%^JQ=<3=D5"1#5V527<R^CHR=*9N7-\.
M[^0S&S,X?F+#^5;*M(%LYO$=  G-#$9?M<,AL#@4A/#,MJCSRQANRR2S 3;6
M!6Q!8^O$V9A!8$XNG(:G] N)20@IP/!!J[TXQ[)4D<%@]6@1EZ*9;2H*0M7+
M1FFF7L_&/N&R\VR?/+M4QN4EI6"5=.0-670$15VM=1OL0U)\PBE_]Z43BEP?
M/HS\0A3P38N:3H.;D.'1%N0RX'"_A:(7Z3="C=G?A05AJ#.+KL!':_>NJIA:
M1$@,HEJ,Q4F]7.((+TF>%':#.A!7YXFIBUU:]]?$;&ZXTJI^+0\8^P#>$JJU
M24HWPY\O%--S]$-JW1O/U767S;=RB-Q[1JB+WU+0\\##KA <K#3!M2JX0A)>
M@2?8C;CE;7T=_T9[:X/#B[ *W?U2OY.,AFC%4.-BAAIL'&"<"J7;5&KA^64^
M9:^F0"*'LCS%W/CE^&K<A]RS=^60++$_R*!,,LF5"M#9E)-=7,%N?V!#/2YD
M#3:P#[,5*F%R7(HUIROKQ29J8F5*-;"O-VS[.28%!"'V3)97CO;W0<U'+&4@
M*^G7!2-+0X7:GT_/;RZN_A*\OJ$@^UK&WC4JY9B:2_DDV H4&--!3L,S?=I(
M$IXS@VA8QP^NNKM*> :3OS\@XW^@_"L&V"ML$CJ;A;/)C#YWL<W5=&2NHB=C
MXZ"PJ.!@+/^8FXN;XX_&;1!?PS+<W=Z(AYB,PT&_5U-F+FY^.KT*3CY?79UB
M>N/U]>G-]4'0:1(Y#P(4"8*F(JMZ?48. MDE(FJR,.6X-*:"KX+9#/O*3.D3
MEC:?Z?->0#$_.QJ,0.@><T'/_EO['"C_VYS8W@"+H$]ZP1C$\^[ C92WJ&RR
M"!DPH KP@Y%]S1-J["/<CM$^(A7Q%C%%&< :J7S!<(B%KPU#;VU'P[D&@TDX
M&<(C7=C,N"NXT'BRKP)JEAE.1B/^#)#JCOHUM/AP]N?3]R]!!\X=> $:?, 7
MS%<>OTN&-,5SL8E76+N^BX41QNZ304,BGTE_. E'XVG0[XW"WK1/SM4MQA<#
MLUL\(66:=L-^KR?_F _;/"7K -%'V!M;"GJ@B8V&_8 *+DQFA@K<8'JY25;(
MJ<4K#L<QG4[E'S/!+L?=43"!-0Q'8US[EA(,T-D9>\[MUW@88U 'W\!'V#)]
ME,,LG<>K8 ACCJ=3*M,_#J>#6>T S\YOCL]_/'OW\?0EIUA+H3OH*$%<-RYV
MC8EQ(6FC4D?E/K?5FET.L4IB"@[UZ;N.<*115;/ZZKW1)Z:Q9N</Y6X:YD=<
MA __X#S>V%811^:8IT>LJLWZ@[FX/+TZADO;FPS?FE<XR6S4@Q-X#<<ZY:8-
M_6$X' _@0E/S#$<3C#6FS*5H%A82O24C%Q"HR7 0O)9_WUBRD'X?&>[!"XCR
M +PWX]8M>;1^KO:Z5H6J%_:[D[ _G@2O>T#9^M,^K:M'!?EGTU'0&W5&YB<>
MS.P9[#66?@1@O$%6 N1G-.TYFF6_P66B63[:";Q/2/- S#241(=4&!8[FX;C
MT<2-*7^[9%0I8H*$:C89AKT9LD.X&S!S;\ 0#R<#N#33L?'I [=+:3QN\\W'
M/0Z'LRY//H+C[N%Q3_Z[CKL[&P!1Z6.GD3Z(##@@LKSN:!8 !+[BH/O= 2"*
M=RCVFV\XZ"D":N3&E+\;#WK<Q>ZA4SIHX)WCOG1/"8F[3>JLRJ=?SHA=(B6B
MPAQ$S*Q^99J&L)$?:?QEX_=<M^E1!%-.F7!QN;>Q4#UN*$RA()6Z0$;* KGY
MD6:]'AM7$@AN]&@RXXI KP*XT;W1A$L">7_UNZ6_>NXO2MSAYF'P'<B#_>$^
M>?#CV?&[LX]G5-O\Y4*AEZC^%9*AG^;^%?(!JL:FHLZK?#CJ3ZQLW9_"=9EV
M]14T'%"I=@P'VEJS #KRV #'8\#M'4RQ%5 P"$<#I(9N!&M@1ARZ+;AQ Q8!
M&DRZP7@,ASCNV8?9JH4FM\@5>%!DZX]!=)@ U8;#&O6F]B4;4VI<WINL"ZX,
M7#*:9C(9&+6Z5@IO]  EAG"G^\"QIN.1*>>6VY!:4XOI!!(]Z<\"6H_;<4X!
MK7A0,.X$%MR'W[N3RK 2NFHD&X)B[P'VO5DX'0V"R0R6TAO;HR,<Z(\  (,A
M4 Q\<-0HV?HX^@J;JI$,1S<$J =H0,#V:I6P3^&]B^OK (A\</W3\=7I0>B]
MSB@60[SKRZT$$FKIIX.%):\%6""A"<6^P0,I;XA^?B[0S):!<G@/O0@G@IDA
ME%_FFAUA<#&9G@P;?599ZK?7]4B81$3*RN(%&F2U4,)UI5#"SH9EW(59HW&\
MIE5](.QCXO;F%PT!&H0]D,YG("GW^J#QDM9E^H3XH #!1>LCZJ'V4F<!-Q<G
M?_SIXN/[TZOK?PM.__3Y[.8P%?\E/>&R2IN\6O4&.-A_1H^Y2L6[4H\Y-=+]
M/]%C;N=-7$:IM1Q7'_S_O>G^?V^Z?;WI7E1G]S +R,YRD0?QAF/*]?_GE*$T
M.\I0FG]P&4JSOPQEC::_.[X^N\;R:Y=7I]=P+-2A@H[FZA1;5GS\2W!V??T9
MK2)>3;:KBW/X?'+*!_GZ/24B%<$Y,AEDJ+43!&!W++ _7[\/7K^J/?..(E8N
M[L@NC^ GRG",51SC.0OX9QPCYQ7INLRS-,.P0=YJ;24UHF5#IESU$>(1MLE2
M*7'-!;!PN.2WU*_[.BB)1Z;Z*.!3Q]*J%H">VW0>SWPO1OLB^*^@9>@KM_W6
M&)QCYV'\ST^$V+4V*,=5A^9_!:]V> H$.F^"HZ!E.VJ_5X=';=W1DXW+K$D-
M*-$&=KK#S//[E\1R_XFH4L=-MKS?.YMXS8;>_FA)W6A[S%K/VQYH#:'9.:RS
MG;<]43&=-T.E9#QO/H\FL.\VD>\_$B (0)@Q(08E#C9^.@OU?W[$V+BS3;PJ
M:@C[P;.MAVQ*K>&T9^7RC<K-V_.7WC"2K3/(IO6V>^0MON4):V;_2<WL;4^6
M#>X?U.#>]K@UO =GON&]=?2FH_+(7?NAO?<-],UFI"93^WYL 'G+E\F;2,HF
M/OI(WM(S9V9KOLG^Z1][5JMZ%TY;YN_ D<F&2NWK2-!E)E4CYZ!^-/\B!DBJ
M&8,&2(IT.K$&R$LQ0!X%KR_5!-EVAFI8Y#IW;%AL>Y9:$ 37V=V&D(ZG:7WZ
MEVK;8.Y"Z5GL^/A9+VXX2+8 #D1=:WU@UO* S[Y.R(IS<6>[:Z"ZP);C5G8F
M1N/@0&"WC=,;R3K';1L9\P.'XW_0J^']Z4X+K;5!X$0_5-]E@ZC62&_0O\6\
M^8(%ODSD8;EEUY-M$L_N^[R3^A\WP:E!9'%"E21LB'F_^MSG(L9:>A^3NQHE
M S&^\80_BXXO%PDXV3TJ73EB&[$Q#%M<)-G25EYIQ;+*4%IJ^]#G+Y-U3%'D
MU+ 3%'"L6GF)_?Z"&RS\E2VS^^=VNM!NW-Y/L:UYM\&FW/:L&I.#7<;DUHF<
M'3E0.W+;L]:,'-3-R&WON,H$>\2Z9B-R;=AF&W*M+D#;<JP1>?? 6@#!LR*W
MCMB@0S3)=QXB'&(H]E"%+*OU^0'\UH);[@S $=L4_L3"D;7<GD94R[\(+@'6
M9&+:315@CB-G)F:35%R:(-81G0W8LQ;7N*#:8=LN3]G(U?;4#H 1L85/+'"]
M"KYO 5^S-=>#^F$K\2H8E#+G@V.O:N7MLU_I0'/-@F-,4=H)_[J=E%/2C]10
M4^.>G>FP9M)$4VKMRQU#1U^:AB:S;'WH2=V$ZMEK6Q=*AMS:FV31W3->\^K8
M)%P;CVS#M=M9-A77AMHC:I5MR=5?&XW*G\0RU89%^X2B3[SI=BS<A<P@'^U0
MX34!],)5.&YYQEJ8:WO6![PJR:'K']3VM)B/VV>KF(</FC5NW,'/8KTMFX)K
M4H!8>5MA9&7X9IM[7:UIW& K& _=<<-"KJPR<>)EGS=)7PU0:\/&B;J&QE3]
ML.TQU3B"WK3QN:$\U^OJ@_UAXX/3 P=L/'CKY@@J;HZVM^.V8]A]F0[1Y_\0
M@:S>Z[.LWOAC=]S\H^W)X;M.5=06OYV?3NR["MMWY(3V;QHV>,VLM+9?<E)I
M_H_MS@[P^3%;+E816[%/LJ<X;>?H=HDB9907YSS&C0Q8DOZ1IB] $D8DLN)(
M;;4G[3!HG^;8-6-K@B&[_:A"5L.%<INC2NT27R*%(+#@@G;#;A95!MW&:W @
MGNXD_RJ/U;1@*ZCMH!,VR$U-&G[E"V?>6#;I@'MX;,U:HD@H)^U7]3CLU!E/
MVI,S:V0"]HW%JDYL5E^P5W@]_=9%VAG458^OM5RZ'QL3K ^;Y]0U-]3$=EUI
M7?3(@9:-0O,O_]+O]ON-U*S?DY]K#D]DO!YQV3&/+5#9L%97]Z6%!^V0&%&H
M;1 6^W4Q$R7B@"3BIG=ZG>&D]LHA2!+\%YD1YG#C+])=!K;\$$#N.Z[2,'7^
M\L(%WSQEK0NV!3^_=0XJL]QJF4E=/&.CV: J6L/(7W-U)\-.KRZW]SK=.IY4
MA?%OF+&NL8#",JW'I!Q(Z?N[9!+/?CBH;^DYZ/7:?QOL_ZU&&=1;9L,!CS1D
MLW;QO/X4CE!L]YV\\I#A'K'R^N0,YMY['C7:ZS/F$L]O$X/.M1# O+T6Y.]=
MM,O3-T_8LK,#*<Z'4J$56D0;TC UJ1W_<-29SAI0N%?7N44#^V?L>1?1PA4W
M&4B&==/& 1/MI%SOO5+%3JSE>@_->F9_2G&H1AZE+&=\DJL-<IKK/(8A ^[0
M0.U1GJ7X#.;24_% .%%.[ZW$X5-D)V[J(5ZNJ;P<5JY-[N&$SRB#&1N2S9,U
M1133P]@<,<#:QI)Q385+--@PQ:J 4NNI]2H!-4JCNSO@Q&1?/L7Z<\YPWGY*
MP\ZD?B#=SJ1^=(>2QL$.TGB]IVY'S7Y$:03;U*]J9!U.APQPY=4HK\K0S>I'
M31YN+J_SNEWDD[*=93FZ12YMN'6-QE"X"_LL6^TO[C%I4?CD1ZQD2.:ZLQ1C
MH/ D2U96#'(X7*>,MIL'ZK7(:B[J;DWQ(_7W;#7$7:^59=T6*\@.2;S%\]OB
M+:.H4H:N@\U.<#21LC/;R6N/B=LJY @!BT2>($I] K[AU5VJCD=/3H"_8J=T
M9WK;N]U6L\C5Z<?CF]/WP>7QU4U+B!K-"+<=:2" N6-!UTI,-'SLDKH4D0-1
M>ECO,O1_*G>^<.%EV$Y%72T:F$<-D&KBEK1 /=K]V+O/UV?GI]?7&'J* 8Y7
M%/'XPGB5DRSEDO*T+]*;=GHQI$M,#3NX=%,>-(W7&NQ3?;1^81I-\+-QT[<G
MVJ5BQQ(P5)"<F-KZS/OA4@ODGZ5I]BA%&6[^W+[\WV*^R^/?;+YC[,C,?</>
MQ?G]#@/>M\YT0N5[@*_^%$?+S<-O-L^G^1^!?, ;&OM"5_,WFNP7K"9#-%H.
M+MY*<]N4W878; EO_&^VVWA!\YW$W.A*T>>WFN_]%D.)0&3]S6?Z0+* [035
MJF4W$H/?:/(#Y*'>;[(>UD3V0V/\3YW] '#L28A0=WQ-==V9K1!RR?*XGGK0
M($1A)D)KL!<)^LUI!5^WDX/8*UI5NKUF!]'YSBR,1AOIN,W(?L5@:U%2*C;B
MFCZ!'6<&#?;*[XMB\_O_ U!+ P04    " ";BP-+9CCY'S\"   C"P  #0
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MW@N+H$RV=]C;=>S_.>#Z+U!+ P04    " ";BP-+%O],-MH!  ";'@  &@
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M>M#5=- 5/>AZ.NB:'B1S(..<GX2PYFLM@&OA>RT ;.&++8!LX9LM &WAJRV
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ME\U?23Z,61[FL^X/Z.D74$L! A0#%     @ FXL#2Q\CSP/     $P(   L
M             ( !     %]R96QS+RYR96QS4$L! A0#%     @ FXL#2V;S
M"V""    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    " ";BP-+?EY23^X    K @  $0              @ &9 0
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " ";BP-+F5R<(Q &  "<)P
M$P              @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( )N+ TL0[M9&A (  $8)   8              "  ?<(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " ";BP-+*W2I)JX#  "&#P
M&               @ &Q"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ FXL#2Q(H48E: @  2@@  !@              ( !E0\  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( )N+ TL:G]7Z800
M )T2   8              "  242  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " ";BP-+Y>LUY34$  "*$0  &               @ &\
M%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ FXL#2\4A
MBM2O 0  T@,  !@              ( !)QL  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( )N+ TMAP6Q9M $  -(#   8
M  "  0P=  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " ";
MBP-+UI#N%+4!  #2 P  &               @ 'V'@  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ FXL#2]?D/WBR 0  T@,  !@
M         ( !X2   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( )N+ TL?&)7EM $  -(#   9              "  <DB  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ FXL#2\60;%RT 0  T@,
M !D              ( !M"0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " ";BP-+3AT#9[0!  #2 P  &0              @ &?)@
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( )N+ TL.1ANV
ML@$  -(#   9              "  8HH  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ FXL#2_./Q&.T 0  T@,  !D
M ( !<RH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " ";
MBP-+5>OBD;(!  #1 P  &0              @ %>+   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )N+ TNU,+:^L@$  -(#   9
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M970R,"YX;6Q02P$"% ,4    " ";BP-+Z+Y?G;8!  #2 P  &0
M    @ $].   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M )N+ TN\(+Q>M0$  -(#   9              "  2HZ  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ FXL#2R,8K%NV 0  T@,  !D
M             ( !%CP  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " ";BP-+/'@S3<8!   W!   &0              @ $#/@  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( )N+ TO-6646M0$
M -(#   9              "  0!   !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ FXL#2_2V2]^W 0  T@,  !D              ( !
M[$$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " ";BP-+
MOM/:?<8!   V!   &0              @ ':0P  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( )N+ TMUOCNCMP$  -(#   9
M      "  ==%  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ FXL#2U([=7Z^ 0  U@,  !D              ( !Q4<  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " ";BP-+_.Z?Y.$!  "Q!
M&0              @ &Z20  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( )N+ TLZ9BXZZ $  /4$   9              "  =)+  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ FXL#2[:?#^54
M @  3@<  !D              ( !\4T  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " ";BP-+?J'7O*@"  !F"@  &0
M@ %\4   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( )N+
M TO/N&@K$P(  )0%   9              "  5M3  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ FXL#2VQZ3E23 P  <Q   !D
M         ( !I54  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " ";BP-+0:2D8.X!  !D!0  &0              @ %O60  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )N+ TOH?(:%QP(  $4+
M   9              "  91;  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ FXL#2Y]Z&N>Y @  ?PD  !D              ( !DEX
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " ";BP-+I5AF
MZSH"  ":!@  &0              @ &"80  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( )N+ TN?^5MGL@$  -,#   9
M  "  ?-C  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MFXL#2Y3VL(=K @  R @  !D              ( !W&4  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " ";BP-+<I<()/X#  "/$@  &0
M            @ %^:   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( )N+ TMD\_(#+@,  . -   9              "  ;-L  !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ FXL#2R</:N2=!
MOA@  !D              ( !&'   'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " ";BP-+OR_Y0?@#  #1$P  &0              @ 'L
M=   >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( )N+ TL<
MW.$[' 0  *<3   9              "  1MY  !X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ FXL#2_6I(]8V @  I@8  !D
M     ( !;GT  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M2P$"% ,4    " ";BP-+9CCY'S\"   C"P  #0              @ ')ZP
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )N+ TLJE(C-O0,  (L@   /
M          "  3/N  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ";BP-+
M%O],-MH!  ";'@  &@              @ $=\@  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " ";BP-+2I4EW<<!  "('@  $P
M        @ $O]   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .P [  \0
(   G]@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>115</ContextCount>
  <ElementCount>222</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</Role>
      <ShortName>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FIXED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssets</Role>
      <ShortName>FIXED ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Inventory</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - FIXED ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsTables</Role>
      <ShortName>FIXED ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/InventoryTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - FIXED ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsDetails</Role>
      <ShortName>FIXED ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - FIXED ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative</Role>
      <ShortName>FIXED ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - INTANGIBLE ASSETS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>INTANGIBLE ASSETS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NetLossPerShareTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - NET LOSS PER SHARE (Details Narrtaive)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareDetailsNarrtaive</Role>
      <ShortName>NET LOSS PER SHARE (Details Narrtaive)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NetLossPerShareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/RelatedParties</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BusinessConcentrations</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>txmd-20170630.xml</File>
    <File>txmd-20170630.xsd</File>
    <File>txmd-20170630_cal.xml</File>
    <File>txmd-20170630_def.xml</File>
    <File>txmd-20170630_lab.xml</File>
    <File>txmd-20170630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001387131-17-003894-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-17-003894-xbrl.zip
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M,/T\,/!+X+LL+'R'?BEXR?,]+YX4PV5'P=OH><K>PD-'\!0+G%'RWLLOY5]
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MQX_=\G7+UWOK<B^NG?;)]^YO63"Y\$:([2/+.FVO7,O3575X&/R,V,Q46JV
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M4$6WKJFKWV\/>D9M4U<[>0YUS2PW=?8.YW(\6_BFEE@*(W<=N'S"6L"KYM$
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M0"&&A^E^Y2^_5S[X(^MGF,G#<5X .WGVO6)Y-HUQ"M,I5Z E1H%#^A0)\^B
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MDZ$OL(BPKKWM2\N>0E%MAF6CL=8E@&Q3H-,C6MO __GD8V>2Q*Q2BAEG.:G
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MP.3M80 _!U<Y4G)-FLBA^P6 D)V<0EF "]\ZEA]$"2^NH29I(2XE:>089/)
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M_.;/]]%[?!=?R;[^3M'4:53B95BACF%T__P_FO$^)-HH3X[K*NB/5.*I[RE
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M5Y+OSH_@3)<^C<J(WK#E&P7$WBQA(WL)-(*01QQNF&\:[0(:6!!88EA%/5E
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M(YX5RHG0/3(-L&]I]%LYMQ@^RBQP!6'SGL")>JQCY2S>!T@V_S3^?^GR_7S
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MIP8-1UVC:]:B8K<AB!<AB-[0Z/5KT17JJ/7BD\DDF>,8]]Q$,(<O0HZSV-W
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M'?Z:3AM[AY?=]>9:']E!9TW$2X];=!,O?)9V$5\EC*:-N*:9OTT;\2.V]C5
MRZO>?$,3#4TT--'01$,3^U.NFC;B31OQG40$FS;B#>GH23IO!D9O;.J$H*:-
MN-X4T^D;O4'#;&I!.AJW$1\V;<2?ZK4[7!OQIGFX7A:8)KVB&XM<$WIHFH<W
M=)#!TG3-JM_F]T@438LD356NIGGX<5PPRS#'7:/7/WRKZ(;G:D(2;RRS8W3'
MC4;VV@EA#)JYV:]:FZ@!3O0XA>,CB,KY]'56QG1W>C4=Q \-R@[GMW2-\:B9
MWU*OS3>^D(8H&C[1D$3C'JNE>ZSI(*XQQ33YH U--#31T$1#$PU--#2ADQ+6
M=!#7H2):KM)TSGW08!YAVF_5G$U]FIXV%%AW"FPZB.MWM*^/"AL^>*0JW8MI
MNDT'\::#N&X\L^F@BU_N& -S8/3'HUT<L=;\O2%";8D0.*)I##K:=G%N.H@?
M+>EUC)[9-\;#JOG+#?]K--RG:Y#THVK-_9=?XQ]SY[>KR8P[B<<OIN=ID/>$
M8KS7^.0UP/S>"R;?__:__X,[^DL2M6YM>Y%^+YA^) W[DWO'G=57?$SB).3Y
MQH%G/Q;<CWCQW6P"<,,OEWSZUY\^AL&\8UK#EFG!_^) _#QH=<V?_H8[>'(G
M<>HBGC^#_R11[$Z7*SJLV=Z) GL&[YY3*U4D!CO?.Y$+'+!I$&+Z(_-A>38%
M_+$EM\,H_5RD/E)),)LD80B_>$MVP[$QHWPA=Y@;,1N_XWG!?5E<OJ1_>4U0
MN)>N[ 3X7W^2S3457++BO:]-CW9=FH?^&R@R!>V,$F\)0M7[4[4PQ];EM?:$
M: *-)L=>Y%X*OAIWA#Z 'T7RE-6^'GJT&^D-]M2R!J3UFT&Z]AR^.XN>V&=(
M3\QU-&AALQ_,/+'[4:^WIU9K?:,_K%K&=6C2V1&?J5S%<UQF#7"1JIY!#1"B
MQQ$<AA?L@0B&EF%5'B!<YTO_G$3QH[O_3?UN<_]?V?U_]4*_4[4[J@8(T>,(
MFDM?UTO?"/W<_:_:ZU8#A.AQ!,W]K^O]?^5"_WK&0VY/8Q[6X<R;J[_/JS\<
M&)U>+41 R=W/!];W$2-?C;]?8..<4Q$5_N3:-Z[GQBZ/= JL/_\H:).$8AG_
M9EZV5=Q<Y$8Q=LO&<+D(@;O^[8&"X)H&O(N.\5%W-Q'N=!Y[OA!N!V'ODEO]
M(NC5,FBI9VSXGTFN?5?7- JA860J]<2N7M!H<M:E$^I7SON(I]7O* 5@L!IL
MWQE+.YE,PB27I3'Q0-& ;; X=.'_:9I$Q>,Y^DDM3QWRLZ<P=[\S-,9/C7-K
M.LNFH9V7H1W+Z(PLPQQI-55,4]_)KGDN6]C+$/1F(UW[)O"3"+YL^RB_YW,W
MBC#=MPH3/B:7@DYN)LL8@KCNC:M6$VN %3W.X?A(HFOT09GM]6H1<SR [KI7
MW@GL$7U<A0QC^R;B_H0WK/*P]V+<[1G=82UN14,0+T$0@T'?Z%<>0UIG-GE8
MO=+CMV"Z@Q*9<<;)!,"+L?9&UHXU5^*@5Z(SZ */;)3)>FU^G_;%<&#TZY&S
M?FRJ9&1[PN;.BH[L\#LG;MF8WAI<#=,T1DUF5\TVOV=]<C@\_)RV8]<G*7D"
M=4=BDU)Q;+CAH14%R^@ULU!JMOE]FA*=GC&JW.6RSMSP\)HCYHG9_D1T8+F?
M!:! VKDNVXX;Q:%[D\3PUREO6.:A'9(C8]AIR@'KM?D]T@.9VK7P3]=:?53V
M=1@L;0_S;1NR/RS96V UU4)/:.CA97S01M^LA2%QG'KC)$@6@1]E01H?>"6/
MD]!O..6ADWU,:VR,^K5P,34D\2+"<PQ6=C,'_I$T_!=*4L="KHHGH4E5AERE
MF=ORH&+2[QK=;N_Y)ZP5(AL*K \%6I@4;]5W<M !%.9#-);?\J?KB^N33RG8
M%]?_.+MDI[]?7IY]N6:?SD_>GW\ZOSX_NWKF:1^Z3WTS+&%SA91AC4RC4SF]
MIAF6T!#A[BP(8]#I&>;HN5+ED$18(E?*VE9LU5IBTSR(B^F)'[N.ZR6Q>\>O
M^"0)Z=MG/R9>XG 'NU"<!O-%$MO8Z^)B>F:'/B H^LK#JYD=ZM*\8C\C#:YG
M(LPH6C?<<"^X9XN01[!&Q!8!SGMP;<];,H5 %J489/',QFD0B><P>SKEDY@%
M2<A %9@D'B$3.V'0%[G#?!XS+XC@K1Q4!T0L@Q<'$SIN B&@(C7X5A0#MF>!
M![<J-WP"8 Z<2$''G?8Z636C);8?+3'49[3$/GVD=;>OTKX+@X/V7;B>A3Q+
M2$#7\I7[0W;39QSN@E,3]#[!E&EHMIZ]0M;ZPC2]8([^?)O>+QNWJN3^ZBB*
MG;&M*U3;TL6#!6J 3;.774.U"M:NG.1=HV=V#,NL6^N.AH[THB/3& Q&QJ!R
MS]Q#8VM''%FC,.<W.PQMOW*_+4V4C":PM 6L7<.R^L;8K&]HJ:'!NM.@U3',
M@6GTAU5+*O4AP@-HX[I%6G2#YR"1GY>"=H<9M];(,)_-_IM 9$...U!&.E@7
M970Z=8Z+EXB"ASKI[RZZN#E^2<^]MR/N?+67<^[')_=VZ)"WY4(X6?ZPO83>
M?Q)%R5Q\IE/C_?W&+NULTRR)< *]3Q'#]TCV+< CUE.RSX'#/8HF2L\4NT7K
M"!YWX,S\6_I*M!+48.AC3'W'%/= )R/#Z&7$8WQ=/",@Y)JY.&H3GZQ5?#(.
M%MOH:\0K?V/]=N_ OO?N,WSO[YC:CIB60+O)/MSM'J_<'^DF/HN[=?9@P+"2
M-O[(L>6GB^MRA$70.H.,SG4]PEU$TC8,PC[ ;E[KB6V.C56]<;LR?G>[YTLW
M^MZ:AIR# @#XYE&<57C8\;8M"LLB^P<X0*L]ZK4Z;=/ZY1EP$TCUN%L'1W=G
MT++:H'3L]9)L'1W8[>[^"# ?SW/C9;U.96"U^X/6H-L>]YMK\!)P#\UVK]<:
MPFWH[/<B'%Y:7/-PSMZ V;;D=AB]K=<Y]=O]UJ#=>4[WA>92;,V%'D)TC:7"
M!_?.=;COL*7+O:KYFP<^$[-M/B"J&^I_*4Q7=I?NPIFYC:OT5 UT@*_GWWXR
MB8'LX^5AW:,[]LZ=$/(!6[#.$HLN;+E+!ER&B_J)CFF.E0.SP[YZMA_)%B$>
M3KT FVD:A'/"EYQ<&KW8W-(Z."M7TI1,;<HG#L>9-,G2T"0=^4M2&$P)MY"X
M4<1^QSOH+3'&0)R(73PI-583;.L%C29G_XVCS,VU%#F!^VO?<G;V@X<3-^+L
M:^A.JKJ@-,&Q7M#H>N+X-C6$5IU^_K-+/K==#/T6/CV%-4.0UHGM%3[_Y$[1
MC<G^C<9I/0]*+V@T(9N3V]N0WZ(W6L%W#@3@^I$[8:CXUH5%5#)[=UJ_TC-W
MD-/_WO:H;YX=,S51FB9)/Z&"J*DT> RJU9#?KK+?+&,X&!JC?M7.3GICZVCI
MZ*FCBO=$/MUV_\E7O2&<6F%F3Q34;U=-=-0;34=+0)IQGH&)@Y^-8;=NI98[
M4OJV#G<([[;9MCH[<0O^7>1[;HGTP]T%C5C#/M0VPQKUC'[E.F,-L*+'.1R&
M)^Z##[;K,<3W>(E )[Y09[2\ZLTW-''X*M(=:THJ:M'H2H>E_S<XJ];L'7Y,
MP+;I<7I@_V@TI Y<Z(/CH9&&FG"#.J/EF#:O 6/H=8?&8/":AFT]K:_2WO2C
MA1MRY]>/03CE[O8^I4-';2MT"VC:VR@=K-<WC8[YW)X&>VIN4[5N02_*.TK>
M/&A7CDCKTPGI=5+-46AY#1$U1'1$1+0CO5&#GFRY9+-]M"1O6F/IWQKKR=V5
M=6J-M26$6F4;=_:#K:IJYJ-@[2RI;3C6$V,-?>D!W\YRWYX[::$&F-,+FM?$
MQ_H@*P=]HW=LK23WXOE<W=P&M^=*K6UK9][0/WB4+X3"HF(90*;"6JGV5E5W
M];#'CL\TM$;&L&L9H\H>30W0HL=!'(VGLMNVN@?'PZLF IT80Z]=U730 !]Z
MG,#1<(2^90S[IM'OO:;0\C8NPF=OYW?_CM2D1AW2C.L9@Z%I=,9-GM5KYWV#
M=J_1ANJU^3U2PZAR<:<&^-#C!(Z&(_2LGC$:;:Y1*M$_MFU^5ZT]W>:&=Q^3
M. GY9]=WY\G\DONQ[<F^>M''(+Q8\!"6\&\_<5CT%8P$.8GH)()I4<<RV)3P
MQ.8"42PD3+&%1!4+?.8'?FN"<5J/O%:!0AV0,^*.1G[8T8NWQCO.X1Y];;KG
M/26S<%?-@$1S)P7/F8^X*_2CJ<@"]<JPT02:7..GUX>+%[205V[XL+>7+@4T
MANG-(%U;#&NJF@5[Z$8*#T+5;?IP%('IF/OIP]'KC8W.H&[=HW9TI2M'%7=R
M=QN;JEZ;WZ-Q->Y;AC6N>OOJ?.6J2-&]W+XFOE.OS>\S"\ PQSW#JMSMLL[W
M[R BK]/T.:K7YO=ZZ2RK:YB#6O#A PB]%RH^@4M9M>^4/F4Q>OD7FH+B)RB^
MO:YA=9Y;]5/[PJS*!?U[2^6]#F+;RSQ*,D1 ;O\T0O#,TZI!V<YKK"*KZI Z
M3/%8S^CW36,XK'/M6 G3>#A4^HS YFJT5 SFN9A>\D40TJ)7_%;$_;8,@;+$
M=\5#\IL_,8=/W+GM17_]Z?S+QY_^9F5[V+S<*F"7?,+=.WPBN@YMAY_XSD4\
MX^')9 *<,HZROY]@T!&#D[#W#T!I\33QU%-?05)-EH>-YNZ AN#+"7%CQ 01
MB=H@R_! Q04I,M@T")E"!U./$VTE*=4]%LW4$1?5XK$UB3)G!VNK@PUS!QMR
M-H'E@SD/67 #\%!N1,2<A,LI=C[.I_-8C.\!",-YU&;?.+SDSH5ERUZ*])'X
M&%;FD]BE9121$!Q 3).0.V[,)G8(/\\ +;R%NHJ8C;<( QR1"3\SNT!TCB(Z
M]3X#]9G)C+D1J#H1=UBR".!+"KA@RH(DCF);Q'@S$".#()FYL/,0%2>FH(6O
MYT;R&00/_P'/X0LXW/9@[D[PU@/XB"C"!?P:N33QCY!4AI.%'<6$5-S'/ "T
MQS/;)RC&)G/L9<3B@-UPX'">Z_^9  G0J^]#T-=@(]/<'_(;8?:M[?KP[B )
M'\.6Q!%MT<$II(E4P.1I\#LU Q(0B\,+0QXE'N9I3//XX5-X.^(><1,M@"-/
M$25N.$GFB.L)%]^09*7(90)2G/X%RJHK'BF0Q0(/+4@B;TF;CKE/V[Z?P0]B
MPYC&BQ0"X /$J">Z/L'YR+[;[#J@Y^!Z(?H<.[;9/= WO &0#L<_23PU' B>
M@X\Y'#B0 (#I!/!_?A#CVQ(<: _PA7R*R !\.G L-X0+!V^Q$&\QK181_GAX
M!]^?VTL\VY#_F6 'J_8&!I-)LUW*J+4TIM)T*)$)!>N<^YAH =BF895')N9H
M[RW:/)UV'@.-!--3@GT3%W,.-SXAOHD,-SLV^"42/"JBPQ5,KO"$'8:V?\O%
M[4R9(+[H%H<3M( A .NPW9 A!^1R0.LDN/7=_]*"@DO2.I+E3%T?+IT+D@-8
M7BQ?C:R-_@IZLAL ;TA"%!M"1O'YP@N67.:T*5: S$+).V06+G#/MAAA*78B
ME]ZT&^0LP Z]Q,'D.<F[@>_$(-:P[B'"+,?U3TBUAB<!4!)V<.<EXFP<#*R8
M.X(A9/8"V#-LEP @ TNP=1M$68Q(BA+88A',N131+C!Z?VEDV %@%BA+[M(M
M2X31*1)#1R!H >#1BBVS]VCXM<!8"8 MMC[S,(9EQ*8!AR[FQ(%H!3D):XF5
M"M]@G\7?4*V83/A")-31%_!445J$#DF1>S>>L9.K4S:T1L8:GVB)<:+YCPP\
M1D$[\A#:<MPH2V6J6"E2)T_PN?XBB4D29D.7#7F>N!M%>OP'(@Q.Q\,!A1))
M=) KIT923LHN==2(&L[N A!QKN?&2RG;W>A[:QIR! *T.O@20^DF#EX(2[$F
M > 4AI:#0-W\AMQ>5O2RX(;$H5-\GM) _\M#$,0!/?9[^PH6".FZ+VGU&U"W
M(KA& <A4V!G<JGBI[A@L@<09P"[I%LN31T55(0KUHS"9DTIUEB(G0PB]@RG^
MHDB0R)?=" C$%48=*X]3^%YZ,D  4R_!D9( !;?AZ26W0\4"5D&2!/X5MA#B
M5_]I^PD.D;94YNS:">3 5:Q.T1J[![4H._64P=DLI^#FOF_[MK>,7+IM"PZ7
M$N5]C#J90'%NB_ 1ERQ@D8!Y, 'MQ[ZS79&M"RIL3 ^PR)W#9[051!(R KCS
MXB+)ZXY_ \D DB($$@2N>4NX)HJ>+"<>D!Y(E^\<K8*%&X-D^6^F@Q,$&<_U
MN!CU";?,7\?=/6[!#A$728381Y"">[]X=CY]G$.+T@.)>7D!,FX$/[X/1'8S
MZE_;X8L] 5>P%?PE!P,@)SW451)P<W(L=\@%2(C?VNJ> -=!*RXH4-8Z34;B
M;MMRE&J!!!7SN2<)A+)P19JBEJC&JI*EN,VK4YZFJ'GEK5( ;GBSV+$4 N*T
MZ6,7I"W8)?"6.8]G@10FB#T05C8K\C-\&7&@PFZF-A(M')O@ )S- '3F(^F!
M.>>"CF%'L_1-PG05CP K2T),=B=.YQ-L*.?MY<IWVNQ4'3@ 'CTD]1%=?I0J
M#E%1?LQ ) .Y1<G-?Z1D_4_BD/N+P"J(E\RV00HKD2RT>%Z9HN,S-H@3H2V5
MRP)UY-GR*-!1 &24+D\LIWX%TW((4'8NT*;RA;E[@\NDNS'831*S5?/-]0'2
M.P0+;B]^,0$!'\9@,],%5L(.1 A<6'7OA+X);%)H62DNV^PD(N\"FL6DV""-
M!&&$/@Q0R>AUTK!TW.E4K%A /HF037JJ/&-Y^ D0Y@T)/+C!8.(N<^]46BBY
M:S>9D[74]H_3ACF#2QL+52+31B+V1NQVU.F8^<_33ZUW;X$=1HG0+[!69M6*
M0)TU8UE 4V[*&@LW:D41D@XP.\H,D9LEJ;Q]LV\P 2YK,;*4F0H!(!!? (@S
M!00IVO);;?4#<SA(:LFAI%8UEWZ7@FU%1C>I%D)$H>Y&=D0.SC8[]]DM]T%F
M>$;Y&]U(.(FX2Q+ZC?U62#UEV. =F[ODFS'0@23  W[FXNYMC'T( 0_?O7DK
MY*,=>BYZ1*?LC2L^RB._\'8WHDOL<?33P2M<^87\.>-9B4)TP1 S94VQ=5<X
MP5*KTQ$ZI,1,4<I*V;)^OE*K+#"IG"XKV;V0(IXMM5;)6E?I2S AL)4RK3:"
M>X*^/I#]R(PRS5:=7QC,Z7<Z%@D36=CP4Q@DM[/4=/;6CE$@1G[JB'U)E*2@
MKJ*5#C!%6%'?61/E@MFON2D%FFV,GR>HE0EX,S*1=S:E\F/B2L?):[_QXE5:
M]QBI6X ,!P3K9H%\*V97EOB,V*K/*+O2!5^"T!US_@121"5#(U?RHU"2)0=$
M;Z/;I>4!42H^KQPJZM(JN6$-WTG&'F'T0#I9<JRVS58Q+--#_E^GC_^5>&2V
M YHU;.GDZG<:TMXRQP;Z_Z6.N69Y<8H1(%<(E/>=D#P5$QN2D M>K5PZ8,NB
M5SUG"*.^;; ".=[GD4NW.7V;<#BDIX/*5<X:0@2&+D<F#1<]!\.Q7N+'KG,N
MXE\]!E :1KA9?<5)YIQ\O\P>D1K$"<H:67-]D47FOG$D;>Z<"-/PDL]!/X?/
M3S.K[QJ,OLZ688C_DR#^G])3<J7>GZG*\Z>_?>W_>_AY\&$%(R^['4TQ.LAA
M=-"R.JVNM25&QY^MD88H7:/S=1#>KX+P$3C['\C83S+K[1*,W(]@XYY+$_<2
MF(],E=D=969)+U^!5:UEO)AMTQKU'KO(N]^@3H@M$N@.$=L9O ;$VC]>FF+A
M=2^)6+%!G1"[-XH=FD>&V#/IC_PC]2\>AF8'W7%_3ZA]<(MZ(7=/=#NT.IW7
M@MP7UP\&5G]?8NS!+>J%W'U1KMG;E_*U%7+C'W/GMZ_ D">A2U_[&@9.,E&I
M7IITF=I-PI9;R-S*;YI,=+7SE;2M]%M- I<N'@KID(NXYY&+QK?GG-V$%)B$
M?\@9YD[8(G?"F!-%IXOA1H#9]9:I#_F>LGEL#V-LF-5TDU (3@068MOUV (N
MW=R>+ L/M D(F8HJ7&XAO^,^YN2BX[IL>8;+P%Y\3MYS^@U?JK*/1>HR92X;
M&5PAFU)L)$VL1A,W%M%&D<Z3NK, X"3TC]8A=42[NA2TLAJ2*"?:*/"<Q^BU
M&+R@"!;%4DI?B &D:.8N%C(@(8,A:Q<@S<((/!6 R6Z2'6%'/?@JQ3QRWQ6I
M?)03IR@2OYV 0!/)*Z5 B4N]Q4[1_>V*M'Q\MXK0X(5R?\A>4GC/A0<8MY$L
M\">KH_XHVO^A8UE=3(ZS@$G<BGN-R3/EJ)/A,F @E)QA QZY-TWS'3J]=)'5
M\!400H*1HR;$7H==40A!78XK(&71ST_$)@:4%9:[;XKU5[O*#\F7] K+:@9!
MIYB:!T]1)(=B["(!=N-K#.Q4+K(-%X&+D4@0F@I8O!JI],F#3E'S=$F5L??=
MQZ0WK(C@F#/E^FDM%P;*.<'F!R*=%^E=7L_5I+W\RRGAKARY&#$(,6M/1&ED
MVJC<&.5ISVS?YQX%A&Z"6*13/HA12J<IY2D&Y>^%5',38'@7%6:*49.(1C8"
M&D9@PP/B.()%+JVNN*C* YJ[,98_469:(%+-D1LM6>"O'5F;O>= X3YE%Y9B
M!,^-ZH^*?"E/'(*MI]O"=$6JN$(2*=VV3%9VZ'4WF!9U$]PUO$G_74D-.,#T
M+78'ZFR01%(KQ)MU&]ISJBRP5745DAZ&.#!1#4B9XL*8<PH"#&C3E75J(A^&
MDF87GCV1=YL*"N9!>ADH[4&JHB*/,UC:7KPDJ:]4T9(Z*JQJ2U;45YFC':ET
M5B%3:5_Y,#E2?2[ZBE]4J;\B[TB$<?+U>Z)D#]-RR"Z@<BH,ID]!^9[P*+(Q
M:YA"X7\FF-L;@D"G,'B^O"Q_5U 'S^5"BVH$4:V1)G6HM%*QMQ07.;6^&/KW
MJ<A8Z$:N$@ZY1)W-A5W;&NX%0_\"T'0]XZ<(.@]?C:F/VVX!NEMRXXVY7T=F
M)W)<X#9=7)^N6MHYXSIOX =*S"K6DUWN4H,]_QHJ'4$3B?+\9-&&M*E$P1*)
MXWL "I]*LY:I!B&((L')R$9*<\T4& 1%6F65Q#?844788Z@ B,1OW_'P%V'Z
MNU-9ZKPD347"+3P)@L/=N* @P"+S(N2%I=(59"H0R0@L0T.@;P,LF$(.U&8G
M<-#_"4)9'(+<%Y N,OA4%2YEGR-;%QJ)5$!(U\L58\O"+\IA3E2"$I;>"GQ@
M\GK$X]@3>7LH@>X#@2W,_;ZQ_>\(+I8SM]DIO5;F$0)S%N=$C5XH";^D2OI&
MS.R6NBTM&Q#]B.^^.0\!51WKU^%;PE.N4!SKS65-MNVQKMD"&-"PXTLJ+)=F
MNS _14FKT+6$_+E/S5]%5,H,)DK+*:HD)TZ#.:!T(DA[O<ZYA%;5<13]26M^
M(%%U5_0R43XGMM8O*7.9<)).F:&JR#%3O&7Y"T(J]R9K.7P$A/^@72-=I+A5
M0IDNA,,G^"C6DG';P5LJLL[@TLL44UP!",&=JT1UL8%'1.%6HFUG(84O*K=)
M)#:?9SFD<F0F)?Z5B='>:H1&'/?_?1,U,)VUP $!$*V%#@;]L0G_V4'L8(N]
M:("WM<A6G?#F</>W,ZSQ6N)-EZ-"!("YG*3"SD^BBZG8[;#5M1[?5\?LF9VA
MU>O\Y=?M5EL]T],TJ3TZ\1W,@X*'0-L&:_8#L Z/+-AG*HFI]@ L8I,&45G7
MNRGH>E\NKL^8U1.:T ^ I/N.G5Y\_GQ^_?GLR_45._GR 7[_<GW^Y>]G7T[/
MSZY6]+^;$H5)]63:XSZ*BMN++IUJR>FH%.K&M(*7^F)C726M" Y(8=%%SG90
MV<#,:5(EP$K%RC6<GD+EG^^#B<TN[1A+3#]ZH#TY-ELD(>@]?BP\2 \/IQ$V
M,!:7H)%+-N(_$T\)Z"[)87CK+98[P,=261%E+C8;=%OD=Z9R1G*K?>0WH9#P
M(WI#GT0\#3T1-=,!E:[?@J9%VI>H3L5B1XRG@<B-T&<&3ZG=I^K0(XC(WA&(
M$CBCB <?W\7!?I^G[D!:@FISU#)DG)^ ,N^QSB#G%CP$_%A+@C7=V5)8()VF
MK=^DKKO/MCJN@>ST$\,^99JY.KM<K$'%5.3Y8_$L*JB3.)"C8QAV.:735!_V
M#HR+K<]2H$S]T2U'V!?0_O)^SK86-UXS!D3-$:AW7EF]%=5\RQ(N<;KY'@%D
M1\F E"#%PD@MHE(B5R1I:GSP@TP(8# _=P9] W0E>N9G:]3!7XQ<MPUO*1LW
M/ VV7+"N*F1]*P=9%Z!:ATR+D].,D*3A]Q(SU0Z]U4<Q+[JUK(PW6YU^MCH=
MK3@\AL:?;>\[VS@HK=@^-P7PT6Z\U1"2?_^C/5'?KW90WGZ;&T:LT92TC=/1
M5CJ@EL-8VCSY.52AXZJY06>[\ %KLT7Q>?@(J:\WF/Y_DPD'S>$=>XE;H*:>
M=4O&0CUW);7:D_W@<FA:^;"TLGUM=_@/3,)Z@=LE5^]5X*3/76L'._VY\J+E
MT\\J+IL?=:;=V3[U@E,'^9>YWL_$03KY;"O<'^ R[7V! ^SIN7<F/Z!,CSW6
M0A(^_ZJ,-4)Y<U6J3Q/38Y>O0:K(X6)Z(+RY*M5G@.FQRUK(E:T&(%6_0=8S
MC=T#D.!AO!G[\?-D VBT 2F;VI.?U*4QA=1 TFTYBNC@GA(:!;;5"+"GNTWV
MA(L=,!()R6%827&,UC.Y204WR]Z R?A(<8"7UD12 UZBST71!Y)&TZ[W09==
M._&9FI'W2$1T_^'EYUSB59E,^'2P4L;&S)#?1 HTIO?2=S_Q6Y#"7\, S L\
MC@VB]S'0=QX?5E4,K3A84!0Z_4#1B[DHU68?*J'8/Y0$T87,B2( ,'HO8O@V
MB_@$QUA@[>'$LZ.(V6*XEF??1XDK,I:FKH<U?KD!7VJN E5BB3;F*N%?) +)
MHDG'#;EH3"Y3@G"F!L'PP16#8-@I?"E.QV5<!0G6A/HL_3N\5B7%O3E%A>Q+
MT&;CWZQA:W+7&IF]8;=U^>GRK4B"6R0A3EVDC"6JL,*:-<]VYZK%*K_%GKYN
M(&HP(UD-!YB;B*[PEHFMET4*"39PEGE65QF6SG[('NLG CAKW.U1.V=[3MDH
MHG#A,O$XO.RFU1<UKD3A1E;$E0WK(1#F.*Y-%N4Z? HOLN5\2D"EKQ)?OGPX
MH7U<_ZMEFKU_7(HL&FKZC"5Z8/<D6$&;^'(8&BSEV'-1WZ;:X6-=+QR(SY=1
MENLZ%H1)E6J4+4@-K&G.D)AL0>F$H_Q,D&Q5I)"[P$O\6%3/.&XT=Z-<E3'H
MT0X3#[LX2,V-9W#*6(WZG\0!6A%5_[(EQ7;41)DC7A2H00-4^G$?B :ZL\##
MB@KXQ[VS*6],$C.6<]S:H;,)GZ):!ZML!<7G:)8]A5[AG#&Q+\U,*J/?P6@@
MZ)?P[HN2I71Y]29!RQ-:&C[^:GMS]I[J_:AP82ER/@'P_MI2?>QZ-SP],<U!
M9S3^%_SG\WM1M7+#/9>+BIHHAZ-8C!FYX>E)S0&3L2R>Q+Q$&C+DW@:AF)(G
M"#;E#UA+)"BS[ 3PY"1>05M<4H?SI9C"0H=,=>?Q3+8ACX&Q&5@;CN50440I
MBM@+G,81.)0])$JDW)!Y[G?,\0* @3:I!?K]C!,A4Q*E_/@>RYURTPSP^TGT
M:-;77O**LF*":DGT?_O?__G+KS]N0&+^AO\/O_[_4$L#!!0    ( )N+ TM3
MBI<P/PX  !J-   1    ='AM9"TR,#$W,#8S,"YX<V3M76USXC@2_GQ7=?_!
MEZJKFZLK0B"3F4DVLU?&D,2W!%A,YF5KJK846X NQF(EFY#]]=?R6XQ?A"',
MQ7NP'V9!:LEZ^I%:W6U%7/YK.;.5!6:<4.?C4>/XY$C!CDDMXDP^'MT9-=70
M=/U(^=>/?_FS O]=_K564ZX(MJT+I4W-FNZ,Z0]*#\WPA7*-'<R02]D/RB=D
M>Z*$7A$;,T6CL[F-70P5P9,NE+?'C7.DU&HE^OV$'8NRNZ$>]SMUW?E%O?[X
M^'CLT 5ZI.R!'YNT7'<&]9B)X[X&%]\Z[6MU2'['[)MF$^RX_-MH"DCFV'.)
MR6_;W[ZTAMUOS9/&^Y-WIR??W.7,^E5\:KP_7HX!;1NYT)&H_UNS??)!_-,<
M-1L79^<7C0^_E!R5BUR/QZ,Z69Z$_Y5K?DNX&3?^YSL^?WR_')(O4\_YX&GW
M3N/60#/]M_O!^>.9]3O"=LN=G9_?X(=WIT]?:7\Q_*5A_!O]/#EKGMQ]& 2/
MO.3F%,^0 A/$X1^/$CI_/#VF;%)OGIPTZE]NNX8O=Q0(7BQMXCSDB3?.S\_K
M?FTDFI%<WC,[ZOJT+JKO$<=QSU!+)/+$X2YRS!5YRXT;)(7/ZD'EBBC)%7T7
MB))(U,(I.8[-XPE=U*$"Y!MO:R>-VFDC$O=X;8+0/&XR1OS>[SJL$$W>KS9Q
MJ.-XLWR@ELOJ[M,<UT&H!E*8$3-NM[[1:@,QD>,6;F+*SRQ83;-Z-./!)-AX
M!@OCBK)9&X^19X-:?_.03<8$6T>*B]@$NV(F\CDR<:D^HTF-'(?"W >C$):(
MLOF<P.2&@C]=BEEPP:B-1X! $1_ $LB>($3JL#X\,6+5L3J.2]PGL5C8S'_.
MD4( ME1"/!G&X3_;PF/B$'^ X9)L*#4E:I[\B!Q+"?I2$IU=UM/=)#KW.+;Z
MSH_^YSG#'+KQ&W6A(&P8BA0T,I%M>O9F;9Z'DMLD+(AT_@(6-.IP:A,+[*/5
M0K98G,848Y<'%!17R_7?!*4+>XE# K1^S^AW];8ZZK25EMI5>UI',6XZG9&A
MO+ESD&<1>,(_#D1D-3U #)!.,31 ]AI65F7E%)UN1Y'R9N4A!\H"&F)-\OZX
M/Q=.%CP_9Q$5R,FI>BNCRAC!_VX[/:"I?Z7T!YVA.M)!X+"NI"1IB$^O;/JX
MAJ-G,3E%9^4ITE3C1KGJ]C\?*(HHFLV1\Q01$7R1J_N=V-3!H;8I]QB&+Z.;
M#NC\=J#VONZQ)EN($YBT@P0P<)Z&V(1O]I/.N8<MU32I!RZ0,QDPZL!',YCK
M@?I?U(.<L_=ISEJJH?LK8C#L&+ Z?+NEJ+VV,NQH\+W[5=$-XPX6D*II_;O>
M2.]=@VR_!Y^U8#WM,=>&-YLA]M0?&V3B@)=O(O"4GYD!8V82'+):4E;.WX<T
M?\;=[:TZ_"H8-/3KGGZE:VIOM$(6F$!-[^PS3;JS $"4A>;M^:M<V>=I9>N]
M3S#A^\-]-F]]4:%Y3/B?*N=QE))3+M5NXR2MW3[L'T-%NQL..V(&&T9GKVW+
M%5F"F4]H.%D@5VTCK=HK_8NPX/NN4AW0.!-R;^.D7C.E<N4VLU9AI/:N]5:W
M<]!PT@IT";HG-CP5YYB(9*5<WZ=R.]'5U9;>U4?[O</UL-NEG \P,Z:(X4#?
MZ4*YGM^F]=SK@';[AJ% .*L8-^JPL\<*-EQJ/DRI;6'&.[]YQ U]B9QRN9K/
M,A[<J*_]=-/OMCM#X^]*Y^<[?;3/_H7NP$<\0DL<F^?G KEJ,P&IWH-PM*.,
MU"][;1R&V!8IE0%BS[8X5297;"9J'':Z?E)EH [WW/"V/$X<S+E&'1&>K^0<
M"^KDNLY$>*T[0^]UP QK_9Z(R,/4XA[K7*.S&7']=(?J6*!=$4!CYSG4E@G(
MM9\)^<" W.JC(&\HLB) @HBJ.[T]#ZG+93.VR8"4RX0T,^%C^4R(\B9ZQCYG
M?.,LR A!Z,-3J9&P4,Y!)LZ,$R3*FZ"#?59P-B.2U'1AK5SEF>@S+VMRT/Y*
M^B2I]FRQ7-^9Z#.92CGH.9M36;4FN75RC6?BT$Q^Y:#VPD1+D87)BLA)R$2I
MA4F7 QF9[$N2A/PJN?(S<6PV$W/0>EY*)JGXPEJY[C.A;EYZYJ!]:1"6I&&]
MF)R/3#@L#<@.Q+SL_$$;NXC8O(>82%8L\,O/(V1ZE-.=B;]W<#Y!>1,.0HE'
ML<_SHUP4GC\3MFPKY?ST19'\@=J\D#[42BJFCTKE=,B"^K"'?=9Q-FY?479Q
MM5SK)>/Z P')P'Y%\SGE<I6O">T/JLY1=6H_D G(E9^)\G.5?S#K>2F6E'7/
MKY2K/Q/?YR19#@N@2/,-J>H;:W2?\YJZ2/=*XZ#]C'Y3-FBME)R-3, O8>-@
MC8HSCX5>4(Z,G)%,R"_)/1YL5#KYN,)#09U<_YD8/"_]>%!\@>*%C8 /B_PS
M>!DA*15O,Z&QA HE[G2?2<FF?5<61'&UG(A,4)R?%CZLBF("&FL86.,VO<U$
MR%(*]MMS*E1R.I^W7DY.2B:&EI-R<*!*D;-NJ20$Y?1DHNR2]!Q6CUSOS;($
M-=<05.HT>!Y!S0-!,KV?EB7H= U!F6"]+$&G^TS0ZNGR_+UGC8R<EG4GT@];
M3HE3Z@5O>\O)RODI>XK]P%/90Q4K84P).3D_FYUS/P0VI;A)+:1-&DC9.LND
M <JQ]7^YIL0_XKJ[(1XK_C5Y%^+.MH]'G(C+$X_"LBG#XX]'XN:V6G25VJ\
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M[=A:Z[9XZP,][ 'HZS<+:],5LAIL\5,4H+6<[\%5XKNF=F.*01B$>;VD_;A
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M@CHT74O;@VNIP5X!Z3<H^HX3&E]M[*21I-,"BFNZ\+8'U2(SZ<<R1_^>%Z#
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MNZV%32:N81*>TL.[HNX7RS?FEN.-@\7"EIRA\U:R-:+K3+T@&',PB_3,7>#
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M&@E>L)UWA 3*WIZ*%=(38Y$49(J@XWS@"YW(*&O,X0\9\,#\$-L-D^4\F,M
MB16;IJE1%=$/*2I.)62"(T'OK'-CO"B)/5I,5P2T@M@39(+:KE?L7=OPO.'#
MK]R1=/RA.^*W3R7QD7 5W)97RBNV4^U4@F6A=,)*FJ(AI8)7  IY$&316&&V
M] 7B66E\(S\LM$S2I8['V&>DG BC'*'BTS,]9D=E6%!%\B&1G^DU1RO>9%Y
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MB^P]5Y][)G+ORB+>=MZ9#=6QM#,_;Z>=&?6N.Y/>9>NV,YKT>^.4C#,Z\\T
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MS(A(+3=Z:+9I+F&4*?7$XEZ<!RHD\ZZ<^"--82YX3UG0;8I<+7E'1:G)'"-
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M8T+TPVUW]N%FHMV-VDQ*[7E'Q]R6"DM^LI# SQ"^%#*(MQ%"%A193'@7K9W
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MK8A.9VRO?!,*(IO0SE@@;Q)>.):7EDP5=$U?^"=M"B]+9@2.3V.0-=!+SL.
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M+!XJ7EW_B6&.X7#.YGK.:GT69X]3R/(-O>R6_9_9=46;SV9L)0!78V^I?1,
M.3O)^0D((*4$DHL@0L8H[;QU^QYFN[[Z]KR"X6T5T'GL>!3B='C#]8.?.DLV
MF-UG*_9I:6C5;NRXVG8KW:6+RKD0LI%"F!A2R"$506.V\RSTZ,(/_91>^L_P
M*&?*K/ ? CI)$@K97=P@@P/U/T:1!T%'X_;,MC)PM?CV!D@KIRQRK"Q0<?8C
M%H[E @@KA<68/HN^Q#<^[7G,Q1Z1P'$_\A1P3^O$=QE5DCW <Q@L*@7")^>9
M1ZX0]OV#NK#"Y9>J5]Y!?* A^W&<I=#<=[W3.(;Z9UPP4.HF;Z^QMDP83$A
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M_/!VWI:L@1_$V#S2<N(L]'PVBV >2#?B2A2XFDFGGOX*>>@LRQ7@VJ-:HS3
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M:-#J3Y?L+_9S\1/[!\27[)?_#U!+ P04    " ";BP-+GFF44($T  #IL0,
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M^C6TIL*(DW9H<GV%0JKJ=8"UUAQ>:><&UUT8E<I.S:[!, )U_0XTJ\.(!0]
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MH*%NZ1M)V"4L?F1*HZC(+VQI 9>^.QXOLR6.%1:OZ8<=N7) <&$BI %WS&W
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M>6G[;,['UD419MMA1P'ILS<EA%,Z#4G4ZB;RY_=\"QY<<:[3;8RG1<5(R+&
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M\Q?Q#U&?E__F_P-02P$"% ,4    " ";BP-+:AO-%RJU  "ES0@ $0
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64$L%!@     &  8 B@$  $)\ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
